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ABSTRACT 
The prevention of material-mediated innate immune responses, which may lead to severe 
side effects, is an unsolved issue in invasive medicine. Neutrophil granulocytes are activated 
upon contact of blood with artificial material surfaces in medical devices. This unappreciated 
non-specific immune response provides a challenge for invasive medicine, since it may 
cause systemic inflammatory reactions and severe sequelae such as organ failure or even 
death.  
This thesis investigates the design an anti-inflammatory surface coating, which avoids or 
reduces material-mediated innate immune responses on the example of the material 
polymethylpentene (PMP). PMP is a polymer, which is used as hollow fibers in medical 
devices like oxygenators enabling the exchange of oxygen and carbon dioxide in the blood. 
Therefore, a biofunctional anti-inflammatory coating has been developed to avoid material-
mediated neutrophil activation during respiratory support. The biofunctional anti-inflammatory 
coating is based on the covalent coupling of the agonistic FasL-molecule APO010, the 
covalent coupling of albumin (Recombumin® alpha) to passivate the coating and an amino 
acid-based stabilizing formulation to enable stability and functionality of the coating even 
after ethylenoxid (EtO)-sterilization and subsequent storage of the device.  
To investigate the stability and functionality of the coating, different methods were 
established: an ELISA to investigate the stable coupling of the biofunctional coating, a 
sandwich ELISA to detect detached APO010 and a chemotaxis assay to investigate the 
reduction of neutrophil activity after incubation with the coating.  
The novel coating has been upscaled from laboratory scale (bench setting) to a serial 
production scale, whereby the methods from this work were able to show a rapid reduction of 
neutrophil activation by approx. 10 % after contacting the surface in the second serial 
production run and the stability of the surface coating even after accelerated aging for up to 
82 days at 55 °C in the third serial production run. Three upscaling steps were performed to 
generate homogeneous distribution of the coating on the PMP matrix. 
The biofunctional anti-inflammatory coating is a new technology to reduce unappreciated 
material-induced immunogenic responses. In principle, it should be possible to transfer this 
technology to other surfaces. This could allow for expansion of the positive effects to other 
medical devices in direct blood contact and can possibly show the way for new biofunctional 
coatings in the medical device sector. 
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CHAPTER I 
 
GENERAL INTRODUCTION AND OBJECTIVES 
 
1 General Introduction 
 Medical need 1.1
The prevention of material-mediated innate immune responses, which may lead to severe 
side effects, is an unsolved issue in invasive medicine. Neutrophil granulocytes are activated 
upon contact of blood with artificial material surfaces in medical devices [1-3]. This 
unappreciated non-specific immune response provides a challenge for invasive medicine, 
since it may cause systemic inflammatory reactions and severe sequelae such as organ 
failure or even death [1-5]. 
This thesis investigates the design an anti-inflammatory surface coating, which avoids or 
reduces material-mediated innate immune responses.  
 
 Medical devices with blood contact 1.2
1.2.1 The development of the heart-lung machine as an example 
In 1931, John H. Gibbon started with animal experiments to substitute the functions of heart 
and lung by a machine [6]. 20 years later, the first successful open heart operation was 
performed using a heart-lung machine [7]. Another team of surgeons worked on a different 
approach: the team of Clarence Walton Lillehei established a method of cross-circulation, 
where a healthy person served as a donor for a sick person like a biological oxygenator [8, 
 Chapter I: General Introduction and Objectives 
 
 
 
2 
 
9]. Thus, the first operation in March of 1954 on a sick boy was successful, but the boy died 
after 11 days due to pneumonia. Later, Lillehei used dog lungs as oxygenator, because it 
was not always possible to find a donor. To decrease the risk for two persons he moved on 
to use the heart-lung-machine [9]. Many scientists worked on this issue for a long period of 
time, but were not successful. However, Gibbon and Lillehei achieved success with different 
approaches. Thus, 60 years later the foundation in cardiac surgery was born and today open 
heart surgery is a routine procedure, which is performed on a daily basis [10]. 
 
Even through the success of the first surgeries, which forms an important milestone in 
medicine, related problems of inflammation and thrombus formation during and after the 
surgeries are still leading to the dead of many patients. Therefore, to date many scientists 
work on the issue to reduce systemic inflammation and thrombus formation during surgeries.  
1.2.2 Biocompatibility of artificial material 
Artificial surfaces of medical devices may consist of different material like metal, ceramic, 
glass, synthetic materials (plastics), or biopolymers depending on their application [11]. A 
high number of medical devices consist of plastics, because plastic is cheap and easy to 
handle in the manufacturing process and can be adapted to any application. Whereas 
polypropylene (PP) is often utilized for syringes, filters, etc. due to its thermal stability during 
sterilization, silicon is often used for breast implants, and polycarbonate is often used for 
housings due to its robustness. Most medical devices consist of several materials, for 
example the housing of a membrane oxygenator comprises polycarbonate, whereby the 
inner membrane for the gas exchange may consist of polypropylene (PP) or 
polymethylpentene (PMP) [11, 12]. 
 
In literature, many investigations to generate biocompatible materials are published. Cao et 
al. (2007) demonstrated a reduction of protein adsorption, platelet adhesion and thrombus 
formation in in vitro models by using a tetraglyme coated material compared to the untreated 
materials. They assume that one main advantage of improved blood compatibility of plasma-
deposited tetraglyme, a hydrophilic polymer, comes from a generalized reduction in blood 
interactions [13, 14]. 
Ishihara et al. (1994) showed on grafts that the zwitterionic phosphorcholine, consisting of a 
hydrophilic side chain with phospholipid polar groups and a hydrophobic tail, decreases 
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protein adsorption compared to the original graft coating. Thus, blood cell activation and 
aggregation on the surface were inhibited [15].  
However, more or less the same materials have been used in the clinic for more than 50 
years. The reason is the lack of understanding of the biology and physicochemistry of the 
interaction between blood proteins, cells, and artificial materials [16]. One of the main issues 
for using basically the same materials is the difficulty in analyzing and evaluating the new 
biomaterials in the relevant biological environment [16]. 
Some researchers suggest that only the uppermost layer of a biomaterial is in direct 
physicochemical contact with the biological system, which means that the distance of the 
liquid biointerface is just some atomic bond long [17, 18]. Therefore, it is important not only to 
study the biocompatibility of a material by microscopic or spectroscopic data, but the 
aqueous milieu of the bio-system in contact with the biomaterial [16, 17].  
1.2.3 Blood-contacting medical devices induce inflammatory response and 
thrombus formation 
Through the interaction of air, blood, synthetic components, and mechanical stress in the 
cardiopulmonary bypass (CPB) device, an inflammatory response is mediated. This 
inflammatory response gets enhanced by the physical trauma of surgery and effects of 
ischaemia and reperfusion [19-22]. Therefore, the stress by the artificial surface and the 
biomaterials should be kept as low as possible. Blood-contacting medical devices, such as 
vascular grafts, stents, and heart valves are necessary in cardiovascular treatment. For 
patients with cancer, venous catheters and ports are required to get access to the veins. In 
these devices not only inflammation but also thrombus formation is a common cause of 
failure. Due to the complexity of the different aspects, which have influence in the health of 
patients, it is of major importance to understand how blood-contacting medical devices 
induce coagulation and inflammation and how to prevent it [23]. 
 
When blood comes in contact with surfaces of medical devices, there is a fast adsorption of 
plasma proteins on the surface. The formation of the protein adhesion is related to the 
physicochemical properties of the surface and is the first step for a potential inflammatory 
response and thrombus formation [24].  
In Figure 1-1, the activation of thrombus formation and inflammation via the medical device 
surface is shown. Protein adsorption to the artificial surface activates several cascades. 
Platelets attach to the protein layer and get activated to form aggregates. The intrinsic 
 Chapter I: General Introduction and Objectives 
 
 
 
4 
 
coagulation cascade begins with the zymogen activation step of the factor XII. Factor XII is 
self-activated by adsorption to form factor XIIa, which converts prekallikrein to kallikrein. 
Factor XII activation also initiates a cascade of reactions resulting in the generation of 
thrombin from prothrombin. Thrombin generates fibrin polymers from fibrinogen monomers 
and further promotes platelet activation. The platelet aggregates get stabilized by the fibrin 
polymers resulting in the formation of a thrombus. The activation of the complement system 
by kallikrein, thrombin and other coagulation enzymes results in an inflammatory response in 
the body of the patient [1, 23]. 
 
 
Figure 1-1. Activation of thrombus formation and inflammation via medical device surface. 
Via protein adsorption on the medical device surface several cascades are activated simultaneously. 
The protein adsorption activates the platelet adhesion, followed by the platelet activation and 
aggregation. The factor XII gets auto-activated to factor XIIa by adsorption, whereby factor XIIa 
converts prekallikrein to kallikrein. This initiates coagulation and thrombin generation. Thrombin leads 
to fibrin formation and promotes platelet activation. The platelet aggregates get stabilized by fibrin 
resulting in the formation of a thrombus. The activation of the complement system by kallikrein, 
thrombin and other coagulation enzymes induce an inflammatory response in the patient (modified 
from [23]). 
 
1.2.4 The role of leukocytes during inflammation and neutrophil physiology 
The circulating leukocytes comprise neutrophils, monocytes, lymphocytes, basophils and 
eosinophils. In the application of blood-contacting medical devices, especially cardiovascular 
devices, neutrophils play the major role in inflammatory response [25].  
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In healthy humans, the release of mature neutrophils from the bone marrow is a highly 
regulated process, whereby chemokines control the neutrophils in circulation. This process 
leads to a pool of neutrophils is always ready for release in case of an infection [26].  
 
 
Figure 1-2. Neutrophil recruitment. 
When circulating neutrophils recognize signs of inflammation, first they get captured by stimulated 
endothelial cells, which expose P- and E-selectins on which the exposed L-selectin of the neutrophils 
can bind. Further, the neutrophils roll along the endothelial cells mediated by expressed selectins until 
integrins lead to a tight adhesion. Then, the neutrophil passes through the endothelium and arrives at 
the site of inflammation. There, the neutrophil releases cytokines for recruiting other immune cells, 
start with engulfment of microbes via receptor-mediated phagocytosis, the release of granular 
antimicrobial molecules by degranulation and the formation of neutrophil extracellular traps (NETs) 
[26]. 
 
 
The common opinion is that neutrophils have a short half-live of about 8 hours in vivo [27, 
28], whereby the lifespan is decreased to < 24 h ex vivo [29]. By infection, several disorders, 
and some diseases the amount of neutrophils and their lifespan is increased after migration 
into tissue for up to several days [5]. Controversially, Pillay et al. (2010) followed up with the 
different approaches to investigate the lifespan of neutrophils and found a lot of inconsistent 
results in neutrophil lifespan depending on in vivo or ex vivo models. By labelling of 
neutrophils, he and his colleagues could show an average lifespan of 5.4 days in humans. 
The at least 10 times longer lifespan than previously reported indicates a novel role of 
neutrophil functions in health and disease [29]. 
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As neutrophils are essential cells in inflammatory response and during material-mediated 
immune response, their behavior after and during pro-apoptotic contact is investigated in the 
work presented in this thesis. 
When neutrophils get activated, they migrate to the inflammation site in a process called 
chemotaxis. Thereby, they roll along the vessels and get attached to endothelial cells. By 
migration through the tissue they reach the inflammation site, whereby dysfunction during 
severe inflammation can lead to tissue damage and organ failure [26]. Severe inflammation 
can be induced by cardiac surgery, trauma, sepsis, reperfusion, organ transplantation or 
other disorders. By these disorders, dysfunction as the systemic inflammatory immune 
response syndrome (SIRS) and multiple organ failure are common, whereby highly activated 
neutrophils may worsen the situation by their prolonged survival and their aggressive 
immune defense like chemotaxis, the movement of neutrophils to a stimulus, NETosis, a 
form of cell death by the release of DNA in forms of neutrophil extracellular traps (NETs) or 
the release of reactive oxygen species (ROS) during respiratory burst [5, 26, 30, 31].  
Gorbet et al. (2004) demonstrate in their review the evidence that the normal behavior of 
circulation neutrophils to roll along endothelium, adhere to stimulated endothelial cell and 
platelets, may happen as well on biomaterials. However, the mechanism to material-induced 
leukocyte activation is not fully understood yet. Therefore, a strategy to inhibit the material-
induced inflammatory response is a crucial issue for many researchers in the field of material 
surface coatings.  
 
In conclusion, the excessive immune response due to artificial materials in extracorporeal 
systems is going along with the activation of neutrophils and other disorders. The high 
number of activated neutrophils in the blood combined with the ability in inflammatory 
response enhancement confirms the assumption that inactivation of neutrophils is a central 
aspect in order to avoid material-mediated inflammation. 
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 State of the art of material surface coating in the field of 1.3
medical devices 
Previous approaches to address the issue of a material-mediated immune response aim 
primarily at a passivation of the medical devices by masking their surface. In this part such 
anti-inflammatory coatings with the function to inhibit instead of to passivate shall be 
discussed. 
1.3.1 Coating of surfaces 
In 1916, McLean discovered an anti-thrombin, which is known today as heparin. It is a 
sulfated glycosaminoglycan, which is naturally produced in mast cells and today is used 
therapeutically as anticoagulant during surgeries and other medical applications [32, 33]. In 
nature, heparin is a polymer mix with different chain sizes, whereby the pharmaceutical 
production offers unfractionated heparin and low-molecular-weight heparin, which was 
developed in the late 1970s [33].  
By its high anionic charge the heparin binds efficiently to the plasma protease inhibitor anti-
thrombin III, which further inactivates prothrombin, factor Xa and other proteases by their 
conformational change induced by heparin binding. This results in an inactivation of fibrin, 
whereby heparin increases the effect of anti-thrombin III by up to 2000 times [34]. 
Due to the ability of heparin to anticoagulation, it is used for novel drug treatments for several 
diseases, including cancer and inflammatory diseases [35]. In the medical device sector 
heparin is used to mask artificial material and to support the anticoagulation during blood 
contact [36]. A negative side effect is the heparin-induced thrombocytopenia (HIT), which is a 
degradation of platelets in the presence of heparin resulting in thrombocytopenia [37]. 
 
Another well studied molecule is the human serum albumin, which is known to passivate 
artificial surfaces mostly by adsorption to the surface and therefore is often used to generate 
a biocompatible material [38-40]. 
 
Using thin biofunctional coatings like polyelectrolyte multilayers in the layer-by-layer method 
allows new biocompatible materials, which combine the mechanical properties of the classic 
materials and the new biocompatible property of the coating. These coatings can change the 
contact from tissue to biomaterial, which can tune the response of the tissue to the contact 
with the biomaterial. The coatings can consist of Heparin and Collagen or other components 
depending on their application. The coatings can be used as drug carrier, by loading active 
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substances, or they can specifically respond to the changes in the surrounding [41, 42]. 
Therefore, biofunctional coating may result in a better application of the biomaterial. 
1.3.2 Leucocyte filters 
In the 1990s, leukocyte removal filters were developed for incorporation into the 
cardiopulmonary bypass (CPB) circuit. Some of these filters show efficient depletion of up to 
99.5 %, which means almost no cells could be measured post-filtration [43]. However, 
Boodram and Evans (2008) nicely summarized in their review 40 publications from the past 
10 years with the summary that the efficiency of the leukocyte depletion filters is 
controversial.  
On the one hand, some researchers observed positive results for the patient, e.g. they could 
demonstrate that strategic leukocyte depletion during reperfusion phase reduces myocardial 
damage when using the filter in arterial line [44]. Other researchers could not find beneficial 
effects of leukocyte filtration on postoperative myocardial function when using the filter in 
arterial line [45].  
The same controversial findings were summarized by Boodram and Evans (2008) regarding 
inflammatory mediators using the filter in arterial line. They summarized that the value of the 
complement component 3 (C3), one important part of the complement system, was 
significantly lower in the leukocyte filtered group 24 hours postoperatively, but that no impact 
on the patient recovery was observed [46]. Furthermore, Mair et al. (1999) could show no 
significant difference in inflammatory parameters measured except for plasma elastase 
concentrations, which were significantly higher during and immediately after CPB in the 
leukocyte filtered group compared with controls [47]. They do not support routine use of 
leukocyte-depleting filters [48]. Summarizing, there is no evidence for the benefit in using 
leukocyte depletion filters for CPB. 
1.3.3 Leucocyte inhibition module (LIM) 
A new approach to avoid material-mediated immune responses is the biological modification 
of the artificial material surfaces to reduce the activity of neutrophils, which are known to 
trigger further pro-inflammatory immune responses.  
In 2000, Cinatl et al. observed a decreased neutrophil adhesion to human cytomegalovirus 
(HCMV)-infected retinal pigment epithelial (RPE) cells. They recognized that this 
phenomenon is mediated by an up-regulation of FasL on RPE, which was induced by the 
virus as a mechanism to escape from immune surveillance. This suggests a novel role for 
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FasL in the RPE regulation of neutrophil binding [49]. Based on these findings and with the 
idea to inhibit unwanted material-mediated immune response during CPB, Scholz and 
colleagues developed a leukocyte inhibition module (LIM) (Figure 1-3): a plastic device 
containing a polyurethane matrix with covalently bound anti-Fas molecules, the IgM CH11, 
for extracorporeal immune therapy [5].  
 
A         B 
 
Figure 1-3. Schematic illustration of the leukocyte inhibition module (LIM). 
A Localization of the LIM within the venous line of the extracorporeal circulation (ECC) during cardiac 
surgery. B function within the LIM: 1. Blood flow through the LIM, 2. neutrophil adhesion, 3. neutrophil 
inactivation, and 4. neutrophil apoptosis [5]. 
 
The studies show that immobilized anti-Fas molecules, which get in contact with the blood of 
the patient, are able to prevent excessive neutrophil activity when using extracorporeal blood 
circuits. The downregulation of the neutrophil activity by Fas/FasL during cardiopulmonary 
bypass shows the high potential profit in decreasing the material-mediated immune response 
([5], [50], [51]). 
 
When LIM was introduced in a porcine model with cardiopulmonary bypass in a heart-lung-
machine, they could show reduced inflammatory markers. Furthermore, in the porcine model 
LIM functionally inhibits leukocyte activation, which limits pathogenic sequelae related to 
cardiac surgery with CPB. Used LIM in cardiac surgery patients LIM proved to be effective in 
reducing perioperative inflammation [50]. Furthermore, LIM did overcome apoptosis 
resistance of highly activated neutrophils in patients and induced anti-inflammatory effects 
[52-54]. Furthermore, Scholz and colleagues could demonstrate that a proprietary Stabilizing 
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and Protecting Solution® (SPS®), mainly consisting of amino acids, enables stability of the 
immobilized anti-Fas IgM molecule CH11 during sterilization [55]. 
The following chapter describes the extrinsic apoptotic pathway to explain the underlying 
mechanism of inflammation reduction by the agonistic apoptotic molecules. 
1.3.4 Apoptosis as model to study efficacy of anti-Fas molecules 
As one possibility to decrease the inflammatory response is the coating of these artificial 
materials, Scholz and colleagues used immobilized anti-Fas molecules, which get in contact 
with the blood of the patient, to prevent excessive neutrophil activity when using 
extracorporeal blood circuits. Thereby, the inactivation of neutrophils is based on the 
principle that neutrophils express the membrane receptor Fas (also called FasR or CD95) on 
their cell surface [56]. This receptor plays a crucial role in the process of programmed cell 
death, also called apoptosis.  
The extrinsic death-receptor pathway is activated by members of the death receptor 
superfamily like the CD95 ligand (FasL) or the tumor necrosis factor receptor I. By the 
binding of these molecules, e.g. the FasL, the Fas trimerizes, which results in the formation 
of the death-inducing signaling complex (DISC). The DISC recruits adapter proteins such as 
the Fas-associated death domain protein (FADD) and the procaspase-8. Multiple 
procaspase-8 molecules generate the caspase-8 activation through induced proximity. This 
leads to the activation of the caspase activation cascade. The mechanisms of caspase 
activation comprise proteolytic cleavage by an upstream caspase, induced proximity and 
holoenzyme formation. The activated caspases initiate endonucleases and proteases to 
disrupt the DNA and the cell proteins (e.g. cytoskeletal proteins), which results in cell death 
(Figure 1-4, left pathway) [57].  
The intrinsic apoptosis pathway is induced mostly by DNA damage, but showed to play a role 
during neutrophil apoptosis as well. In septic patients the antiapoptotic Bcl-2 is 
downregulated after 5 to 10 days after trauma [58].  
Scholz and colleagues could show that stimulation of neutrophil Fas not only stimulates 
apoptosis but also induces inhibition of neutrophil function [53]. In addition, apoptosis 
resistance due to high levels of antiapoptotic Mcl-1 and low levels of pro-apoptotic Bax 
proteins can be overcome by immobilized agonistic anti-Fas [54]. By these findings, they 
propose the use of Fas for therapeutic strategies to prevent neutrophil hyperactivity, 
prolonged life-span and sepsis [53]. 
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Figure 1-4. Schematic illustration of the apoptosis mechanism. 
Extrinsic apoptosis: The binding of CD95L to CD95 leads to the trimerization of the receptor, which 
allows binding of the FADD (Fas-associated death domain protein). Thus, procaspase-8 activates 
caspase-8, which results in activation of other caspases that ultimately lead to apoptosis. The intrinsic, 
mitochondrial apoptosis mechanism is induced by DNA damage [57].  
 
 The innovative anti-inflammatory coating 1.4
The design of the innovative anti-inflammatory coating consists of a three step process: first, 
the selection of the molecule, second, the coupling chemistry and third, the stabilization of 
the coating.  
1.4.1 Selection of the biomolecules 
In the scope of this thesis, five anti-Fas molecules, which have optimal binding and 
trimerization properties to Fas, were pre-selected in this work (Table 1-1): SuperFasL, 
MegaFasL, Fc-FasL, E09 and CH11. SuperFasL, MegaFasL (two variants), and Fc-FasL are 
recombinant proteins, which trimerize to homotrimers. Three FasL are located in spatial 
proximity enabling the induction of apoptosis in Fas positive cells such as activated 
neutrophils expressing Fas on their surface.  
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Table 1-1. Overview of pre-selected anti-Fas molecules 
Ligand Structure Size 
SuperFasL The extracellular domain of human FasL (aa 103-281) 
is fused at the N-terminus to a linker peptide (26 aa) 
and a FLAG
®
-tag.  
Monomer 35 kDa 
glycosylated in 
SDS-PAGE 
MegaFasL, ACRP-
FasL 
[59] 
Human FasL (aa 139-281) is fused at the  
N-terminus to mouse ACRP30 headless (aa 18-111) 
and a FLAG
®
-tag. The FasL and the ACRP30 lead to 
trimerization and disulfide bridges between ACRP30 
lead to a stable hexamer. 
Monomer 40 kDa 
glycosylated in 
SDS-PAGE,  
Hexamer  
192 kDa 
APO010, ACRP-
FasL 
[59] 
Human FasL (aa 139-281) is fused at the  
N-terminus to human ACRP30 headless (aa 16-108) 
and a FLAG
®
-tag. The FasL and the ACRP30 lead to 
trimerization and disulfide bridges between ACRP30 
lead to a stable hexamer. 
Hexamer  
192 kDa 
Fc-FasL 
[59] 
FasL was fused to C terminus of the dimerization 
domain of IgG1 (Fc domain), this generates a hexamer 
structure, and a FLAG
®
-tag. 
Monomer 50 kDa 
glycosylated in 
SDS-PAGE 
IgG1 E09  
[60] 
Antibody 150 kDa 
IgM CH11  Antibody 900 kDa 
 
This structure makes the proteins extremely efficient because it enables the trimerization of 
the Fas receptor, which allows the activation of the extrinsic apoptosis pathway. IgG1 E09 
and IgM CH11 are monoclonal antibodies (Figure 1-5). E09 has been reported to induce 
apoptosis in an effective way although the affinity to the Fas receptor is relatively weak [60]. 
CH11 has been used previously for anti-inflammatory approaches [61] but was shown to be 
instable over a longer period of storage time. Therefore, CH11 was only used as a control 
molecule for the assay development. 
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A 
 
 
B 
 
Figure 1-5. Structure of the pre-selected anti-Fas molecules. 
A FasL compared to MegaFasL (APO010) and Fc-FasL [59], SuperFasL (not shown) has a similar 
structure as MegaFasL. B schematic structure of IgM and IgG1. 
 
When investigating an anti-inflammatory coating for invasive medical devices several 
requirements need to be respected. The medical device has to be biocompatible and all 
components need to be in Good Manufacturing Practice (GMP) quality. A stable coupling of 
the anti-inflammatory biomolecule is necessary for safety reasons and the functionality 
during blood contact has to be maintained.  
During CPB up to 6 l/min blood are pumped through the medical device, which require high 
stability of the coating. In addition, the anti-inflammatory coating needs to be 
haemocompatible, which includes the prevention of clotting and the inhibition of the 
complement activation. The anti-inflammatory coating should be specific to activated 
neutrophils, which get in contact with the surface. Thereby, the medical device may not lose 
its function. As the medical devices have to be sterile, the anti-inflammatory coating has to 
be resistant to sterilization, e.g. via ethylenoxid (EtO). As well, long term storage for two 
years at room temperature (RT) is common in medicine and has to be reached. 
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1.4.2 Stabilization of proteins and biologics by stabilization formulations 
Many proteins and biologics are prone to chemical degradation, like oxidation and 
deamidation, and physical degradation, like aggregation and denaturation. These routes of 
degradation are dependent on pH changes, reactive oxygen species (ROS), free radicals, 
e.g. during processing, production, and storage time. Furthermore, increased temperature, 
freezing and terminal sterilization are crucial issues for biomolecules.  
In order to overcome these issues, the formulation development in biotechnology has further 
advanced over the past decades as shown in many excellent publications, reviews, and 
books [62-72]. 
The use of specific formulations is important during the manufacturing of proteins, 
therapeutic antibodies, recombinant proteins and vaccines. Furthermore formulations for 
medical devices undergo especially harsh conditions, where they have to enable and protect 
biofunctional surface coatings for implants, bone cements, extracorporeal blood treatment 
devices, apheresis columns, wound dressings and patches during terminal sterilization and 
storage. Insufficient stability during the manufacturing process and long term storage are 
main issues in the development of pharmaceutical products and may lead to unstable 
products and low yields [73, 74]. Therefore, it is necessary to adapt the formulation to the 
desired applications. Formulations mostly consist of small molecules, e.g. sugars or sugar 
alcohols, in addition with amino acids, salts or other pharmaceutical excipients [63, 65, 69, 
71, 75].  
Especially the amino acids glycine, alanine or proline, which are called osmolytes have been 
reported being excellent excipients for protein stability, consistent with the fact that in nature 
an intracellular high osmolality can protect the organism in high environmental salt 
concentrations. In addition, these osmolytes do not seem to interfere with enzyme activity or 
functional structures [65, 75].  
The combination of amino acids and sugars effectively stabilizes biologics in dried state as 
many organisms can survive dehydrated in a process called anhydrobiosis, when they 
concentrate disaccharides like trehalose intracellular [76, 77]. In dry formulations the 
excipients replace water and build hydrogen bonds and other non-covalent interaction with 
the protein [78, 79]. The replacement of water by the formulation excipients prevents oxygen 
radical formation during increased temperature or irradiation [55]. By choosing optimal 
excipients and additionally surfactants like Polysorbate 20 or Polysorbate 80, the protein is 
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thermodynamically stabilized and unfolding and aggregation is prevented [64, 65, 67, 69, 71, 
78, 79]. 
In liquid formulations the excipients are excluded from the hydrated protein in a process 
called preferential exclusion. In this process, the water-protein interactions are stronger than 
the excipient-protein interactions. Thereby, the hydration shell is stabilized, which results in a 
lower free energy and thus increased stability of the protein [64, 65, 71, 78, 79]. 
In this thesis a stabilization formulation should be added to the anti-inflammatory coating to 
protect the coating during drying and storage. The formulations will be selected based on the 
knowledge that amino acids and sugars can stabilize proteins. In nature an intracellular high 
osmolality can protect the organism during water stress as with high environmental salt 
concentrations [65, 75].  
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 Objectives 1.5
This work addresses the design of an anti-inflammatory coating to prevent material-mediated 
neutrophil activity on polymethylpenten (PMP) as a relevant model for a synthetic material 
used in medical devices.  
In the first part (Chapter 2) of this work an optional pro-apoptotic anti-Fas molecule should 
be selected for the purpose to couple it on an artificial surface. Therefore, literature research 
and analytical assays should be screened. 
The next part (Chapter 3) deals with the design of the anti-inflammatory coating. The goal of 
this part is the selection and design of the coupling chemistry and to investigate and 
characterize the designed coating.  
The final anti-inflammatory coating should be investigated by analyzing different aspects of 
the coating. The coating has to be stable and no leaching is allowed. This should be 
investigated in a sandwich- Enzyme- linked Immunosorbent Assay (ELISA) called 
detachment assay. In addition, a reproducible coating process is necessary for an upscaling 
production. Therefore, the quantitative efficacy of the coating should be determined with an 
ELISA, which detects the bound anti-Fas molecule, called coating efficacy assay. Finally, the 
functionality of the coating should be guaranteed by a functionality assay called neutrophil 
activity assay. The neutrophil activity should be decreased by up to 20 % in solution and 
>10 % when anti-Fas molecules are immobilized, due to previous investigations with the anti-
Fas IgM CH11 in LIM. LIM was incorporated in the circuit of a heart-lung machine and was 
successfully tested in a clinical study with 150 patients [80]. 
The characterization of the anti-inflammatory coating should be done by different relevant 
methods. Due to the shape of the PMP material several known methods cannot be applied. 
Therefore, the methods have to be selected in regard to the model material.  
Chapter 4 deals with the upscaling of the anti-inflammatory coating to the whole medical 
device and a serial production scale. Therefore, the coating parameters need to be adapted 
stepwise to the larger scale. Furthermore, stability testings with an accelerated aging 
protocol need to be performed and analyzed. 
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CHAPTER II 
 
SELECTION OF A SUITABLE ANTI-FAS MOLECULE, WHICH CAN 
BE USED FOR THE ANTI-INFLAMMATORY COATING 
 
2 Introduction 
This chapter describes the work which was conducted to define the most efficient anti-Fas 
molecule that leads to an inactivation of neutrophils. Thereby, a pure and homogenous 
neutrophil population is needed for proper results. Based on these findings the most suitable 
anti-Fas molecule will be further used to design an anti-inflammatory coating.  
According to the defined requirements in chapter 1 the aim in this chapter is to decrease 
neutrophil activity for up to >20 % in solution and about >10 %, when anti-Fas molecules are 
immobilized. 
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 Materials and methods 2.1
Table 2-1. Equipment 
Name  Reference 
Analytical balance, AT460 Delta Range Mettler-Toledo, Columbus, Ohio, USA 
Centrifuge Megafuge 1.0R, max. 4000 rpm or 
3345 x g 
Heraeus, Hanau, Germany 
CFX-Connect Real Time PCR-Cycler with 
C1000 Connect 
BioRad, Hercules, California, USA 
CO2 Incubator BINDER GmbH, Tuttlingen, Germany 
CO2 Incubator Sanyo Denki K.K, Moriguchi, Japan 
Flow cytometer BD Accuri C6 BD Biosciences, San Jose, California, USA 
Micro-Centrifuge Galaxy 14 D, max. 13 000 
rpm or 14 000 x g  
VWR International GmbH, Ismaning, Germany 
Micro-Centrifuge Sprout, 2000 x g Kisker Biotech GmbH & Co. KG, Steinbach, 
Germany 
Microscope Axiovert 40C  Carl Zeiss AG, Oberkochen, Germany 
Mini-Shaker PSU-2T Biosan, Riga, Latvia 
Mini-vortexer, Vortex V-1 plus Kisker Biotech GmbH & Co. KG, Steinbach, 
Germany 
Neubauer counting chamber Glaswarenfabrik Karl Hecht GmbH & Co K, 
Sondheim/Rhön, Germany 
Sterile bench Biowizard KR 170 Kojair, Vilppula, Finland 
Thermo-Shaker TS-1000 Kisker Biotech GmbH & Co. KG, Steinbach, 
Germany 
Water bath Memmert GmbH + Co.KG, Schwabach, Germany 
 
Table 2-2. Biomolecules 
Name Reference 
Anti-Adiponectin/Acpr30, 0.2 mg/ml in PBS R&D Systems, Minneapolis, Minnesota, USA 
Anti-Fas IgG1 E09, 2.252 mg/ml in PBS kindly provided by MedImmune, Gaithersburg, 
Maryland, USA 
Anti-Fas-AK (IgM), clone CH11, 0.5 mg/ml MBL, Nagoya, Japan 
Anti-FasL mouse IgG2B, 0.5 mg/ml in PBS R&D Systems, Minneapolis, Minnesota, USA 
APO010-API, 490 µg/ml in PBS Oncology Venture, Hoersholm, Denmark 
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Name Reference 
Bovine Serum Albumin (BSA) Sigma-Aldrich, St. Louis, Missouri, USA 
Fc-APRIL (TNFSF13), 100 ng/ml in PBS kindly provided from Pascal Schneider, University 
of Lausanne, Switzerland 
Fc-FasL, 100 µg/ml in PBS kindly provided from Pascal Schneider, University 
of Lausanne, Switzerland 
MegaFasL, 100 µg/ml in PBS (Human FasL 
(aa 139-281) is fused at the N-terminus to 
mouse ACRP30 headless (aa 18-111) and a 
FLAG
®
-tag) 
Adipogen International, San Diego, USA 
Mouse anti-Human CD11b/Mac-1, PE-Cy™5 
labeled 
BD Biosciences, San Jose, USA 
Mouse anti-human CD18, FITC labeled BD Biosciences, San Jose, USA 
Mouse anti-human CDI77, FITC labeled Abcam, Cambridge, United Kingdom 
rhIL-8 recombinant human R&D Systems, Minneapolis, USA 
SuperFasLigand, 100 µg/ml in PBS Enzo Life Sciences, Inc., Farmingdale, NY, USA 
 
Table 2-3. Materials 
Name  Reference 
Aqua B. Braun, purging solution, sterile and 
pyrogen-free 
B. Braun Melsungen AG, Melsungen, Germany 
Ethanol, 70 % Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Ethanol, absolute Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Human albumin, 20 %, >95% human albumin Biotest AG, Dreieich, Germany 
Phosphate buffered saline (PBS) w/o Mg
2+
/ 
Ca
2+
  
Biochrom GmbH, Berlin, Germany 
Polymorphprep™ Axis-Shield, Dundee, Great Britain 
Propidium iodide solution (1.0 mg/ml in H2O) Sigma-Aldrich, St. Louis, Missouri, USA 
RNase A (100 mg/ml, 7000 units/ml, solution) Qiagen, Hilden, Germany 
Sodium citrate tribasic dihydrate, ACS 
reagent, ≥99.0 %  
Sigma-Aldrich, St. Louis, Missouri, USA 
SYPRO Orange, 5000 x stock solution in 
DMSO 
Sigma-Aldrich, St. Louis, Missouri, USA 
Triton X-100 for molecular biology Sigma-Aldrich, St. Louis, Missouri, USA 
Trypanblue, 0.4 % Sigma-Aldrich, St. Louis, Missouri, USA 
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Table 2-4. Media and solutions 
Name Reference 
Dulbecco´s Modified Eagle Medium (DMEM) 
w 3.7 g/l NaHCO3, w 4.5 g/l D-Glucose, w Na-
Pyruvate, w/o L-Glutamine 
Biochrom GmbH, Berlin, Germany 
Fetal bovine serum (FBS) Superior Biochrom GmbH, Berlin, Germany 
L-Alanyl-L-Glutamine, 200 mM Biochrom GmbH, Berlin, Germany 
Penicillin / Streptomycin, 10.000 U/ml / 10.000 
µg/ml 
Biochrom GmbH, Berlin, Germany 
RPMI 1640 (Roswell Park Memorial Institute) 
Medium w 2 g/l NaHCO3, w/o L-Glutamine 
Biochrom GmbH, Berlin, Germany 
RPMI 1640 Medium w 20 mM HEPES, w/o 
NaHCO3, w/o L-Glutamine 
Biochrom GmbH, Berlin, Germany 
Trypsin/Ethylenediaminetetraacetic acid 
(EDTA) (0.05/0.02%) in PBS w/o Ca
2+
, Mg
2+
 
Biochrom GmbH, Berlin, Germany 
 
Table 2-5. Kits 
Name  Reference 
Annexin V FITC Apoptosis Detection Kit I: BD Biosciences, San Jose, California, USA 
Annexin V, FITC labeled 
Propidium Iodide (PI) 
Binding Buffer 
Pappenheim-Staining Kit MORPHISTO GmbH, Frankfurt a. Main, Germany 
Giemsa stock solution 
May-Grünwald-Eosin 
Weise buffer pH 7.0, (10x) 
 
Table 2-6. Cell lines 
Name  Reference Cell type characteristics 
Jurkat 
DD3 
[81, 82] 
Suspension cell line: 
DD3 was designed by a chemical mutagenesis and subsequent 
selection with the anti-Fas mAb CH11 (Peterson, 1998). DD3 
has a deficient in Fas-mediated signaling secondary to a 
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Name  Reference Cell type characteristics 
mutational loss in the cytoplasmic death domain of Fas and is 
resistant to Fas-mediated apoptosis, kindly provided by Prof. 
Martin Zörnig, Georg-Speyer-Haus Frankfurt 
Jurkat 
wild type 
(wt) 
[83] Suspension cell line: 
Established from the peripheral blood of a 14-year-old boy with 
acute lymphoblastic leukemia at first relapse in 1976, # ACC 282 
from DSMZ 
Human 
blood  
 Different healthy donors 
 
2.1.1 Cell cultivation 
Suspension cell lines 
The suspension cell lines Jurkat DD3 and Jurkat wt were cultivated at 37°C and 5 % CO2-
atmosphere. The cells were split at a confluent state. Cell concentration was determined by 
Trypanblue method: 35 µl of the cell suspension was added to 35 µl Trypanblue to stain dead 
cells. 10 µl of the mixture was transferred to the counting chamber and the cells were 
counted in the Neubauer counting chamber (Hecht Assistant) according to the manufacturer 
data via light microscopy (Axiovert 40C microscope, Zeiss). To maintain the cell line the cells 
were distributed to cell culture flasks according to Table 2-7. 
Table 2-7. Split mode of cell lines 
Name  Split mode/week Cells/cm
2
 flask 
Jurkat DD3  3 times 133,000 
Jurkat wt 3 times 133,000  
 
Solutions used: 
Cultivation medium: Jurkat DD3: RPMI 1640, 10 % FBS, 4 mM L-Alanyl-L-
Glutamine, 100 U/ml Penicillin/Streptomycin  
Jurkat wt: RPMI 1640, 10 % FBS, 4 mM L-Alanyl-L-
Glutamine, 100 U/ml Penicillin/Streptomycin 
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2.1.2 Isolation of neutrophils 
The neutrophil granulocyte isolation was established with Polymorphprep™ solution (Axis-
Shield), which first was established by Boyum (1968). Boyum developed a one-step 
centrifugal technique for the isolation of mononuclear cells where polymorphonuclear cells 
are centrifuged to the bottom of the tube together with the erythrocytes [84]. 
Polymorphprep™ was further developed to separate erythrocytes from mononuclear cells 
(Figure 2-1): Polymorphprep™ is a mixture of Sodium Metrizoate and Ficoll. The high 
osmolality of Polymorphprep™ causes erythrocytes to lose water and shrink, thus increasing 
their effective buoyant densities. This enables rapid sedimentation of erythrocytes through 
the dense medium. It is crucial to keep the temperature of samples between 18 °C to 22 °C 
to obtain optimum results, as changes in temperature effect the density and viscosity of the 
Polymorphprep™. 
The isolation of the neutrophils was carried out according to the manufacturer. Therefore, 
human blood was collected from healthy donors in lithium heparin S-monovettes (Sarstedt, 
16 U/ml). The time from blood sampling to performance of the following tests was about the 
same in all experiments (2 h). In a 15 ml Falcon tubes 7 ml Polymorphprep™ were filled and 
layered with up to 7 ml of whole blood. To separate the blood components the falcon tubes 
were centrifuged for 45 min at 470 x g at 20 °C. The rotor brake have to be turned off in order 
to avoid mixing of the gradient. 
By centrifugation the whole blood was separated by the difference in density of its 
components in two leukocyte bands, the mononuclear and polymorphonuclear white blood 
cells (Figure 2-1). To obtain the polymorphonuclear leukocytes (neutrophils), the band was 
removed with a disposable pasteur pipette. To remove the excess of Polymorphprep™ in the 
sample, the isolated neutrophils were washed with 20 ml PBS (10 min at 400 x g). The 
supernatant was discarded. The pellet was resuspended in 2 ml cell culture medium with 
20 mM HEPES. The buffering of the cell culture medium with HEPES allows the use of an 
incubator without CO2 supply.  
To determine the neutrophil concentration 100 µl of the sample was diluted in a ratio of 1:5 in 
cell culture medium, whereby 5 µl of the diluted cell suspension is measured five times with 
the BD Accuri C6 flow cytometer (BD Biosciences). By setting a gate for the neutrophil 
population the number of cells can be calculated through the sample volume and the event 
number. 
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Figure 2-1. Schematic representation of isolation of neutrophils by Polymorphprep™. 
Blood is layered on Polymorphprep
TM
. Centrifugation at 470 x g for 45 min at 20 °C leads to separation 
of blood components. The erythrocytes are located at the bottom, followed by a reddish layer of 
Polymorphprep
TM
, which is contaminated with erythrocytes, then a whitish layer of polymorphonuclear 
neutrophils (PMN) and a whitish layer of monocytes (MC) are present. The top layer in yellow consists 
of plasma. 
2.1.3 Staining of blood cells 
The Pappenheim staining was developed in 1912 by Artur Pappenheim and is nowadays the 
standard method for staining of blood smear. This method is based on the staining of May-
Grünwald and Giemsa [85, 86]. By combining the dye mixtures May-Grünwald [87] and 
Giemsa [88] it is possible to visualize nuclei and cytoplasm with depiction of their granules 
[85]. 
The appearance of hemocytes after performing a Pappenheim staining is different for nuclei, 
cytoplasm and granules. For example the cytoplasm of erythrocytes appears reddish, the 
granules of basophils appear blue-violet, the granules of eosinophils appear dark, the 
granules of neutrophils appear light violet, the nuclei of leukocytes appears blue-violet, 
platelets appear violet, the cytoplasm of the lymphocytes appears blue and the cytoplasm of 
the monocytes appear grey-blue [89]. 
To generate a blood smear 20 µl human blood was placed on a glass slide and was 
distributed by a second slide. The blood smear was incubated for drying for up to 20 min at 
RT. 
For the staining, the dried blood smear was dipped in three different composite solutions of 
the Pappenheim-Staining Kit. The procedure was carried out according to the manufacturer.  
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First, the smear was incubated in a 50 ml Falcon tube with May-Grünwald solution for 2-3 
minutes to fix the cells. The excess solution was removed by washing with water (B. Braun). 
Second, the slide was dipped for 2-3 min in a 50 ml Falcon tube, which contains a mixture of 
May-Grünwald solution and Weise-buffer (ratio 1:1). Then, the slide was washed with water 
(B. Braun). Subsequently, the blood smear was incubated for 12 min incubation in a 50 ml 
Falcon tube, which contains a mixture of Giemsa and Weise-buffer (ratio 1:10). Finally, the 
slide was washed and dried at RT. The staining was visualized via light microscope (Axiovert 
40C microscope, Zeiss) and a camera. 
2.1.4 Specific staining of neutrophils  
Neutrophils and monocytes have similar properties with respect to their morphology, size and 
density. This makes a pure isolation of neutrophils of whole blood difficult [90]. The nature 
and composition of surface molecules of neutrophils and monocytes is similar as well, both 
cell types have, for example, the receptors CD11b and CD18 in common [91]. However, only 
neutrophils express the surface receptor CD177 [92]. 
In order to define a pure population of neutrophils, different surface markers were 
investigated and analyzed by flow cytometry.  
Therefore, first 100 µl of isolated neutrophils (see 2.1.2) at a concentration between 1.0 x 105 
to 1.0 x 106 cells/ml were washed with 400 µl PBS/2 % FBS and centrifuged at 400 x g for 
5 min. The supernatant was discarded. Second, the samples were blocked with 500 µl 
PBS/5 % FBS solution for 15 min. Afterwards, the cells were washed as above. Third, the 
samples were stained with fluorescence labeled surface markers (FITC Mouse Anti-Human 
CD18, PE-Cy™ 5 Mouse anti-human CD11b / Mac-1 and FITC anti-CD177). Therefore, 20 µl 
of the antibodies were added for 45 min in the dark at 4 °C. Finally, the cells were washed 
again and the cell pellet was resuspended in 500 µl PBS/10% FBS and analyzed by flow 
cytometry. In addition, an isotype control was analyzed to define a proper gate.  
By flow cytometry, 10 000 events were analyzed in an BD Accuri C6 flow cytometer (BD 
Biosciences) using the FL-1 (for FITC detection) and the FL-3 (for PE) detector filters. 
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2.1.5 Apoptosis assay 
During the establishment of an optimal apoptosis assay different assays were tested: first the 
Nicoletti assay was tested [93, 94], second a method was tested designated Annexin V 
apoptosis assay.  
2.1.5.1 The Nicoletti assay 
The Nicoletti assay is based on the detection of DNA laddering as it occurs at the late stage 
of apoptosis. DNA laddering can be detected by the fluorescent dye propidium iodide (PI), 
which intercalates into DNA. Flow cytometry allows the quantification of cells undergoing late 
stage apoptosis. The Nicoletti assay was carried out based on the assay described by 
Riccardi and Nicoletti [94]. 
The Fas sensitive cell line Jurkat was used for the apoptosis assay. Jurkat cells are robust 
suspension cells that are sensitive to Fas signalling and are widely used to quantify FasL-
mediated apoptosis. As negative control a Fas deficient cell line Jurkat DD3 was used [81, 
82]. As well freshly isolated neutrophils were tested. 
500 µl of Jurkat cells or neutrophils, in a concentration of 2 × 106 cells/ml in cell culture 
medium (RPMI 1640 20 mM HEPES, 10 % FBS, 4 mM L-Alanyl-L-Glutamin, 1 % 
Penicillin/Streptomycin) were transferred into a 96-well microtiter plate (MTP). In case that 
wells were previously coated with the anti-FasL molecules cell culture medium was added. In 
the other case soluble anti-FasL molecules were dissolved in cell culture medium. The 
samples were incubated for 16-24 h in an incubator at 37 °C. The samples were tested in 
duplicates. 
When anti-FasL molecules were coated to 96-well MTP, 100 µl (1 µg/ml in PBS) were coated 
for 4 h at RT. After incubation, the wells were washed three times with 300 µl PBS. Then, 
unspecific binding sites were blocked with 5 % HSA (Biotest) in PBS for 1 h at RT. After 
incubation, the wells were washed three times with 300 µl PBS. Then, the wells were 
incubated with 250 µl cells (cEnd= 1 × 10
6 cells/ml) for 16-24 h at 37 °C. 
When soluble anti-Fas molecules were used, 250 µl cells (cEnd= 1 × 10
6 cells/ml) were 
incubated with 250 µl anti-Fas molecules at different concentrations for 16-24 h at 37 °C.  
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After the incubation, the cells were transferred to 5 ml FACS-tubes. The cells were 
centrifuged for 5 min at 209 x g at RT and the supernatant was discarded. Cells were 
washed in 500 µl ice-cold PBS and centrifuged (209 x g, 5 min, RT). Cells were fixed 
dropwise with 500 µl ice -cold ethanol (70 %) and incubated for 15 min on ice. Then the 
ethanol was removed completely by centrifugation (409 x g, 5 min, RT). Cells were washed 
twice in 500 µl ice-cold PBS and centrifuged (209 x g, 5 min, RT). The pellet was 
resuspended in 200  µl ice-cold Nicoletti-Staining solution (50 µg/ml propidium iodide, 0.1 % 
Triton X-100, 5 µg/ml RNase A in 38 mM sodium citrate) and incubated for 2 h on ice for 
staining the cells. Then, 300 µl PBS was added and the samples were vortexed for 5 s. The 
samples were analyzed via BD Accuri C6 flow cytometer (BD Biosciences), whereby PI was 
determined with a 585 nm filter. 10 000 events with a medium flow rate for the Jurkat cells 
and 5000 events for neutrophils were analyzed in a defined gate in the forward site scatter. 
All samples were normalized to the untreated negative control. 
 
 
 
 
 
 
 
Figure 2-2. Example of flow cytometric analysis of apoptotic cells stained with PI. 
The G1 population or the diploid nuclear fragments (2n) show a stronger PI signal than the sub-G1 
peak, which includes the apoptotic hypodiploid nuclear fragments (< 2n, see gate). The percentage of 
hypodiploid nuclear fragments is evaluated by gating.  
 
2.1.5.2 The Annexin V assay 
The Annexin V assay is based on the phenomenon that cells undergoing apoptosis in the 
early phase exhibit modifications in their cell membrane. This modification can be detected 
by fluorescently labeled Annexin V. The addition of PI allows the differentiation between early 
and late stage apoptosis. In the late stage apoptosis, the cell membrane becomes porous 
and the cell can be identified by Annexin V and PI in the flow cytometer. 
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In apoptotic cells the phospholipid phosphatidylserine (PS) is translocated from the inner to 
the outer leaflet of the plasma membrane. Annexin V is a 35-36 kDa calcium-dependent 
phospholipid-binding protein and has a high affinity to PS. Therefore, it binds to cells with PS 
on the outside of the plasma membrane. When Annexin V is conjugated to fluorochromes 
such as Fluorescein isothiocyanate (FITC),  it can be detected via flow cytometry [95]. 
 
Figure 2-3. Schematic illustration of the externalization of phosphatidylserine. 
By induction of apoptosis, the phospholipid phosphatidylserine (PS) is flipped from the inner to the 
outer leaflet of the plasma membrane. Annexin V, a calcium-dependent phospholipid-binding protein, 
has a high affinity to PS and can bind to PS on the outside of the plasma membrane. When Annexin V 
is conjugated to fluorochromes such as FITC it can be detected via flow cytometry (modified by [95]). 
 
After the overnight incubation, the samples were transferred from the MTP to 1.5 ml 
Eppendorf tubes and centrifuged (300 x g, 5 min, RT). The supernatant was discarded and 
cells were washed with 0.5 ml ice-cold PBS, centrifuged again (300 x g, 5 min, RT) and the 
supernatant was discarded. This washing step was performed again to completely remove 
the cell culture medium. During the washing process the cells were kept on ice. 
To analyze the samples by flow cytometry, the cells were stained via the Annexin V FITC 
Apoptosis Detection Kit (BD Biosciences) according to the manufacturer instructions. For this 
purpose, the pellet was resuspended in 100 μl of binding buffer (1x) and 5 μl of Annexin V 
and 5 µl of PI. Then, the samples were incubated for 15 min on ice in the dark. In order to 
compensate the two different fluorochromes four untreated controls were stained as 
followed: one was not stained, one was stained with Annexin V, one was stained with PI and 
one was stained with Annexin V and PI. By these controls a compensation factor for the 
fluorescence channels 1 and 2 of the fluorescent dyes FITC and PI was determined. 10 000 
events with a medium flow rate for the Jurkat cells and 5000 events for neutrophils were 
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analyzed in a defined gate in the forward site scatter with the BD Accuri C6 flow cytometer 
(BD Biosciences). All samples were normalized to the untreated negative control. 
2.1.6 Chemotaxis assay 
The chemotaxis assay is based on the migration activity of neutrophils and represents an 
early event in neutrophil activation. Chemotactic activity is important for the transepithelial or 
transendothelial migration from the blood into solid tissue. When the chemotactic activity is 
reduced by any intrinsic or extrinsic factor, the pro-inflammatory response is largely limited. 
Therefore, it is an important assay in this work. 
Indeed, agonistic anti-Fas CH11 impaired spontaneous or interleukin-8 (IL-8) mediated 
chemotaxis of neutrophils as reported previously [5, 53]. The experimental set-up is shown 
schematically in Figure 2-4. Transwell chambers are used that allow the spatial segregation 
of cell culture medium with IL-8 in the lower compartment and the neutrophils in medium 
without IL-8 in the upper compartment. The bottom of the transwell inserts is porous with a 
pore size of 3 µm diameter. Neutrophils are attracted by the IL-8 gradient and start to migrate 
within minutes through the pores of the transwells towards the higher IL-8 concentration. 
After one hour, the neutrophils in the lower compartment can be quantified and the number 
of cells is a measure for the activity of a given neutrophil population by flow cytometry. 
 
 
Figure 2-4. Schematic representation of the chemotaxis chamber. 
The chamber is divided into two compartments: the upper compartment contains the neutrophil 
suspension, the lower compartment contains cell culture medium (negative control) or cell culture 
medium with the chemoattractant IL-8. Between the two compartments there is a porous membrane 
with a pore size of 3 μm. The neutrophils can actively migrate through the pores and after 1 h 
incubation the neutrophil suspension in the lower compartment is analyzed by flow cytometry. 
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In this setting, the anti-Fas molecules were incubated with the neutrophils before the 
chemotaxis assay was performed. For this purpose, 600 µl of the isolated neutrophils  
(1 - 1.5 × 106 cells/ml) were mixed with 600 µl of anti-Fas molecules in several 
concentrations (4 ng/ml - 40 ng/ml). In the controls, cell culture medium is used instead of 
cell suspension. The samples were incubated from 0.5 h to o/n at 37 °C depending on the 
experimental setup. The 1:1 mixture halves the end concentration of the cell suspension and 
the anti-Fas molecule solution. 
When using coupled anti-Fas molecules, the anti-FasL molecules were coupled as described 
in 2.2.6. 500 μl of cell suspension (1 × 1.5 × 106 cells/ml) were added to each coated well. To 
bring the cells into the spatial proximity of the coupled molecules, the MTPs were centrifuged 
for 5 min at 300 x g and incubated from 0.5 h to o/n at 37 °C. 
After incubation, the cell suspensions were transferred to FACS tubes and the cell count is 
determined. 100 μl of the samples were diluted 1:5 with cell culture medium and 5 μl of the 
sample were analyzed by flow cytometer to calculate the cell concentration.  
To test the vitality of the samples, PI was mixed to the cell suspension. 200 μl of the cell 
suspension used for the cell number determination was mixed 1:1 with PI solution (50 µg/ml) 
(0.1 - 0.15 × 106 cells/ml). The cell number determination and the vitality test before the 
addition of the cell suspension to the chemotaxis chamber is necessary to ensure that 
sufficient cells are present for the following cell number determination (> 0.5 × 106 cells/ml) 
and are also vital (> 60 % cell viability). 
Then, 1 ml of pure cell culture medium or medium with IL-8 additive (25 ng/ml) were added 
into the lower compartment of the chemotaxis chamber, 500 μl of cell suspension with 
different pre-incubation with anti-Fas molecules were added to the upper compartment. Then 
the samples were incubated for 1 h at 37 °C. 
Finally, the contents of the lower compartments were transferred to a FACS tube and 25 μl of 
the samples were measured with the BD Accuri C6 flow cytometer (BD Biosciences). The 
number of events in the previously determined gate was counted. A vitality test was carried 
out after the chemotaxis incubation as well. All samples were normalized to the untreated 
negative control for each group (with and without IL-8), respectively. 
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2.1.7 Differential scanning fluorimetry (DSF) 
Differential scanning fluorimetry (DSF) is an assay to monitor melting profiles of proteins via 
the fluorescent dye SYPRO Orange. In an aqueous environment of a correctly folded protein, 
the signal of SYPRO Orange is attenuated, by thermal unfolding of the protein, the dye can 
interact with the hydrophobic sides of the unfolded protein, which results in an enhancement 
of the fluorescent signal of the dye. Further unfolding results in protein aggregation, thus the 
dye dissociates from the protein and the fluorescence signal decreased [96]. 
The resulting melting curve delivers the melting temperature (Tm) of the protein, which can be 
calculated using a sigmoidal Boltzmann equation. 
The anti-Fas molecules were diluted in a 1:100 dilution of SYPRO Orange (5000 x stock 
solution) in PBS to different concentrations (18.75 µg/ml to 90 µg/ml) depending on the 
availability of each protein. 
For each sample 20 μl solution was added to a 96 well q-PCR plate (BioRad) and centrifuged 
briefly for 1 min at 500 rpm at 4 °C (Megafuge 1R, Heraeus). The samples were analyzed 
according to the parameters in Table 2-8 in the real-time Polymerase Chain Reaction (q-
PCR)-Cycler (BioRad). 
 
Table 2-8. Settings of DSF measurement 
Settings  
Repeats 141 
Start temperature 25 °C 
Interval duration 10 s 
Temperature increase 0.5 °C 
Final temperature 95 °C 
Measuring time in total 55 min 
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 Results 2.2
The selection of a suitable anti-Fas molecule is the crucial issue of this chapter. Not only the 
functionality of the molecule is important for the design of an anti-inflammatory coating, but 
as well the stability and the availability in GMP quality of the molecule is very important. To 
reach these goals, different assays were established. The purity of isolated neutrophils was 
investigated to ensure reproducible results. Neutrophils were used in a chemotaxis assay to 
investigate the influence of the anti-Fas molecules to the neutrophils. To demonstrate the 
efficiency of the molecules an apoptosis assay was developed with the Jurkat cell line and 
neutrophils. The thermal stability of each molecule was determined as well. 
2.2.1 Purity of isolated neutrophils 
Neutrophils are sensitive cells and always have to be isolated freshly from human blood. 
Therefore, it is important to guarantee a consistent quality. Before neutrophil isolation, fresh 
blood sampling from healthy donors was performed. Thereby, EDTA, citrate and heparin are 
mostly used to inhibit blood clotting after blood sampling for clinical analysis in vitro. But it is 
known that blood cells behave different by using different anticoagulants during collection.  
Thus, before the selection of the anticoagulant a literature research was performed and the 
findings may be summarized as follows: as EDTA is a chelating agent for Ca2+ and other 
bivalent cations and citrate as well interferes with Ca2+ levels, these anticoagulants affect the 
respiratory burst of neutrophils, which is associated with intracellular Ca2+ concentrations. 
Freitas et al. (2008) investigated the influence of EDTA, citrate and heparin with the result 
that by use of EDTA the highest yield of isolated neutrophils could be observed, whereby the 
isolation by citrate and heparin was lower.  
On the other hand the respiratory burst induced by phorbol myristate acetate (PMA) was 
drastically reduced by EDTA, whereby citrate and heparin were twice as high. The 
intracellular Ca2+ concentration was highest in the heparin pre-treated sample [97]. Each 
anticoagulant has advantages and disadvantages, e.g. heparin leads to more aggregation 
and the layer during density centrifugation is more difficult to separate [97]. But in this work 
heparin was chosen as the best option. In the following chapters the heparin concentration 
during blood sampling was decreased as far as possible from 16 U/ml to 5 U/ml to decrease 
unwanted side-effects. 
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In the first step, the neutrophils were isolated via PolymorphprepTM and stained via 
Pappenheim staining. Figure 2-5 shows the characteristic morphology of hemocytes, 
whereby erythrocytes appear reddish without nuclei, the cytoplasm of the monocyte appears 
grey-blue, the granules of neutrophils appear light violet and the polymorph nucleus appears 
blue-violet. In Figure 2-5 A blood smear of whole blood is shown, with many erythrocytes, 
one monocyte and two neutrophils. After isolation of neutrophils a pure population of isolated 
neutrophils with their characteristic polymorph nuclei was shown in Figure 2-5 B.  
A             B 
                       
 
 
 
 
 
Figure 2-5. Images of blood smear stained via Pappenheim staining. 
A Image of blood smear of whole blood stained with Pappenheim staining kit. B Image of blood smear 
of isolated neutrophils stained with Pappenheim staining kit to confirm the high purity of the population 
used in the functional experiments.  
Neutrophils and monocytes have a similar cell shape, why the separation via 
PolymorphprepTM is not entirely pure. To obtain a pure neutrophil population analysis via flow 
cytometry were carried out. The neutrophil population was identified via fluorescence-labeled 
antibodies analyzed by flow cytometry. Three different surface markers were identified, which 
are common on neutrophils: the cluster of differentiation (CD) 11b, CD18 and CD177.  
CD11b, an adhesion glycoprotein, interacts with CD18 (integrin β2), which results in the 
CD11b/CD18 complex. CD11b is expressed on activated lymphocytes, monocytes, 
granulocytes and a subset of natural killer cells, whereby CD18 is expressed on 
lymphocytes, monocytes and more weakly on granulocytes. The complex is important to 
form cell-cell contacts e.g. during inflammation and is known to be highly expressed during 
neutrophil activation [98]. Another surface protein which is specific for neutrophils is the 
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CD177, a glycosyl-phosphatidylinositol-anchored receptor, which is expressed on circulating 
neutrophils in healthy humans [92, 99, 100]. 
Neutrophil cell surface staining with markers detecting CD11b, CD18, and CD177 was done 
to confirm the neutrophil population by flow cytometry (Figure 2-6). In the dot plots (Figure 
2-6 B) the samples show two point clouds, which show the neutrophil population and a mixed 
population of erythrocytes and monocytes, respectively.  
Figure 2-6 A shows that CD177 is a suitable marker to specifically detect neutrophils (green 
dots), whereas CD11b (red dots) and CD18 (orange dots) are expressed on granulocytes 
and also on some monocytes, respectively. The black dots in the dot plots indicate residual 
erythrocytes. The neutrophil point clouds were gated in the dot plots, which results in a pure 
neutrophil population for further analysis. 
 
 
Figure 2-6. Flow cytometry analysis histograms and dot plots. 
Neutrophils were isolated via Polymorphprep
TM
 and afterwards labeled with specific surface markers 
CD177 in green, CD11b in red and CD18 in orange. In A the histograms and in B the dot plots are 
shown. All dot plots show a specific labeled neutrophil population with some residual monocytes 
(labeled as well with the surface markers) and a big population of residual erythrocytes in black. The 
histograms show the percentage labeled cells for the whole sample. 
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2.2.2 Results of Nicoletti assay in solution with Jurkat cells 
As the Nicoletti assay is based on the detection of DNA laddering as it occurs at the late 
stage of apoptosis, DNA laddering can be detected by the fluorescent dye propidium iodide 
(PI), which intercalates into DNA. As DNA laddering is the last step in apoptotic cells, flow 
cytometry allows only the quantification of cells undergoing the late stage of apoptosis.  
To establish the Nicoletti assay only two model anti-Fas molecules were tested in Jurkat wild 
type (wt) and Fas deficient DD3 cell lines. The result is shown in Figure 2-7. The Jurkat DD3 
cells show low kill-rates < 5 %, whereas the wild type cells shows concentration dependent 
kill-rates, whereby 10 ng/ml SuperFasL indicates medium kill-rates of 36.6 ± 20.1 % and 
10 ng/ml CH11 only 13.3 ± 2.2 %. The concentrations were determined due to earlier 
experiments and due to manufacturer information. 
 
Figure 2-7. Results of Nicoletti assay with Jurkat cells. 
Apoptosis was induced by incubation of Jurkat cells o/n with different concentrations of SuperFasL 
and CH11 in Jurkat wt and Jurkat DD3. The kill-rate was normalized to untreated sample (Mean ± SD 
from n=2). 
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Figure 2-8. Flow cytometric dot plot and histogram of Nicoletti assay. 
A Dot plots (FSC-A/FL1-A) of different treated Jurkat cells stained with PI. The three gates indicate 
three populations in different cell cycle stages. B Histograms of different treated Jurkat cells stained 
with PI. The gate indicates the apoptotic nuclei. C Apoptosis was induced by incubation of Jurkat cells 
o/n with different concentrations of SuperFasL, MegaFasL, Fc-FasL, CH11 and Fc-April (negative 
control, TNFSF13). The kill-rate was normalized to untreated sample (Mean ± SD from n=2). 
 
In Figure 2-8 the results of all pre-selected anti-Fas molecules, except the E09, are shown, 
whereby in the dot plots the different gates define the different stages of cell cycle with 
different DNA content. Gate 1 defines the apoptotic cells with a DNA content < 2n, whereby 
gate 2 defines the normal cells with a DNA content of 2n. The gate 3 shows normal cells with 
higher DNA content due to the different cell cycle phases. In the histograms the cell count is 
plotted to fluorescent intensity and shows the different DNA content of the cells. It is divided 
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from left to right in the sub-G1 apoptotic peak (hypo diploid DNA < 2n), the G0/G1 phase peak 
with normal diploid DNA content, the S phase peak (> 2n) and the G2/M phase peak (4n) 
followed by peaks with cells with higher DNA content than 4n [93, 94]. The effect of the pro-
apoptotic anti-Fas molecules as shown in the previous experiment is not shown here. All 
anti-Fas molecules induce low apoptosis rates in a concentration independent manner to 
Jurkat cells as shown in Figure 2-8 C. 
Due to these inconsistent results of the Nicoletti apoptosis assay, the next experiments were 
carried out with the Annexin V apoptosis assay as described in the next section.  
2.2.3 Results of Annexin V assay in solution with Jurkat cells 
Figure 2-9 shows the results of the Annexin V assay carried out with all pre-selected anti-Fas 
molecules in Jurkat wt. By plotting the fluorescence channels of FITC (FL1) and PI (FL2) 
against to each other, the different cell stages are located in the different quadrants: 
quadrant 1 low left (Q1-LL) shows the living cells, Q1 upper left (Q1-UL) shows the cells 
undergoing necrosis, Q1 upper right (Q1-UR) shows late apoptotic cells and Q1 lower right 
(Q1-LR) shows early apoptotic cells. The incubation of anti-Fas molecules induces apoptosis 
in Jurkat cells and leads to a shift from Q1-LL to Q1-LR and Q1-UR (Figure 2-9 B). After an 
overnight incubation of untreated Jurkat cells 14.4 % cells died. Thus, this number changes 
slightly, all results in his work were normalized to the negative control for comparison of 
different experiments.  
To investigate the efficiency of the pre-selected effector molecules the Annexin V assay was 
chosen to determine the optimum concentration of each molecule to induce apoptosis in 
Jurkat cells. As depicted in Figure 2-9 C, the molecules SuperFasL, Fc-FasL, MegaFasL and 
CH11 induced apoptosis in a concentration dependent way. Therefore, the well reported 
feature of the SuperFasL, Fc-FasL and MegaFasL to induce apoptosis via Fas signalling was 
demonstrated. Interestingly, MegaFasL was highly efficient at 2 ng/ml whereas the other 
molecules required more than 5-fold concentrations. The Fc-FasL molecule showed the 
highest apoptosis induction, but at these high concentrations the Fas deficient cell line Jurkat 
DD3 shows high apoptosis rates as well (data not shown). This unspecific apoptosis 
induction is generally not appreciated, but Fc-FasL is known to kill highly efficient at high 
concentrations.  
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Figure 2-9. Flow cytometric dot plots and histograms of Annexin V assay. 
A Dot plots (SSC-A/FSC-A) of different treated Jurkat cells stained with Annexin V / PI. The three 
gates indicate three populations in different cell cycle stages. B Histograms of different treated Jurkat 
cells stained with Annexin V / PI and gated with Gate 1. C Apoptosis was induced by incubation of 
Jurkat cells o/n with different concentrations of SuperFasL, MegaFasL, Fc-FasL, IgG E09, IgM CH11 
and Fc-April (negative control, TNFSF13). The kill-rate was normalized to untreated sample (Mean ± 
SD from n=2). 
 
The goal was to reach more than 20 % of apoptotic cells after o/n incubation with the soluble 
effector molecules. This could be reached with all effector molecules (Figure 2-9 A), except 
the IgG1 E09 for unknown reasons (Figure 2-9 B). 
C7 
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Although the IgG E09 has been reported to efficiently induce apoptosis [60], we were not 
able to confirm this finding even by using high concentrations. Thus, the IgG E09 failed to 
induce strong apoptosis and therefore was not further evaluated. 
2.2.4 Results of Annexin V assay with soluble and immobilized effector molecules 
with neutrophils 
In another set of experiments, the two variants of the MegaFasL (MegaFasL and APO010) 
were compared in their efficacy to induce apoptosis in human neutrophil suspensions. The 
molecular structure of MegaFasL and APO010 is similar, but the MegaFasL has a human 
FasL (aa 139-281) which is fused at the N-terminus to mouse ACRP30 headless (aa 18-111) 
and a FLAG®-tag and it is available for in vitro use only. To use it in clinical studies the 
APO010 was designed with a human sequence instead of the mouse sequence and the 
FLAG®-tag was removed. Figure 2-10 A depicts the results of the Annexin V apoptosis assay 
after neutrophil incubation with soluble MegaFasL and APO010. Interestingly, the efficacy of 
2 ng/ml of APO010 was comparable with 20 ng/ml of MegaFasL. 
A              B 
 
Figure 2-10. Results of Annexin V Apoptosis assay with neutrophils. 
A Apoptosis was induced by incubation of neutrophils with different concentrations of MegaFasL and 
APO010 in solution. The kill-rate normalized with untreated sample is shown (n=3). B Apoptosis was 
induced by incubation of neutrophils with (1 µg/ml in PBS) Fc-FasL, MegaFasL and SuperFasL coated 
to a MaxiSorp plate for 4 h at RT. The kill-rate was normalized to untreated sample (Mean ± SD from 
n=3). 
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In the experiments with immobilized anti-FasL molecules, the effector molecules were coated 
on MaxiSorp plates in saturation and the coupling efficiency was detected by ELISA. As 
shown in Figure 2-10 B, all coupled test molecules were able to induce apoptosis in 
neutrophils. The kill-rates were around 80 % to 90 % for SuperFasL and MegaFasL and 
about 40 % for Fc-FasL (Figure 2-10 B). However, it shall be noted here, that the 
immobilization of the anti-Fas molecules is not covalent. This means, some of the attached 
anti-Fas molecules can be detached from the MaxiSorp plate during the incubation with the 
cells. Therefore, this approach allows only to determine a trend. As a conclusion, MegaFasL 
and SuperFasL were superior in eliciting functional apoptosis and seem to be more suitable 
for the coating than Fc-FasL. 
In summary, the apoptosis assay was established successfully and the goal to induce 
apoptosis in more than 20 % of target cells was reached for the recombinant proteins Fc-
FasL, MegaFasL/APO010 and SuperFasL and for the IgM CH11. The IgG E09 failed to 
efficiently induce apoptosis and therefore was not further considered in this work. The CH11 
served as control to compare the efficacy of the molecules in the apoptosis assays and was 
not evaluated further. 
2.2.5 Results of chemotaxis assay with anti-Fas molecules in solution 
For the chemotaxis assay, neutrophils were incubated with anti-Fas agonistic molecules for 
different times.  
Figure 2-11 A compares the different inactivation efficacies in chemotaxis between Fc-FasL, 
SuperFasL and MegaFasL after normalization to the negative control. A control group 
without IL-8 was included to differentiate between spontaneous and stimulated chemotaxis. 
To compare the different neutrophil activities with each other, both groups were normalized 
to the untreated negative control, respectively.  
The group without IL-8 showed lower neutrophil activities than with IL-8, but the tendency 
that incubation with the anti-Fas molecules reduces neutrophil activity was demonstrated in 
both groups. Thus, the MegaFasL and Fc-FasL (20 ng/ml) efficiently inactivated the 
neutrophil chemotaxis (> 90 %), whereby SuperFasL even at high concentration (20 ng/ml) 
inactivated the neutrophil chemotactic activity by approximately 50 % in the group with IL-8. 
The largest inactivation effects were obtained with MegaFasL with almost 100 % inactivation 
with the highest (20 ng/ml) and medium (10 ng/ml) concentration. With the lowest 
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concentration of MegaFasL (2 ng/ml) the chemotactic activity was reduced approximately 2.5 
fold.  
In addition, the two MegaFasL variants were compared in their efficacy with each other to 
reduce chemotactic activity in neutrophils (Figure 2-11 B). Here again, it becomes apparent 
that even the 2 ng/ml APO010 could inhibit chemotactic activity by approximately 90 %. In 
these experiments 20 ng/ml MegaFasL was used as a benchmark (99 % reduction of 
neutrophil chemotaxis).  
 
 A               B 
 
 
 
 
 
 
 
 
 
Figure 2-11. Results of chemotaxis assay. 
A Neutrophils were incubated o/n with Fc-FasL (20 ng/ml) SuperFasL (20 ng/ml) and MegaFasL 
(20 ng/ml, 10 ng/ml and 2 ng/ml) in solution. Afterwards, neutrophils were transferred to chemotaxis 
inserts and incubated      
B Neutrophils were incubated o/n with MegaFasL (20 ng/ml) and APO010 (20 ng/ml, 2 ng/ml). 
Afterwards, neutrophils were transferred to chemotaxis inserts and incubated for 1 h. Analysis was 
carried out by flow cytometry. The kill-rate was normalized to untreated sample (Mean ± SD from n=2). 
 
2.2.6 Results of neutrophil inactivation by immobilized anti-Fas molecules 
Similar to the experiments described for soluble incubation of neutrophils with the anti-Fas 
molecules, experiments were done with neutrophils and immobilized agonistic molecules on 
MaxiSorp cell culture plates. The concentrations of the effector molecules were defined to be 
10-fold higher compared with the concentrations used in liquids, because only approximately 
10 % of the soluble effector molecules may be stably coupled to the MaxiSorp plate. This 
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means, 200 ng/ml coating solution refers to 20 ng/ml coupled effector molecules to MaxiSorp 
plate. After incubation for different time intervals, neutrophils were transferred to the transwell 
chambers. For each time point, a separate negative control was included, including 
neutrophils incubated in the same plate, but without immobilized agonistic molecules. To 
compare the different neutrophil activities with each other, the samples were normalized to 
the untreated negative control, respectively. 
In Figure 2-12, the chemotactic activity of neutrophils, which were incubated for up to 9 h, 
with MegaFasL is depicted. It shows that after 1 h incubation the chemotactic activity 
decreases by 40 %, whereas MegaFasL reduces neutrophil activity after 6 h by 64 % and 
after 9 h by 79 %. Therefore, the immobilized MegaFasL can efficiently reduce neutrophil 
activity. However, there is a huge variation from 20 % to 80 % in reduction of chemotactic 
activity due to the very sensitive neutrophils used in this model and two different donors. 
Samples from 1 h to 2 h were from the same donor, whereas the samples 6 h to 9 h were 
from another donor (see Figure 2-12). 
 
Figure 2-12. Results of chemotaxis assay with coated MegaFasL. 
Neutrophils were incubated for different times with coated (200 ng/ml coating solution refers to 
20 ng/ml coupled effector molecules to MaxiSorp plate) MegaFasL. Neutrophils were transferred to 
chemotaxis inserts and incubated for 1 h. Analysis was carried out by flow cytometry. Samples from 
1 h to 2 h were from the same donor, whereas the samples 6 h to 9 h were from another donor. The 
kill-rate was normalized to untreated sample (Mean ± SD from n=2). 
 
 
 Chapter II: Selection of a suitable anti-Fas molecule, which can be used for the anti-
inflammatory coating 
 
 
 
42 
 
2.2.7 Evaluation of molecular stability 
The thermal stability of each test molecule was systematically analyzed by differential 
scanning fluorometry (DSF). This is an important criterion for the determination of stability 
during storage at elevated temperatures and terminal gas sterilization with EtO at elevated 
temperatures. In general, antibodies, like IgG, have two melting points: one for the 
temperature sensitive Fab-region (Tm1) and one for the more pH sensitive Fc-region (Tm2) 
[101]. Monomeric proteins regularly have one melting point. 
 
A        B 
 
 
 
 
 
 
 C        D 
 
 
 
 
 
 
Figure 2-13. Stability tests by differential scanning fluorimetry (DSF).  
Normalized melting point curves of anti-Fas molecules at different concentrations are shown. A IgM 
CH11 (0.09 mg/ml in PBS), B IgG1 E09 (0.09 mg/ml in PBS), C Fc-FasL (0.075 mg/ml in PBS), D 
MegaFasL (0.0375 mg/ml). Different concentrations were used due to material availability (n=3). 
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In Figure 2-13 the melting curves are shown. The CH11 IgM and the E09 IgG1 antibodies 
exhibit two mean points of thermal degradation, whereby E09 IgG1 is more stable than CH11. 
The Fc-FasL curve is similar to IgG antibodies because of its fused Fc-domain. The second 
melting point of Fc-FasL is missing due to the missing Fab domain. The Tm1 of Fc-FasL is 
similar to the Tm1 of E09. The melting point of MegaFasL was the highest with 81.74 °C and 
thus, MegaFasL is extremely stable at elevated temperatures. SuperFasL could not be 
analyzed due to low quantities tested. In Table 2-9 the melting points are summarized. 
 
Table 2-9. Overview of mean melting points of FasL molecules 
FasL molecule Concentration [µg/ml] 
 
Melting point [°C] 
IgM CH11 90 Tm1 67.39 
 
90 Tm2 72.42 
IgG1 E09 90 Tm1 68.56 
 
90 Tm2 81.65 
Fc-FasL 75 Tm1 68.62 
 
75 Tm2 82.10 
MegaFasL 37.5 Tm 81.56 
SuperFasL 18.75 Tm - 
 
An advantage for the monomeric protein MegaFasL is the high thermal resistance. In 
contrast, the tested molecules with Fab- and Fc-domains (CH11, E09, Fc-FasL) showed 
thermal instability due to the more instable Fab-region in case of the CH11 and the E09. The 
Fc-FasL is more instable due to the fusion of the two protein sequences.  
In conclusion, regarding thermal stability, the MegaFasL proved to be the most suitable 
molecule for the use in anti-inflammatory coating in medical devices undergoing terminal 
sterilization at elevated temperatures as it is the case in EtO sterilization procedures.  
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2.2.8 Summary 
The goals of the first part of this project can be summarized as follows: the read out models 
for apoptosis and neutrophil activity have been established. Soluble and immobilized effector 
molecules were systematically evaluated on their potential to induce apoptosis and to reduce 
neutrophil activity. Except the E09 antibody, each anti-Fas molecule induced apoptosis in 
> 20 % of target cells and impaired neutrophil activity in > 10 % of target cells. Therefore, the 
goals defined in Chapter 1 were reached. The APO010 is the most suitable molecule due to 
the availability and already existing Good Manufacturing Practice (GMP) quality. In addition, 
clinical safety data for systemic application are available [102, 103].  
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 Discussion 2.3
The selection of the most efficient anti-Fas molecule was the prerequisite for the further 
design of the anti-inflammatory coating. Thereby, an assay had to be chosen and adapted to 
evaluate these molecules. 
As neutrophils and monocytes express a low level of Fas on their cell surface [56] the 
specific inactivation of neutrophils due to anti-Fas molecules is characterized by the fact that 
neutrophils roll along the endothelial cells. This is mediated by expressed selectins until 
integrins lead to a tight adhesion [26]. Monocytes do not have this behavior and therefore are 
not the main targets for material-mediated immune responses.  
Therefore, in the first step, a neutrophil isolation method was chosen and the purity of the 
cells was analyzed. It was possible to define a pure neutrophil population by flow cytometry 
after defined gating via different neutrophil specific surface markers. These findings were 
confirmed by the characteristic cell staining by Pappenheim, which leads to a 
polymorphonuclear staining of the neutrophils.  
Before neutrophil isolation, fresh blood sampling from healthy donors was performed. To 
inhibit blood coagulation heparin was selected as the most suitable anticoagulant with the 
lowest influence in neutrophil behavior. The separation during neutrophil isolation is more 
difficult with heparin or citrate than with EDTA [97], but the presence of erythrocytes and 
monocytes is acceptable due to the flow cytometry method, which can gate the specific 
neutrophil population. An additional hemolysis step is undesirable, because it may lead to an 
activation of neutrophils. 
 
The efficiency of the anti-Fas molecules to induce apoptosis in the model cells lines Jurkat wt 
and Jurkat DD3 was successful for the so called Annexin V assay. The Nicoletti assay shows 
more variations in the results when using incubations times shorter than 24 h. The DNA 
laddering in the Nicoletti assay needs probably the full 24 h, therefore the defined incubation 
range of 16 h to 24 h was set too wide. Usually an incubation time of 18 h was applied. The 
incubation time for the Nicoletti assay was not optimized, because of the successful results 
of the Annexin V assay. In addition, the Annexin V assay provides more information due to 
the application of two markers for early and late apoptosis and it delivers more reproducible 
results. Therefore, only the Annexin V assay was further used in this work.  
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All pre-selected anti-FasL molecules resulted in apoptosis rates higher than the untreated 
sample. However, the IgG E09 showed very similar results compared to the untreated 
sample independent of the concentration used. The molecules SuperFasL, Fc-FasL, and 
MegaFasL induced apoptosis in a concentration dependent way. They demonstrated 
efficiently apoptosis rates in low concentration for up to 93 % for Fc-FasL (10 ng/ml), 
followed by SuperFasL (66 %, 10 ng/ml), MegaFasL (65 %, 2 ng/ml) and CH11 (31 %, 
10 ng/ml). Thus, the MegaFasL was the most efficient anti-FasL molecule at low 
concentrations of 2 ng/ml, whereas the other molecules required more then 5-fold 
concentrations. Also Fc-FasL was very effective in Jurkat wt and was able to induce even in 
the Fas sensitive Jurkat DD3 an apoptosis signal. Fc-FasL needs to be applied in higher 
concentrations than MegaFasL, which results in higher costs. On the other hand, Fc-FasL is 
easier to produce than the hexamer MegaFasL [59]. 
The IgG E09 was reported from Chodorge and his colleagues (2012) as to be comparably 
effective as the natural FasL. Here, it demonstrated low apoptosis rates of less than 10 %. 
They predict E09 as an antibody with partially fast dissociation from Fas and therefore the 
possibility to recruit with the free Fab arm new Fas monomers to create an active signaling 
complex [60]. It is likely that E09 has to be cross-linked in this approach in order to elicit its 
activity to trimerize the Fas receptor. Only trimerization of the Fas receptor leads to an 
intracellular apoptosis signal and therefore is necessary in this approach. Since cross-linking 
as an additional coating step is not appreciated, E09 did not reach sufficient priority to be 
further evaluated.  
The MegaFasL was one of the most efficient molecules and has already been further 
developed for anti-tumor treatment in humans [102, 103]. This adapted molecule is called 
APO010 and is available in GMP quality. It was already investigated in non-clinical and 
clinical research. Therefore, APO010 would be the optimal molecule for the design of an anti-
inflammatory coating for medical devices. The direct comparison between MegaFasL and 
APO010 showed that apoptosis in neutrophils was induced by both molecules, whereby 
APO10 needed lower concentrations for the same result (2 ng/ml APO010 compared to 
20 ng/ml MegaFasL). Therefore, APO010 can be used instead of MegaFasL. 
When using immobilized anti-Fas molecules the kill-rates in neutrophils were around  
80 - 90 % for SuperFasL and MegaFasL and about 40 % for Fc-FasL (Figure 2-10). This 
shows that MegaFasL is one of the best molecules similar to SuperFasL. However, it is not 
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clear how meaningful these results are due to the non-covalent coupling of the molecules to 
the MaxiSorp plates. Some of the molecules may be detached from the surface and 
subsequently are more effective in solution than immobilized. Further approaches to define 
the coupling stability were investigated in chapter 3 via ELISA to quantify detached 
molecules. 
As a conclusion, MegaFasL and SuperFasL were superior in eliciting functional apoptosis 
and seem to be more suitable for the coating than Fc-FasL. 
In further experiments to investigate the ability of the anti-Fas molecules to inhibit neutrophil 
activity, chemotaxis assays were carried out. All anti-Fas molecules, the MegaFasL,  
Fc-FasL, SuperFasL and APO010, were able to efficiently inactivate the neutrophil 
chemotaxis (> 90 %) in solution, whereby the largest inactivation effects were obtained with 
MegaFasL and APO010. Interestingly, the spontaneous migration of neutrophils in the 
control group without IL-8 was reduced by incubation of the anti-Fas molecules similarly as in 
the group with IL-8. This means, that the anti-Fas molecules induce apoptosis in the 
neutrophils, which leads to an immediate inactivation of neutrophils migration. This 
inactivation of neutrophil migration indicates the ability for the anti-inflammatory effect of the 
novel coating on the medical device. By an immediate inactivation of the highly activated 
neutrophils, the preapoptotic neutrophils are detached and phagocytized by monocytes or 
macrophages and eliminated in the spleen [51]. Thus, the anti-Fas molecules inhibit tissue 
damage and inflammation in the patient.  
 
When MegaFasL was immobilized to a MaxiSorp plate it was able to decrease chemotactic 
activity of neutrophils after 1 h by 40 %, but the chemotactic activity was further decreased 
after 9 h by 79 %. Therefore, the immobilized MegaFasL can efficiently reduce neutrophil 
activity after a short time span. This makes it interesting for short time applications as 
needed in CPBs and for long time applications in oxygenators. The huge oscillation from 1 h 
up to 9 h incubation is due to two different neutrophil donors (1 to 2 h one donor, 6 to 9 h 
other donor) and due to the sensitive neutrophils, which have to be handled with care 
through the whole experiment. 
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Thermal stability of the anti-Fas molecule is an important property for a suitable molecule, 
which can be used in an anti-inflammatory coating. During the production of a medical device 
the molecule has to go through many harsh conditions, ending in a sterilization process, 
which mostly means EtO sterilization. Here temperatures of about 50 °C are occurring.  
All molecules show high thermal stability and therefore can be used for the further 
development of an anti-inflammatory coating. MegaFasL has the highest Tm value and thus is 
the most stable protein here.  
 
Table 2-10. Scoring of selection criteria  
Value (V): 1-5, Fulfillment (F): 1-10 
 
SuperFasL MegaFasL Fc-FasL E09 IgG1 CH11 IgM 
 
APO010 MegaFasL 
   
F F x V F F x V F F x V F F x V F F x V F F x V 
Apoptosis 
induction: V2 
10 20 10 20 10 20 10 20 5 10 10 20 
Neutrophil 
inactivation: 
V5 
3 15 8 40 8 40 5 25 0 0 10 50 
Specificity: V3 8 24 8 24 8 24 8 24 0 0 8 24 
Stability: V5 8 40 10 50 10 50 8 40 5 25 3 15 
Availability: V5 8 40 10 50 8 40 8 40 8 40 5 25 
Clinical safety 
data available: 
V5 
0 0 10 50 0 0 0 0 0 0 10 50 
GMP quality: 
V5 
0 0 10 50 0 0 0 0 0 0 0 0 
Total 
 
139 
 
299 
 
174 
 
149 
 
75 
 
184 
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All technical, functional, economical, and regulatory aspects relevant for the anti-
inflammatory coating using for a medical device are summarized in Table 2-10, scoring each 
criterion with different values (1-5), according to their importance and their fulfilments (1-10), 
according to the obtained results with a maximum possible value of 300. 
The apoptosis induction has a value of 2 and neutrophil inactivation has the highest value of 
5, because the inactivation is more important for the anti-inflammatory coating than the 
apoptosis itself. The specificity of the anti-Fas molecule has a value of 3, because all cells 
with Fas receptors should be inactivated by the anti-inflammatory coating. The stability, 
which was investigated in this part as thermal stability has a value of 5, but should be 
investigated further with different methods. The availability, clinical safety data availability 
and GMP quality have a value of 5, because these aspects enable a faster and more 
convenient development process.  
 
All effector molecules (CH11, SuperFasL, Fc-FasL, and MegaFasL) except the E09 were 
shown to induce sufficient apoptosis rates in Jurkat wt cells and in neutrophils. The 
trimerization of the Fas receptor on the cells is the crucial step for inducing apoptosis and 
inactivation and therefore is highly efficient. In general, CH11 was only used as a control 
because it was not the intention to select an IgM antibody for the coating. However, CH11 
has been extensively studied during the past years and thus was an ideal benchmark in the 
establishment of different experiments. The values in the scoring table are partly based on 
previous unpublished studies. The anti-Fas molecules SuperFasL, Fc-FasL, and MegaFasL 
(Table 1-1, Figure 1-5) are based on the work of Pascal Schneider and his colleagues and 
therefore have comparable structures [59]. All three molecules proved to induce apoptosis in 
neutrophils and also reduced neutrophil activity, when cells were challenged in solution and 
with immobilized molecules. MegaFasL is the only effector molecule, which has been 
evaluated in clinical studies and is available in GMP quality [103].  
Essentially, the GMP quality variant of MegaFasL, the APO010, reached the highest score 
with 299 of 300 maximum possible points, largely resulting from the criteria “GMP quality 
available” and “Clinical safety data available”. The use of APO010 in the anti-inflammatory 
coating is therefore the best option and will be further used in this work. 
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CHAPTER III 
 
DESIGN OF AN ANTI-INFLAMMATORY COATING 
 
3 Introduction 
In addition to the right selection of an anti-inflammatory molecule, its covalent coupling 
chemistry is one of the most important parts in the design of an anti-inflammatory coating.  
The direct linkage of proteins enables the most efficient strategy, however this method is 
difficult to achieve. Recombinantly produced proteins can be designed according to the 
coupling requirements. It enables a direct linkage via click chemistry or via maleimide linker. 
For example Simon et al. (2012) developed a “clickable” protein, which can be clicked to 
polyethylene glycol (PEG) using copper free click chemistry at the N-terminus. The  
C-terminal cysteine can be tagged with a fluorescent dye (Alexa-488) via maleimide linker or 
can be added to an activated surface via the maleimide linker [104]. The maximum 
functionality is expected when the protein is coupled to the surface in a way that the antigen 
specific paratope remains free to bind to the epitope. When using an unspecific coupling 
strategy, for example via the 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC) chemistry, all free amino groups of the protein to couple can undergo a covalent 
binding. 
However, before choosing a coupling chemistry, it is crucial to think about the properties of 
the surface material. For example it is important to know, if the material has to be porous or 
non-porous and if the surface material is durable in the used solvents, like acids, bases, high 
salt or organic solvents. Most surface materials need to be activated first to generate a 
covalent binding with the biomolecule. When using inorganic materials like ceramics or 
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glasses, silanization is one of the best options. It is one of the most used techniques to 
couple biomolecules to inorganic materials [105]. 
When using polyurethane (PU), poly(hydroxyethylmethacrylate) (pHEMA) is a good choice 
as coupling reagent. It is easy to polymerize and possesses hydroxyl groups that can be 
used for the immobilization of the biomolecules [106]. In addition, it serves as blocking layer, 
which is used in several medical devices such as contact lenses and is known to be 
biocompatible. PU is often used for medical devices due to its good physical and chemical 
properties. It shows higher reactivity with primary amine groups than with secondary amine, 
hydroxyl, acid, anhydride or epoxide groups [107, 108]. Therefore, as well polyethyleneimine 
(PEI), with its high number of primary amine groups, is a polymer, which can react with PU.  
Another method to couple protein to a surface is the thiol chemistry, which enables site-
specific reaction using recombinant proteins with a single C-terminal cysteine. To modulate 
the distance and therefore optimize the functional action of the biomolecule, cross-linkers 
with different spacer arms can be used.  
When using an inert material like the Polymethylpentene (PMP) or Poly(4-methyl-1-pentene), 
which is used in this work as the relevant material for the functionalization of membrane 
ventilators, it is difficult to generate a covalent coupling due to missing functional groups. 
Therefore, plasma activation can be used to modify the surface by generating functional 
groups. The modification of the material via the plasma is based on physical and chemical 
processes carried out by neutrons, electrons, positively charged ions, radicals and UV 
radiation [109]. 
By using different types of gas the modification of the material can be selected. Generally, 
O2, N2, H2O or noble gases are used. O2 generates mostly aldehyde groups, which oxidize to 
carboxyl groups. H2O generates hydroxyl, aldehyde and carboxyl groups. When noble gases 
are used, the plasma generates no oxidation processes, but cross-linking of polymer 
structures [109]. 
This chapter focusses on the finding of the right coupling strategy for the anti-inflammatory 
coating and the investigation of its functionality. 
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 Materials and methods 3.1
Table 3-1. Equipment 
Name  Reference 
Analytical balance, AT460 Delta Range Mettler-Toledo, Columbus, Ohio, USA 
Bruker Tensor 27 FTIR and  
thermostat DC30-K20 
Bruker Optics, Ettlingen, Germany 
Thermo Haake GmbH, Karlsruhe, Germany 
Centrifuge Biofuge fresco, max.13 000 rpm or 
16 060 x g 
Heraeus, Hanau, Germany 
Centrifuge Megafuge 1.0R, max. 4000 rpm or 
3345 x g 
Heraeus, Hanau, Germany 
CO2 incubator Sanyo Denki K.K, Moriguchi, Japan 
Filter holder device (diameter 25 mm, PSU) Whatmann,  Maidstone, United Kingdom 
Filter holder device (diameter 50 mm, PC) Sartorius, Göttingen, Germany 
Flexible-tube pump MCP IDEX Health&Science (ISMATEC), Wertheim, 
Germany 
Flow cytometer BD Accuri C6 BD Biosciences, San Jose, California, 
USAGermany 
Fusion photometer PerkinElmer, Inc., Waltham, Massachusetts, USA 
Incubator BINDER GmbH, Tuttlingen, Germany 
Jeol JSM-6500 F  Jeol, Tokyao, Japan 
Kruess Drop Shape Analyzer DSA25E Kruess GmbH, Hamburg, Germany 
Leica DMi8 Leica Microsystems, Wetzlar, Germany 
Micro-Centrifuge Galaxy 14 D, max. 13 000 
rpm or 14 000 x g  
VWR International GmbH, Ismaning, Germany 
Micro-Centrifuge Sprout, 2000 x g Kisker Biotech GmbH & Co. KG, Steinbach, 
Germany 
Microscope Axiovert 40C  Carl Zeiss AG, Oberkochen, Germany 
Mini-Shaker PSU-2T Biosan, Riga, Latvia 
Mini-vortexer, Vortex V-1 plus Kisker Biotech GmbH & Co. KG, Steinbach, 
Germany 
Nanophotometer 7122 V2.3.1 Implen GmbH, Munich, Germany 
Neubauer counting chamber Glaswarenfabrik Karl Hecht GmbH & Co K, 
Sondheim/Rhön, Germany 
Novex-Mini-Cell Invitrogen AG, Carslbad, California, USA 
Sterile bench Kojair, Vilppula, Finland 
Thermo-Shaker Kisker Biotech GmbH & Co. KG, Steinbach, 
Germany 
Water bath Memmert GmbH + Co.KG, Schwabach, Germany 
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Table 3-2. Biomolecules and amino acids 
Name Reference 
Alanine,L- (EP, USP) AppliChem GmbH, Darmstadt, Germany 
Anti-Adiponectin/Acpr30, 0.2 mg/ml in PBS 
(binds polyclonal to aa 19-244 )  
R&D Systems, Minneapolis, Minnesota, USA 
APO010-API, 490 µg/ml in PBS Oncology Venture, Hoersholm, Denmark 
Arginine, L- (USP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Bovine Serum Albumin (BSA) Sigma-Aldrich, St. Louis, Missouri, USA 
EZ-Link
®
Sulfo-NHS-LC Biotinylation Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Fas-Fc, lyophilized (extracellular part of Fas 
receptor fused to a Fc-domain) 
kindly provided by Prof. Martin Zörnig, Georg-
Speyer-Haus, Frankfurt, Germany 
Glutamic acid, L- (EP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Glycine (EP, USP, JP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Histidine, L- (EP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Lysine, L-, HCl (EP, USP, JP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Recombumin Alpha 10 % (albumin) Novozymes A/S, Bagsværd, Denmark 
rhIL-8 recombinant human R&D Systems, Minneapolis, Minnesota, USA 
Streptavidin conjugated to horseradish 
peroxidase (Streptavidin-HRP) 
R&D Systems, Minneapolis, Minnesota, USA 
Streptavidin-Northernlights-NL 557 R&D Systems, Minneapolis, Minnesota, USA 
Tryptophan, L- (EP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
 
Table 3-3. Materials 
Name  Reference 
Aqua B. Braun, purging solution, sterile and 
pyrogen-free 
B. Braun Melsungen AG, Melsungen, Germany 
EDC (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide 
hydrochloride) 
Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Ethanol, 70 % Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
OXYPLUS
®
, Polymethylpentene (PMP) hollow 
fibers for gas excahnge 
Membrana, Wuppertal, Germany 
PBS w/o Mg
2+
/ Ca
2+
  Biochrom GmbH, Berlin, Germany 
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Name  Reference 
Polysorbate 20 Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Skim milk powder Sigma-Aldrich, St. Louis, Missouri, USA 
Sulfuric acid (H2SO4), 96 % Sigma-Aldrich, St. Louis, Missouri, USA 
TMB (3,3’,5,5’-Tetramethylbenzidine) Invitrogen, Carlsbad, California, USA 
Trypanblue, 0.4 % Sigma-Aldrich, St. Louis, Missouri, USA 
 
Table 3-4. Media and solution 
Name Reference 
DMEM w/o phenol red, w/ 3.7 g/l NaHCO3,  
w/ 4.5 g/l glucose, w/o L-Glutamine 
Biochrom GmbH, Berlin, Germany 
DMEM w/ 3.7 g/l NaHCO3, w/ 4.5 g/l  
D-Glucose, w/ Na-Pyruvate, w/o L-Glutamine 
Biochrom GmbH, Berlin, Germany 
Penicillin/Streptomycin,  
10.000 U/ml/ 10.000 µg/ml 
Biochrom GmbH, Berlin, Germany 
Trypsin/EDTA (0.05/0.02 %)  
in PBS w/o Ca
2+
, Mg
2+
 
Biochrom GmbH, Berlin, Germany 
 
Table 3-5. Kits 
Name Reference 
Pierce
®
 Biotin Quantitation Kit Thermo Fisher Scientific, Waltham, Massachusetts, 
USA 
Biotinylation kit Thermo Fisher Scientific, Waltham, Massachusetts, 
USA Affinity Purified Avidin 
BupH™ Phosphate Buffered Saline Pack 
EZ-Link Sulfo-NHS-Biotin 
HABA 
Zeba™ Spin Desalting Column, 5mL  
XTT (tetrazolium salt) Kit F. Hoffmann-La Roche AG, Basel, Switzerland 
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Table 3-6. Cell lines 
Name  Reference Cell type characteristics 
L-929 
[110, 111] 
Murine connective tissue fibroblast cell line, which was 
established from the normal subcutaneous areolar and adipose 
tissue of a male C3H/An mouse; used as target in TNF detection 
assays 
Human 
blood  
 Different healthy donors 
 
3.1.1 Cell cultivation 
Adherent cell line 
The adherent cell line was cultivated at 37 °C and 5 % CO2-atmosphere. The cells were split 
at a confluent state. The old medium was removed and the cells stuck to the flask were 
washed once with 5 ml PBS. Then 2.5 ml trypsin/EDTA was added and incubated for 5 min 
in the incubator at 37 °C to detach the cells from the bottom of the flask. Afterwards, the 
trypsin reaction was stopped by adding 7.5 ml medium. Cell concentration was determined 
by Trypanblue method: 35 µl of the cell suspension was added to 35 µl Trypanblue to stain 
dead cells. 10 µl of the mixture was transferred to the counting chamber and the cells were 
counted in the Neubauer counting chamber (Hecht Assistant) according to the manufacturer 
data via light microscopy (Axiovert 40C microscope, Zeiss). To maintain the cell line the cells 
were distributed to cell culture flasks according to Table 3-7. 
Table 3-7. Split mode of cell line 
Name  Split mode / week Cells/cm
2
 flask 
L-929 3 times 40,000 
 
Solutions used: 
Cultivation medium: L-929: DMEM, 10 % FBS, 2 mM L-Alanyl-L-Glutamine, 
100 U/ml Penicillin/Streptomycin 
3.1.2 Isolation of neutrophils 
Neutrophils were isolated as described in 2.1.2. Human blood was collected from healthy 
donors in neutral S-monovettes (Sarstedt) spiked with 5 U/ml Na-Heparin instead of 
previously used lithium heparin S-monovettes (Sarstedt, 16 U/ml lithium heparin). 
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3.1.3 Apoptosis assay 
The apoptosis assay was carried out as described in 2.1.5. 
3.1.4 Chemotaxis assay 
The chemotaxis assay was carried out as described in 2.1.6. 
3.1.5 Anti-inflammatory coating 
The anti-inflammatory coating consists of the polymethylpentene (PMP) hollow fibers as 
artificial material, EDC as cross-linker reagent, APO010 as anti-inflammatory molecule and 
recombinant albumin to passivate the surface. To stabilize the biomolecule during drying, 
sterilization and storage an amino acid (aa)-based stabilizing formulation (Table 3-8) was 
added as shown in Figure 3-1. 
Table 3-8. AA-based stabilization formulation 
AA-based stabilization 
formulation 
Content 
F1 (aa-based formulation with 7 aa) Ala, Arg, Glu, Gly, His, Lys-HCl, Trp 
pH 6.5 in H2O 
 
 
 
Figure 3-1. Scheme of the coupling chemistry for an anti-inflammatory coating. 
For the anti-inflammatory coating, first, the polymethylpentene (PMP) hollow fiber was plasma 
activated with O2. Second, the plasma activated PMP, which has now carboxyl groups, reacts with 
EDC. The activated PMP can react in a third step with APO010, which results in a stable amid bond. 
Afterwards, the reaction is quenched with a recombinant albumin, which results in covalent coupling of 
APO010 and albumin to the PMP. Albumin interacts as blocking reagent with free PMP groups and 
avoids unwanted binding of blood components. In the last step an amino acid-based stabilizing 
formulation is added to the coating and will protect the coating during drying, sterilization, and storage. 
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3.1.5.1 The polymethylpentene hollow fibers 
The PMP hollow fibers (OXYPLUS®, Membrana) are woven to PMP mats (14 cm × 10 cm) by 
a polyester weaving thread, whereby 120 to 220 mats are rolled on a coil. These coils are 
then plasma activated as depicted in  
Table 3-9 with O2 to generate functional carboxyl groups on the inert PMP material. The 
carboxyl groups can be used for crosslinking and can be formed by oxidation of aldehyde, 
keto and hydroxyl groups. The OXYPLUS® PMP hollow fibers have a dense outer skin, which 
prevents liquid entry into the fiber and a diffusion membrane for gas exchange of oxygen and 
carbon dioxide. Therefore, this material is used in oxygenators for gas exchange. 
 
 
Figure 3-2. Illustration of the PMP. 
A PMP mats on a coil, B one PMP hollow fiber mat. 
 
Table 3-9. Parameter of plasma activation 
Plasma activation  
Generator power 750 W 
Vacuum end pressure 1-2 Pa 
Gas O2 
Gas flow 300 ml/min 
Rotating time 6 U/min 
Warm-up 15 min 
Activation time 90 sec 
Duration 30 min 
Capacity 4 coils with up to 220 mats 
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3.1.5.2 The coupling strategy 
The coupling strategy was stepwise evaluated in the bench setting and in the rotating setting. 
The information obtained in these settings was transferred to the circuit setting to simulate 
circulating characteristics for further upscaling approaches. 
3.1.5.2.1 The bench setting 
PMP was cut in 1 cm2 slides, whereby three slides were put in a 5 ml PP-tube with a silicone 
slice on top to fix the PMP within the fluid (Figure 3-3). The 600 µl of EDC solution (0.5 mM in 
H2O) were incubated with three slides PMP in one 5 ml tube for 15 min at RT on a shaker. 
Then, the EDC solution was removed and the slides were washed once with 1 ml H2O. 
Subsequently, 600 µl of the APO010 solution (from 20 ng/ml to 1 µg/ml in PBS) were added 
to the slides and incubated for 1 h at RT on a shaker. The solution was removed and washed 
5 times with 1 ml H2O for 1 min. Afterwards, the reaction was quenched by adding 1 ml 1 % 
albumin (in H2O) for 15 min at RT on a shaker. The solution was removed and the slides 
were washed 5 times with 1 ml H2O.  
 
Figure 3-3. Schematic illustration of coupling approach in bench setting with ELISA as read-
out. 
Three PMP slides were coupled to APO010 in one 5 ml PP tube (left) and were incubated on a shaker. 
After the coupling, each PMP slide was transferred to 1.5 ml tube (right) in which the ELISA was 
carried out. 
 
3.1.5.2.2 The rotating setting and the circuit setting 
PMP was cut in round slides (50 mm or 20 mm diameter) and placed in a 5 ml tube, 
respectively. The 2.5 ml (for 50 mm holder device) or 1 ml (for 20 mm holder device) EDC 
(0.5 mM in H2O) was incubated with the PMP for 15 min at RT on a rotating wheel (Figure 
3-4 A). Then, the EDC solution was removed and the PMP was washed 3 times with 2.5 ml 
or 1 ml H2O.  
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Subsequently, 2.5 ml or 1 ml of the APO010 solution (20 ng/ml to 1 µg/ml in PBS) was added 
to the slide and incubated for 1 h at RT on a rotating wheel. The solution was removed and 
the mat was washed 3 times with 2.5 ml or 1 ml H2O on a rotating wheel for 5 min. 
Afterwards, the reaction was quenched by adding 2.5 ml or 1 ml 1 % albumin (in H2O) for 
15 min at RT on the rotating wheel. The solution was removed and the mat was washed 5 
times with 2.5 ml or 1 ml H2O. Afterwards, the PMP was transferred in the circuit setting 
(Figure 3-4 B) for functionality approaches and the whole circuit was flushed with washing 
solutions. The read-out was an Apoptosis Assay or a Chemotaxis Assay to investigate the 
functionality with neutrophils and Jurkat cells or a Sandwich ELISA to investigate detached 
APO010. 
 
Figure 3-4. Schematic illustration of coupling approach in rotating and circuit setting. 
A Rotating setting: The coupling chemistry was carried out in 5 ml PP tubes and the incubation times 
were carried out on a rotating wheel.  
B Circuit setting: After the coupling in the rotating wheel, the PMP was transferred to a mini circuit with 
flexible-tube pump (4). Round PMP slides with 50 mm or 20 mm diameter are fixed in the 
corresponding holder device (3) in the circuit. The circuit has a total volume of 28 ml (50 mm holder 
device) or 8 ml (20mm holder device) and the coating solution (1) is pumped through the circuit via a 
flexible-tube pump into a collecting container (2). 
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3.1.6 Washing of the anti-inflammatory coating  
In order to wash non-covalently bound proteins off the PMP mats, the mats were coated and 
washed in the circuit setting (according to Figure 3-4 B). Three mats (circle with diameter 
20 mm) were placed into a holder device (diameter 20 mm) to simulate layers as in the 
medical device. The circuit setting was flushed with 8 ml of the respective washing solution. 
The mats were rinsed with a flow rate of 31.4 ml/min, which corresponds to 100 ml/min as 
used in the medical device for washing.  
The flow rate for the circuit setting can be calculated as follows: 
   
 
 
   (1) 
 
with: ν = flow velocity, Q = flow rate, A = flow area 
 
                                   (2) 
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3.1.7 Functional Enzyme-linked Immunosorbent Assay (ELISA) 
A functional ELISA was developed and used for the detection of functionally bound APO010 
on the PMP. This method is based on a color reaction, which can be measured 
photometrically. The color intensity corresponds to the coupled amount of APO010 to the 
PMP mat. 
As APO010 consists partly of a Fas ligand, it can bind to the extracellular part of Fas. This 
Fas is cloned to a Fc part of an antibody. It was biotinylated (Fas-Fc-biotin) according to the 
manufacturer (Pierce) and the amount of biotin coupled to the Fas-Fc was measured by the 
Biotin Quantitation Kit (Pierce). The binding efficiency of Fas-Fc to anti-Fas was analyzed in 
an ELISA.  
Initially, the PMP mats were coupled with the anti-inflammatory molecule, APO010, via the 
EDC chemistry according to the coupling protocol in 3.1.5. Afterwards, the PMP mats were 
transferred into 1.5 ml Eppendorf tubes and incubated with 500 μl blocking solution (5 % 
skim milk in washing buffer) for 1 h, respectively. After each ELISA step, the solution was 
aspirated via a vacuum pump followed by three washing steps with 500 μl washing buffer 
(PBS + 0.05 % Polysorbate 20). After three times of washing, 200 μl of a Fas-Fc biotin 
solution (194 ng/ml in PBS) was added to each sample and incubated for 1 h and washed 
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afterwards three times. Then, 200 μl streptavidin-HRP solution (1:200 in 1 % BSA/PBS) was 
added for 1 h. After three washing steps, 200 μl TMB solution (1: 1 in water) was added and 
incubated for 30 min. By addition of 50 μl H2SO4 (3.6 M in water) the reaction was stopped. 
125 μl of each sample was transferred into an MTP and measured at 450 nm in the 
photometer. The reference was measured at 550 nm. 
 
Figure 3-5. Schematic illustration of functional ELISA. 
The functional ELISA is carried out in a MTP to detect coupled APO010 on PMP. The Fas-Fc-Biotin 
binds to the functional FasL domain of the APO010. By biotinylation of the Fas-Fc the Streptavidin-
horseradish peroxidase (HRP) can bind to Biotin. By adding the TMB substrate to the HRP, TMB is 
oxidized which results in a color change from colorless to blue (absorption maximum at 650 nm). The 
reaction is stopped by adding H2SO4 and the solution turns yellow. This shifts the absorption maximum 
to 450 nm [112]. The solution is transferred to a MTP and can be measured photometrically at 450 nm, 
whereby a reference is measured at 550 nm.  
 
3.1.8 Non-functional ELISA 
A non-functional ELISA was used for the detection of total bound APO010 on the PMP. This 
method is based on a color reaction, which can be measured photometrical. The color 
intensity corresponds to the coupled amount of APO010 to the PMP mat. 
Initially, the PMP mats were coupled with the anti-inflammatory molecule, APO010, via the 
EDC chemistry according to the coupling protocol in 3.1.5. Afterwards, the PMP mats were 
transferred into 1.5 ml Eppendorf tubes and incubated with 500 μl blocking solution (5 % 
skim milk in washing buffer) for 1 h, respectively. After each ELISA step, the solution was 
aspirated via a vacuum pump followed by three washing steps with 500 μl washing buffer 
(PBS + 0.05 % Polysorbate 20). After three times of washing, 200 μl anti-Adiponectin-Biotin 
(50 ng/ml in PBS) was added to each sample and incubated for 1 h and washed afterwards 
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three times. Then, 200 μl streptavidin-HRP solution (1:200 in 1 % BSA/PBS) was added for 
1 h. After three washing steps, 200 μl TMB solution (1:1 in water) was added and incubated 
for 30 min. By addition of 50 μl H2SO4 (3.6 M in water) the reaction was stopped. 125 μl of 
each sample was transferred into an MTP and measured at 450 nm in the photometer. The 
reference was measured at 550 nm. 
 
Figure 3-6. Schematic illustration of non-functional ELISA. 
The non-functional ELISA is carried out in a MTP to detect coupled APO010 on PMP. The anti-
Adiponectin-Biotin binds to the Adiponectin domain of the APO010 not being related to FasL function. 
Streptavidin-HRP binds to anti-Adiponectin-Biotin. By adding of the TMB substrate the color is 
changed and the reaction is stopped by adding H2SO4. The solution is transferred to a MTP and can 
be measured photometrically at 450 nm, whereby a reference is measured at 550 nm. 
 
3.1.9 Detachment assay 
In order to detect detached or soluble APO010 molecules, a sandwich ELISA was 
performed. By immobilization of a capture antibody the soluble APO010 can be bound and 
can be detected specifically of the antigen. The quantification is carried out via an enzymatic 
color reaction. The sandwich ELISA binds the APO010 molecules in solution, which results in 
a highly sensitive detection method to detect low amounts of APO010. 
First, 100 µl anti-FasL IgG2B (0.1 µg/ml in PBS) was incubated in a MTP for 17 h at 5 °C. 
Unbound antibody was washed away with 300 µl washing buffer (PBS + 0.05 % Polysorbate 
20) for three times. Second, the wells were blocked for unspecific binding with blocking buffer 
(5 % skim milk in washing buffer) for 1 h. Three washings steps as above mentioned were 
carried out. Third, 100 µl of the washing solution, after washing of the anti-inflammatory 
coating as described in 3.1.6, was added and incubated for 2 h. Fourth, after three times of 
washing, 100 µl anti-Adiponectin-Biotin (400 ng/ml in PBS) was added for detection and 
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incubated for 1 h followed by three washing steps. Fifth, 100 µl of streptavidin-HRP solution 
(1:200 in 1 % BSA/PBS) was incubated for 20 min in the dark and washed away three times. 
Sixth, 100 µl TMB substrate was added and incubated for 30 min at 37 °C. Finally, the 
reaction was stopped by addition of 50 μl H2SO4 (3.6 M in water) and the MTP was 
measured at 450 nm in the photometer. The reference was measured at 550 nm. 
To quantify the soluble APO010, dilution series of APO010 (50 ng/ml to 0 ng/ml) was 
performed in the same washing medium as the PMP mats were washed. 
 
Figure 3-7. Schematic illustration of detachment assay. 
The detachment assay is carried out in a MTP to detect soluble APO010 in the washing solution of 
anti-inflammatory coated PMP. The anti-FasL IgG2B is immobilized at the MTP and binds specific to 
the FasL domain of APO010. To detect the bound APO010 an anti-Adiponectin-Biotin binds to the 
Adiponectin domain of APO010. Streptavidin-HRP binds to anti-Adiponectin-Biotin. By adding of the 
TMB substrate the color is changed and the reaction is stopped by adding H2SO4. The color can be 
measured photometrically at 450 nm, whereby a reference is measured at 550 nm. 
 
3.1.10 Cytotoxicity assay / XTT-staining 
The cytotoxicity assay using tetrazolium salt (XTT)  or so-called XTT-staining is based on the 
described methods for examination of cytotoxicity of medical devices [113-115]. It describes 
the investigation of cytotoxicity by XTT-staining, whereby metabolism processes and 
reproduction of L-929 mouse fibroblasts after incubation with extracts of the test material or 
chemicals is determined colorimetrically.  
The living cells absorb the XTT and convert it to a water-soluble formazan dye via 
dehydrogenases. The intensity of the coloration change correlates with the cell count and 
therefore with the mitochondrial activity of the cells. The dehydrogenase activity of the cell 
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culture serves as a measure for the growth of the L-929 mouse fibroblasts or for growth 
inhibition in the presence of cytotoxic substances. As a clearly cytotoxic effect the 
dehydrogenase activity is reduced to less than 30 %, a slight to weak cytotoxic effect 
decreases dehydrogenase activity to 30 % to 70 %. A dehydrogenase activity over 70 % 
compared to the solvent control (100 %) corresponds to a negative cytotoxic effect.  
L-929 cells were harvested as described in 3.1.1 and 100 µl of 0.1 x 106 cells/ml in cell 
culture medium (DMEM w/o phenol red, 10 % FBS, 2 mM L-Alanyl-L-Glutamine, 100 U/ml 
Penicillin/Streptomycin) were transferred into a 96 well MTP and incubated for 24  ±2 h at 
37 °C / 5 % CO2.  
On day two, the PMP mats were coated according to the coupling protocol on the rotating 
setting in 3.1.5.2.2 and afterwards the PMP mats were transferred to the circuit setting for 
washing. There, the settings were flushed 5 times with cell culture medium at a flow rate of 
10 ml/min for 5 min. The circuits were then incubated for 1 h with cell culture medium under 
the same conditions. The respective solutions were sterile filtrated, transferred to a tube, and 
stored at RT. 
To analyze the incubation solutions they were transferred to the L-929 MTP. Therefore, 95 µl 
of the supernatant of the cells were removed and 100 µl of the washing solution were added. 
The PMP mats were tested as well by cutting them into small pieces. As positive control a 
10 % DMSO solution was used, and cell culture medium was used as negative control. After 
transfer, a further incubation of the MTP for 24 h at 37 °C / 5 % CO2 was performed. 
On day three, 50 μl of the XTT solution (5 parts reagent 1:0.1 parts reagent 2, Roche) were 
added and incubated for 2 h to 4 h at 37 °C/ 5 % CO2. Finally, 100 μl of the supernatant were 
transferred to a new MTP and measured photometrically at a wavelength of 450 nm and at 
630 nm for reference.   
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3.1.11 Hemocompatibility 
Hemocompatibility of the anti-inflammatory coating is important for the approval of the 
medicinal product. Therefore, whole blood was incubated with coated PMP mats and 
subsequently the blood was analyzed by an external laboratory for a full blood count. Several 
controls were included. 
For this test, PMP mats were coated in the rotation setting as described in 3.1.5. After the 
coating, the PMP mats were transferred in the circuit setting for incubation with 0.9 % NaCl 
solution five times for 5 min at a flow rate of 10 ml/min. Then, the circuit was incubated an 
additional time with 0.9 % NaCl solution for 1 h at a flow rate of 10 ml/min. Finally, whole 
blood in heparin (5 U/ml) coated syringes were transferred in the circuit and circulated at a 
flow rate of 10 ml/min for 2 h. After the incubation period, the whole blood was removed from 
the respective circulation and 3 ml were filled into an EDTA coated S-monovette K3E 
(Sarstedt). The samples were analyzed by an external laboratory. 
3.1.12 Contact angle measurement 
To measure the contact angles of deionized water on untreated and stepwise coated PMP 
mats the Kruess Drop Shape Analyzer DSA25E was used using the sessile drop method. 
Therefore, a 2 µl drop of deionized water was placed on the PMP mats under investigation. 
The mats were fixed on the surface via double-adhesive tape. After adjustment of the manual 
baseline, contact angles of the drop were fitted by the Tangent-1 method. Three 
measurements were performed for 10 seconds each after the drop formation with 1 second 
delay between the measurements. On each sample three different positions were analyzed. 
The ADVANCE software v1.1.0.2 was used for data evaluation. 
3.1.13 Fluorescence spectroscopy 
The Leica DMi8 was used to analyze coupled APO010 on the PMP surface by fluorescence 
labeling. Therefore, the PMP mats were coated in the bench setting according 3.1.5 with 
35 ng/ml APO010. The PMP mats were blocked for non-specific staining by adding 400 µl 
blocking buffer (1 % BSA/PBS) and incubated for 45 min. The blocking buffer was removed 
and 200 µl anti-Adiponectin-Biotin antibody (200 ng/ml in PBS) was added. Afterwards, the 
mats were washed two times in 400 µl PBS. 200 µl of the Streptavidin-Northernlights NL557 
(1 µg/ml and 5 µg/ml in 1 % BSA/PBS) was added and incubated according to the 
manufacturer’s instructions at RT for 1 h in the dark. After washing with PBS, the samples 
were transferred to coverslips for analysis.  
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For Streptavidin-Northernlights NL557 the wavelength 557 nm for absorption and 574 nm for 
emission were used. Appropriate controls were carried with. 
3.1.14 Scanning electron microscope (SEM) 
For scanning electron microscopy a Jeol JSM‑6500 F was used at an acceleration voltage of 
2.0 kV and different magnifications. The PMP samples were cut in 1.1 x 1.1 cm pieces and 
were coated according the bench setting described in 3.1.5. Afterwards, they were attached 
to aluminum blocks with double-adhesive tape. To avoid charging during analyzation the 
samples were carbon sputtered under vacuum. 
3.1.15 Fourier transform infrared spectroscopy (FTIR) 
FTIR spectroscopy experiments were performed using the Tensor 27 FTIR spectroscope 
connected to a thermostat DC30-K20. The sensor was cooled with liquid nitrogen and a 
constant gaseous nitrogen flow. The samples were analyzed in solution and coupled to the 
PMP. Therefore, different APO010 concentrations (20 ng/ml to 50 ng/ml) in solution or 
APO010 coupled to PMP in the bench setting (3.1.5) were used. For each spectrum 100 
absorbance scans were measured at a single beam mode and a resolution of 4 cm-1. The 
spectra were analyzed by the Opus 7.5 (Bruker Optics GmbH) and indicated as vector-
normalized second-derivative spectra. The infrared spectra were recorded with a BioATR 
(Attenuated Total Reflectance) cell at 20 °C and analyzed by Protein Dynamics for Opus 7.5. 
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 Results  3.2
After selection of APO010 as the most suitable effector molecule, the goal in this part of this 
work was the covalent coupling of the APO010 on PMP as the relevant material for the 
functionalization of membrane ventilators. 
Each development step in this project was chosen in regard to the general regulatory 
requirements for the approval of medical devices. For the evaluation and selection of the 
ideal coupling protocol the following issues have been discussed. First, the covalent binding 
of APO010 on the inert PMP material was achieved by using plasma activation of the PMP 
material. Second, as coupling strategy the EDC chemistry was chosen due to easy handling 
and compatibility with the APO010. Third, the stability of the coating was investigated by 
leaching experiments and the functionality of the coating was investigated by chemotaxis 
analysis. Fourth, the safety of the coating in blood circulation was analyzed by a 
hemocompatibilty test and finally, the toxicity of the anti-inflammatory coating was analyzed 
by a cytotoxicity test. In addition, the anti-inflammatory coating was characterized by different 
analyzing methods. 
PMP is commonly known to be an extremely inert material. Therefore, the major challenge in 
this project was to define a coupling strategy for the APO010 on PMP, which is in conformity 
with regulatory requirements. This means that the biomolecule has to be stably bound to the 
surface even under stress conditions such as thermal stress during sterilization or 
mechanical stress during blood circulation. Therefore, plasma activation of PMP was chosen 
to be adequate for covalent coupling of APO010 in conjunction with the crosslinking reagent 
EDC. The use of albumin as a blocker of uncovered spots of PMP is used to avoid the 
generation of a biofilm, an adsorption of blood proteins.  
3.2.1 Homogeneity of plasma activation 
As the homogenous functionalization of the PMP material is important for homogenous 
covalent coupling of APO010, the plasma activation process was investigated. Therefore, 
first the PMP mats were rolled on a coil and were plasma activated. Second, the different 
positions in the coil were analyzed by the functional ELISA after coating the PMP with the 
anti-inflammatory coating. 
The ELISA shows a homogenous distribution from mat #1 to #120 (Figure 3-8 A) and from 
#1 to #178 (Figure 3-8 B). The mats #180, #220 and #222 show decreased absorption 
signals but #198, #200 and #218 show similar signals compared to the other mats. The 
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mean of the absorption signal of Figure 3-8 A with 2.44 ± 0.38 RU and of Figure 3-8 B with 
1.26 ± 0.19 RU shows minimal variance in absorption, but it shows as well different absolute 
values due to different TMB incubation times (15 min and 8 min). Therefore, an absolute 
comparison of the two graphs is not possible.  
However, due to the homogenous distribution of APO010 coupled to the PMP, it can be 
assumed that the plasma activation on a role was successful and can be continued in this 
way.   
 
A           B 
 
 
 
 
 
 
 
Figure 3-8. Graphical representation of the coupling experiments with different positions of the 
PMP mats during plasma activation. 
120 PMP mats (A) or 222 PMP mats (B) were rolled on a coil (see Figure 3-2) and were plasma 
activated. Four mats produce one round. The first and the last mat per round were analyzed. Position 
one is on the outside and position 222 on the inside of the coil. The coupling of APO010 was carried 
out via EDC chemistry. The mats were incubated with EDC for 30 min. Then washed and treated with 
APO010 (1 µg/ml) for 60 min. The reaction was quenched by 5 % albumin (Recombumin alpha, 
Novozymes) for 15 min. The read-out was performed by a functional ELISA. The TMB reaction was 
performed for 15 min for A and 8 min for B (Mean ± SD from n=3). 
 
3.2.2 Design of the anti-inflammatory coating 
The coupling protocol based on plasma activation of PMP was tested in two different 
scenarios. The lab scale model referred to as “bench setting” (described in 3.1.5.2.1) was 
carried out to obtain first evidence for the potential of the functionalized PMP matrix in vitro. 
For testing the functionality of the pre-selected coating under flow conditions the 
functionalized PMP material was first coupled with APO010 in the rotating setting (described 
in 3.1.5.2.2) and then inserted into holder devices in mini circuits referred to as “circuit 
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setting” (described in 3.1.5.2.2). The coupling protocols were in principle identical, but 
adapted to the different PMP sizes and volumes. Data from these experiments were used to 
define the final coupling protocol, which is applicable for the serial production. The efficacy of 
the coupling protocol was verified by the functional ELISA.  
3.2.2.1 Crosslinking of APO010 via EDC 
The incubation time of the coupling component APO010 and EDC was systematically 
investigated to get the optimum reaction time. The incubation range was defined according to 
the manufacturer´s instruction for EDC coupling. The PMP material was coated with anti-
inflammatory coating in the bench setting by using the functional ELISA for analysis. Figure 
3-9 shows the different approaches, whereby the highest absorption signal was observed 
with 15 min EDC incubation and 30 min APO010 incubation. The APO010 incubation time 
seems to be more important than the EDC incubation time, because 5 to 30 min EDC 
incubation with 60 min APO010 incubation time show the same absorption signal. As optimal 
incubation time 15-30 min EDC with 60 min APO010 were defined. 
 
 
Figure 3-9. Different incubation times to couple APO010 to PMP in the bench setting. 
APO010 was coupled (1 µg/ml) via EDC (0.5 mM) to PMP in the bench setting with different 
incubation times. The reaction was quenched with 5 % albumin. The coating success was analyzed 
via the functional ELISA. The column chart shows the relative absorbance 450-550 nm in relative units 
[RU], whereby the relative absorbance is proportional to the amount of bound APO010 (Mean ± SD 
from n=3). 
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In the next step, the concentrations of the crosslinker EDC and the concentration of APO010 
were systematically varied to identify the optimum combination for the anti-inflammatory 
coating. The combination of 0.5 mM EDC and 1 µg/ml APO010 is most efficient in the in vitro 
experiments and will be used in the following experiments (Figure 3-10). The first column 
shows the highest relative absorbance due to unappreciated non-covalently bound APO010 
which will be easily washed off, as is shown in the leaching experiments in the next part.  
 
Figure 3-10. Different coating concentrations to couple APO010 to PMP in the bench setting. 
APO010 was coupled in different concentrations (0.1 µg/ml, 0.2 µg/ml, 0.5 µg/ml, 1 µg/ml) via EDC 
(0.5 mM, 1 mM, 2 mM, 5 mM) to PMP in the bench setting. The reaction was quenched with 5 % 
albumin. The coating success was analyzed via the functional ELISA. The column chart shows the 
relative absorbance 450-550 nm in relative units [RU], whereby the relative absorbance is proportional to 
the amount of bound APO010 (Mean ± SD from n=6 from two experiments). 
 
APO010 is a highly functional protein available in GMP-quality, but at a high price. To keep 
the production costs as low as possible a recycling step of the remaining APO010, which had 
not reacted with the EDC crosslinking, was preferable. Therefore, the APO010 solution was 
used for three coatings in a series, whereby all coatings were analyzed by the functional 
ELISA. In Figure 3-11 A it becomes clear that a recycling step is not possible. Already after 
the first recycling step no APO010 was bound to the PMP mats. Therefore, it is necessary to 
use fresh APO010 solutions.  
The amount of bound APO010 was analyzed indirectly by unbound APO010 in solution. 
Therefore, the APO010 solution was analyzed before and after the coating process via the 
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detachment assay. About 17.95 ng/ml of APO010 was detected before coating, whereas 
1.45 ng/ml was left after coating. Therefore, almost 100 % of APO010 was bound to PMP 
(Figure 3-11 B). To quantify the APO010 indirectly, a dilution series of APO010 was carried 
out. The resulting standard curve and the residuals from the non-linear regression fit show 
optimal results and minimal deviation (Figure 3-11 C, D). 
 
A      B 
 
 
 
 
 
C      D 
 
 
 
 
 
 
 
 
Figure 3-11. Detection of bound and soluble APO010 coupled to PMP in the bench setting. 
A Functional ELISA to detect APO010 coupled to PMP after bench setting: APO010 was coupled 
(1 µg/ml, 60 min) via EDC (0.5 mM, 30 min) to PMP in the bench setting. The reaction was quenched 
with 5 % albumin. The column chart shows the relative absorbance 450-550 nm in relative units [RU], 
whereby the relative absorbance is proportional to the amount of bound APO010 (Mean ± SD from 
n=6). B Sandwich ELISA to determine APO010 concentration before and after coating with 20 ng/ml in 
the bench setting (Mean ± SD from n=9). C The concentration was determined by APO010 dilution 
series from 0 to 50 ng/ml. D Residuals from non-linear regression fit performed by PRISM. The 
residuals are the difference between the actual Y value and the Y value predicted by the model. 
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3.2.2.2 Leaching experiments 
In order to determine the necessary washing steps after the coating procedure and to 
document the stability of the coupled APO010 on PMP, the material was washed using 
defined washing protocols. For this approach, the rotating setting was used in order to 
analyze the total washing volume, which was 500 µl in this case. 
The detached APO010 molecules were detected by the highly sensitive Annexin V assay 
with Jurkat cells that undergo apoptosis after contact with agonistic Fas molecules as 
APO010. The kill-rate, which is measured in the washing solutions, is an indicator for the 
detached APO010 from the anti-inflammatory coating. After five washing steps with cell 
culture medium, no detectable amounts of APO010 molecules were detached from the 
surface in the sample, which was coated with EDC. The five washing solutions from the 
sample without EDC show high apoptosis rates (mean = 98.38 ± 0.32 %) (Figure 3-12 A) 
even after the fifth washing step. 
A             B 
 
Figure 3-12. Washing solutions from the rotating setting were analyzed in the Annexin V Assay. 
A Washing solutions were analyzed by apoptosis assay to detect detached APO010 molecules from 
the PMP surface after 5 washing steps with 500 µl cell culture medium in the rotating setting for 1 min. 
B Washing solutions were analyzed by apoptosis assay to detect detached APO010 molecules from 
the PMP surface after an additional washing step of 1 h with 500 µl cell culture medium in the rotating 
setting. Before, the PMP was coupled to APO010 (1 µg/ml) in the rotating setting (Mean ± SD from 
n=3). 
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Afterwards, the PMP samples, which were washed five times, were washed for an additional 
hour. The washing solutions were analyzed by the apoptosis assay as well, whereby the 
detachment was clearly observed in the samples with non-covalently coupled APO010 
(98.28 ± 0.49 %), but not with covalently coupled APO010 (0.26 ± 0.50 %) (Figure 3-12 B). In 
conclusion to these results, five washing steps after the APO010 coupling step were included 
in the anti-inflammatory coating process. 
In order to correlate the kill-rate caused by detached APO010, with the amount of molecules 
given as the concentration, APO010 was serially diluted from 20 ng/ml to 0.078 ng/ml and 
evaluated in the same apoptosis assay for read-out. The results indicate that the amount of 
detached APO010 after five times of washing and subsequent washing for 1 h is below the 
limit of detection. The limit of detection was defined as a kill-rate of 1.39 % (Figure 3-13), 
which corresponds to an APO010 concentration of 0.078 ng/ml. After subsequent washing a 
kill-rate of 0.26 ± 0.50 % was measured.  
 
Figure 3-13. Serial dilution of APO010 in solution detected via the Annexin V assay. 
Apoptosis was induced by incubation of Jurkat cells with different concentrations of APO010: the kill-
rate was normalized with untreated sample is shown (Mean ± SD from n=2).  
 
To simulate the stress conditions of the anti-inflammatory coating during flow conditions the 
rotating setting was used. The approach A represents the anti-inflammatory coating, 
whereby approach B illustrates the coating without EDC and C demonstrates the negative 
control without APO010. The PMP mats were coupled in the bench setting and were washed 
eight times in the rotating setting with 0.5 ml, respectively. In Figure 3-14 all approaches with 
APO010 show high kill-rates with the first washing solution, whereby approach A shows a 
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kill-rate of 38.71 ± 23.85 % and approach B 81.11 ± 11.01 %. With the third washing solution 
the kill-rate decreases drastically to 8.40 ± 2.30 % for approach A, and 6.89 ± 7.35 % for 
approach B. The fifth washing solution shows no kill-rate for approach A and B, whereby the 
values decreases slightly in the eighth washing solutions. Interestingly, the first washing 
solution from approach B is the highest due to non-covalently bound APO010. The control 
group C without APO010 shows no kill-rate as expected. 
 
 
 
Figure 3-14. Washing solutions from the rotating setting were analyzed by Annexin V Assay. 
Washing solutions were analyzed by apoptosis assay to detect detached APO010 molecules from the 
PMP surface after 8 washing steps with 0.5 ml washing buffer (0.02 % Polysorbate 20 in PBS) in the 
rotating setting for 30 min, respectively. Before, APO010 (0.5 µg/ml) was coupled to PMP in the bench 
setting: approach A, without EDC in approach B and without APO010 in approach C (Mean ± SD from 
n=3). 
 
3.2.2.3 Stability of the anti-inflammatory coating after incubation with blood 
In order to show that the anti-inflammatory coating comprising APO010 is bound stably 
during contact with blood, the detachment assay was conducted with anti-inflammatory-
coated PMP samples. PMP mats were washed for 1 h with blood or PBS in the circuit 
setting. To compare the signals of the relative absorbance for every experiment defined 
APO010 concentrations were diluted in blood or PBS, respectively (Figure 3-15).  
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Table 3-10. Results of detachment assay in ng/ml after washing of anti-inflammatory coating 
with blood and PBS 
    Washing solution in blood Washing solution in PBS 
   Approach Mean 
[ng/ml] 
SD [ng/ml] Mean 
[ng/ml] 
SD [ng/ml] 
A PMP  
+ EDC  
+ APO010 (0,1 µg/ml) 
0.59 0.23 1.01 1.13 
B PMP  
w/o EDC  
+ APO010 (0,1 µg/ml) 
1.61 0.31 4.12 5.23 
C PMP  
w/o EDC  
w/o APO010  
0.035 0.10 0.20 0.39 
 
 
 
 
 
 
 
Figure 3-15. Detection of washing solutions of circuit setting analyzed by detachment assay. 
To determine the APO010 amount in solution defined APO010 concentrations (0 ng/ml, 0.5 ng/ml, 
0.75 ng/ml, 1.0 ng/ml, 2.5 ng/ml, 5.0 ng/ml), diluted in blood (R= 0.9846) or PBS (R=0.9847), were 
carried out. 
 
The results of the washing experiments are depicted in Table 3-10. The highest absorbance 
was measured in samples with non-covalently coupled APO010 (approach B, w/o EDC + 
APO010). This confirms that adhesive coupling of APO010 is not recommended in order to 
avoid safety issues. By contrast, the samples with EDC and APO010 (approach A, covalent 
coupling) show low amounts of detached APO010 in blood (0.59 ± 0.23 ng/ml) and PBS 
(1.01 ± 1.13 ng/ml). 
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3.2.3 Verification of anti-inflammatory functionality in neutrophil activity assays 
After confirming the functionality and stability of the anti-inflammatory coating on the 
apoptosis induction features as outlined above, chemotaxis experiments with activated 
neutrophils were carried out to confirm the immunomodulatory efficacy. The ability of 
neutrophils to migrate through a porous membrane towards a gradient of the cytokine IL-8 
within a two chamber model is a measure of activity.  
 
 
 
 
 
 
 
Figure 3-16. Neutrophil chemotaxis assay after circuit setting. 
PMP, which was untreated or coupled with APO010 (1 µg/ml) via EDC, was transferred into the circuit 
setting (50 mm diameter device holder) and incubated for 2 h at RT with a flow rate of 10 ml/min. 
Afterwards, neutrophils were harvested from circuits and transferred to chemotaxis chambers, where 
the samples were incubated for 1 h at 37 °C. Analysis of the migrated cells, which were migrated to 
the IL-8 gradient in the lower compartment, was carried out by flow cytometry (the kill-rate was 
normalized to untreated sample (Mean ± SD from n=4). 
 
 
The goal in this approach was that neutrophils, that were in contact with the anti-
inflammatory coating, reduce their chemotactic activity compared with neutrophils without 
previous contact to this coating. The results show that IL-8 induced neutrophil chemotactic 
activity is indeed reduced by 33 % after incubation of the coating in the circuit setting (Figure 
3-16). In this experiment a concentration of 1 µg/ml APO010, coupled to PMP, was sufficient 
to reduce chemotactic activity in neutrophils by more than 20 %. Therefore, the goal was 
reached. In comparison to the untreated PMP the anti-inflammatory coating reduced 
chemotactic activity in neutrophils by 24 % (Figure 3-16). 
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3.2.3.1 Hemocompatibility 
In order to confirm the hemocompatibility of the anti-inflammatory coating, the circuit setting 
(50 mm holder device) was filled with fresh human blood. The blood was heparinized and 
circulated for two hours via the circuit setting with or without PMP material, with and without 
APO010. At the end of the circulation, blood samples were harvested and analyzed. As 
shown in Table 3-11 no evidence of blood incompatibilities was found on the basis of the 
obtained hemograms in comparison to the control groups at RT and 5 °C.  
 
Table 3-11. Results of blood analysis 
 Unit 
Untreated 
PMP 
Coated 
PMP 
w/o 
PMP 
Control 
at RT 
Control at 
5 °C 
Leucocytes Tsd/µl 6.63 6.67 6.67 8.32 7.18 
Erythrocytes Mio/µl 4.51 4.47 4.47 6.27 4.71 
Hemoglobin g/dl 13.9 13.8 13.7 18.9 14.5 
Hematocrit % 39.4 39.2 39.2 53.5 41.3 
Mean 
corpuscular 
volume (MCV) 
fl 87.4 87.7 87.7 85.3 87.7 
Mean 
corpuscular 
hemoglobin 
(MCH) 
pg 30.8 30.9 30.6 30.1 30.8 
Mean 
corpuscular 
hemoglobin 
concentration 
(MCHC) 
g/dl 35.3 35.2 34.9 35.3 35.1 
Thrombocytes Tsd/µl 285 293 290 171 267 
Neutrophils % 61.3 63.1 62.4 62.5 62.8 
Neutrophilic 
granulocytes 
/µl 4070 4210 4160 5210 4510 
Lymphocytes % 30.8 30 29.7 29.6 29.4 
Lymphocytes 
abs. 
/µl 2040 2000 1980 2460 2110 
Monocytes % 6.3 5.7 6.7 6.6 6.7 
Monocytes abs. /µl 420 380 450 550 480 
Eosinophils % 1.1 0.9 0.9 0.7 0.7 
Eosinophilic 
granulocytes 
abs. 
/µl 70 60 60 60 50 
Basophil % 0.5 0.3 0.3 0.5 0.4 
Basophilic 
granulocytes 
abs. 
/µl 30 20 20 40 30 
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3.2.3.2 Cytotoxicity 
In addition to the hemocompatibility approach, the samples harvested from the rotating 
setting were analyzed for non-cytotoxicity of the fluids incubated with the anti-inflammatory 
coating. For this purpose, a standard XTT-assay was carried out. Therefore, the mouse 
fibroblasts L-929 were incubated with fluids, which were incubated previously with the anti-
inflammatory coating. The mitochondrial activity is measured by means of an enzyme assay, 
whereby a low enzyme reaction indicates a reduced mitochondrial activity and viability of the 
cells. The anti-inflammatory coating and the uncoated PMP show no evidence for any 
cytotoxic effect elicited by the harvested fluid samples (Figure 3-17). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-17. Results of cytotoxicity assay/ XTT-staining. 
PMP, which was untreated or coupled with APO010 (1 µg/ml, 30 min) via EDC (0.5 mM, 15 min), was 
transferred into 5 ml tubes and incubated with 3 ml cell culture medium for 1 h at 37 °C on the rotating 
setting (Mean ± SD from n=3). Afterwards, the medium was transferred to 96-well MTP with L-929 
mouse fibroblasts. After an incubation of 24 h a XTT-staining was performed and after 2 h incubation 
the samples were analyzed photometrically at 450 nm and 630 nm. Negative control contains medium 
and L-929, positive control includes medium + 10 % DMSO and L-929. 
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3.2.4 Characterization of the anti-inflammatory coating surface 
The characterization of the anti-inflammatory coating by visual and analytical methods is 
another approach to determine the quality of the designed coating. In the following section 
the coating was analyzed using SEM, contact angle analyzation, fluorescent labelling and 
FTIR spectroscopy. 
3.2.4.1 Characterization via SEM  
The PMP fibers are woven together by a polyester weaving thread. To analyze the whole 
anti-inflammatory coating on the artificial material, the coating was analyzed by SEM after 
each coating step. In Figure 3-18 A and B the mats were analyzed untreated by SEM in 
different magnifications. The surface of the uncoated PMP appears smooth with slight 
scratches through handling with the tweezers. 
 
 
 
 
 
Figure 3-18. The untreated PMP hollow fibers analyzed by SEM. 
A (x40 magnification) to B (x150 magnification) show the untreated PMP hollow fibers. 
 
When PMP was treated with EDC as shown in Figure 3-19, the surface of the mat with EDC 
appears smooth and unchanged compared to the uncoated mat.  
 
 
 
 
 
 
Figure 3-19. The PMP + EDC analyzed by SEM. 
C (x40 magnification) to D (x150 magnification) show the PMP hollow fiber, which was treated with 
0.5 mM EDC for 15 min.  
 
A x40 B x150 
C x40 D x150 
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The mat coated with APO010 (Figure 3-20) appears smooth with some small deposits and 
does not differ from the uncoated mat. The PMP with EDC, APO010 and Albumin shows 
small deposits and some scratches through the tweezers (Figure 3-21). 
 
 
 
 
 
 
Figure 3-20. The PMP + EDC + APO010 analyzed by SEM. 
E (x40 magnification) to F (x150 magnification) show the PMP hollow fiber, which was treated with 
0.5 mM EDC for 15 min and 20 ng/ml APO010 for 1 h.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-21. The PMP + EDC + APO010 + Albumin analyzed by SEM. 
G (x40 magnification), H (x150 magnification) and J (x750 magnification) show the PMP hollow fiber, 
which was treated with 0.5 mM EDC for 15 min and 20 ng/ml APO010 for 1 h and EDC reaction was 
quenched with Albumin for 15 min. I (x700 magnification) shows the woven thread, which holds 
together the single hollow fibers.  
 
The mats, which are coated with the stabilizing formulation F1, show deposits of F1 and are 
inhomogeneous skin-dried (Figure 3-22). In the images K (x40 magnification), L (x150 
magnification), M (x350 magnification) and N (x700 magnification) the PMP hollow fiber was 
analyzed from the bottom. They show the deposits between and on the bottom of the PMP 
E x40 F x150 
G x40 H x150 
I x700 J x750 
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hollow fiber. There it becomes visible that the protection layer carried out by the dried 
stabilizing formulation covers the entire fiber as expected. At 150-fold magnification, sharp-
edged deposits are shown, which were probably formed during the drying process.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-22. The PMP + EDC + APO010 + Albumin + stabilizing formulation analyzed by SEM. 
K (x40 magnification), L (x150 magnification), M (x350 magnification) and N (x700 magnification) 
show the PMP hollow fiber from the bottom, which was treated with 0.5 mM EDC for 15 min and 
20 ng/ml APO010 for 1 h and EDC reaction was quenched with Albumin for 15 min. The stabilizing 
formulation F1 was added and the samples were dried in a cell culture plate at 50 °C. In O (x40 
magnification) to R (x150 magnification) the weaving thread and the PMP hollow fibers are shown in 
detail.  
 
K x40 L x150 
M x350 N x700 
O x40 P x95 
Q x150 R x150 
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The mats were individually air-dried in cell culture wells and attached to the bottom of the 
well. Therefore, the drying process is an important step in building the homogeneous 
protection layer. In image O (40-fold magnification) through R (150-fold magnification) the 
weaving thread and the PMP hollow fibers are shown in detail. The images show that the 
protecting layer is visible on the fibers and in the weaving thread. In image P the stabilizing 
formulation is coated like a film on the thread, whereby in image R the dried stabilizing 
formulation indicates crystalline structures located in the thread. Here, the layer appears to 
be more crystalline than on the PMP fiber. Also the sharp-edged deposits formed by the 
drying model are visible. 
In summary, the analyzation of the anti-inflammatory coating gives insights to the dried layer 
of the formulation, but not on the other components.  
3.2.4.2 Characterization via contact angle 
The contact angle shows the physical property of surfaces. The drop shape analysis 
obtained for water with stepwise coated PMP mats is shown in Figure 3-23. The 
corresponding contact angles are summarized in Table 3-12. The stepwise coated PMP 
samples with EDC, APO010 and Albumin exhibited high water contact angles of 121° to 
127°. When the stabilizing formulation F1 was added to the coating the contact angle 
decreases to 89°. This means, that the anti-inflammatory coating does not change the 
physical property of the artificial material PMP.  
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Figure 3-23. The contact angle analyzation of anti-inflammatory coated PMP. 
The contact angle of the anti-inflammatory coating was analyzed stepwise as indicated in the picture. 
 
Table 3-12. Contact angles with water of coated PMP, n=3 with 3 sub-measurements each 
untreated PMP  
+EDC 
PMP  
+EDC  
+APO010 
PMP  
+EDC  
+APO010 
+Albumin 
PMP  
+EDC  
+APO010 
+Albumin  
+F1 
122.87 ± 8.41 ° 126.53 ± 8.14 °  124.64 ± 4.54 ° 120.75 ± 9.14 ° 89.33 ± 18.25 ° 
 
PMP 
PMP +EDC PMP +EDC +APO010 
PMP +EDC +APO010 +Albumin + F1 PMP +EDC +APO010 + F1 
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3.2.4.3 Characterization via fluorescent labelling 
The anti-inflammatory coating was labelled as described in 3.1.13 with specific anti-APO010 
antibodies. By analysing the samples no fluorescent signal from the bound APO010 to the 
PMP mats could be observed due to too low concentration of APO010.  
3.2.4.4 Characterization via FTIR 
The anti-inflammatory coating was analyzed at several positions with the IR microscope. As 
well soluble APO010, at low concentrations of 20 ng/ml and 50 ng/ml, was analyzed by the 
FTIR spectrometer. With both methods (solid and in solution) no difference compared to the 
negative control could be observed. Furthermore, no characteristic IR bands for proteins, like 
N-H, C-H or O-H, could be observed. Therefore, the method is not able to show APO010 
coupled to the PMP mats. 
3.2.5 Summary  
The anti-inflammatory coupling protocol to covalently bind APO010 to PMP comprises 
recombinant human albumin, recombinant human APO010 and an aa-based stabilization 
formulation. Each compound has been already approved to be safe for clinical applications. 
Covalent and stable binding of APO010 to PMP was shown in leaching experiments. Five 
washing steps are recommended after crosslinking APO010 with EDC for removing residual 
non-covalently bound APO010 from PMP. Functionality was shown by reduced chemotactic 
activity of neutrophils after challenging with the anti-inflammatory coating. Hemocompatibility 
of PMP coated with the anti-inflammatory coating was shown in the circuit setting with whole 
blood. Moreover, no cytotoxic effects of fluid samples harvested from circuits with the anti-
inflammatory coating could be observed. The characterization of the anti-inflammatory 
coating was investigated via SEM, FTIR, and contact angle. These methods were not able to 
detect APO010 on the PMP mats. However, the functional ELISA and the Apoptosis assay 
could prove the presence of APO010 on the PMP mats. The assays for characterization 
need higher protein concentrations than used in this work. 
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 Discussion 3.3
This chapter deals with the design of the anti-inflammatory coating. Therefore, several 
investigations were carried out to define the optimal coating parameters like concentration 
and incubation time. The parameters for the anti-inflammatory coating are summarized in 
Table 3-13 and will be adapted in the last part to the serial production scale. There, the 
concentrations of the components and the incubation times have to be adapted in regard to 
economic efficiency. 
Table 3-13. The anti-inflammatory coating parameters 
Step Process parameter 
1 Plasma activation of PMP with O2 
2 Activation of the PMP surface with EDC (0.5 mM) for 15 to 30 min 
3 Coupling of APO010 (20 to 1000 ng/ml) for 60 min 
4 Quenching of the reaction with albumin (1 %) for 15 min 
5 5 times washing with H2O 
6 Adding of an aa-based coating solution for 1 h and then air-drying 
 
APO010 was coupled via EDC and the plasma activation to the inert PMP hollow fibers. The 
functional ELISA served as analytical method to investigate the concentration of EDC and 
APO010 and to determine the incubation time of both. As the functional ELISA only detects 
functional active bound APO010, it must be assumed that a higher amount of APO010 was 
bound to the PMP mats. In this regard a specific coupling of APO010 would lead to a higher 
economic efficiency, but is not possible for the APO010 molecule. One possibility to generate 
a specific binding site is to generate a single C-terminal Cysteine to couple it via thiol 
chemistry as done for several proteins like the DARPins [104, 116-118]. Thereby, no 
additional Cysteines can be present in the protein sequence. In this case, APO010 needs its 
Cysteines to form disulfide bridges between the monomers to generate a stable hexamer. 
This stable hexamer leads to the high efficiency of APO010 and therefore needs to be 
maintained. The adiponectin domain is fused to the FasL domain of APO010 and has the 
function to strengthen hexamer formation by its stalk domain. This stalk domain has no 
strong influence to the EDC crosslinking compared to the functional active FasL domain. 
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Therefore, it was assumed that all adiponectin domains could be detected by the antibody 
and can be correlated with all APO010 bound to the PMP mats.  
Stepwise, the anti-inflammatory coating was investigated, initiating with the plasma 
activation. The successful plasma activation was indirectly proven by the detection of 
APO010 with the result that APO010 is coupled consistently over the whole mat. As there 
were some outliers at mat position 180, 200 and 222 and no one up to position 120s, optimal 
results will be generated when at least 120 mats will be plasma activated on a coil. Different 
labeling of activated functional groups on the PMP mat can strengthen this outcome, but 
were not tested in this work. 
The investigations of incubation time and concentrations of EDC and APO010 indicate that 
the incubation time and concentration of EDC are more variable than those of APO010. The 
used APO010 concentration was varied in this chapter between 20 ng/ml and 1 µg/ml 
depending on the read-out methods and the questions to be addressed.  
To analyze the bound amount of APO010, indirect methods as the sandwich ELISA were 
used. By using 20 ng/ml APO010, it becomes clear that almost the whole amount of APO010 
was coupled to the PMP mats. In addition, it was investigated if APO010 can be recycled 
when using higher concentrations of 1 µg/ml. It shows clearly that no recycling of APO010 is 
possible in this setting. This means that the low protein concentration needs to be prepared 
freshly for optimal crosslinking results. One reason could be the low protein concentration in 
PBS without stabilizer, another reason could be that APO010 reacts completely with the 
activated PMP mat. Other labeling methods, like radioactive labeling or immunogold labeling, 
which directly detect APO010 on the PMP mats, were not carried out. The PMP hollow fibers 
limit the analyzing methods due to the irregular surface.  
After finishing the coating process, unbound APO010 has to be washed away. To analyze 
this procedure a sensitive apoptosis assay was carried out. After five washing steps, no 
apoptosis was induced in Jurkat cells, but when no EDC is present APO010 is attached to 
the PMP mats, but is washed away during the five washing steps and as well after an 
additional washing hour. Almost 100 % apoptosis was induced in Jurkat cells during the 
detachment process. Therefore, it gets clear that EDC leads to a covalent binding of 
APO010, whereby without EDC APO010 is attached tight and gets detached by washing 
solutions, as cell culture medium. To increase the stress conditions to the anti-inflammatory 
coating, the PMP mats were transferred to a rotating setting and were washed for 30 min 
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eight times with PBS and only low Tween-20 concentrations (0.02 %) as not to stress the 
Jurkat cells by the detergent. As expected, the samples without EDC show high apoptosis 
rates in the first washing solution, but interestingly from the third washing solution the 
apoptosis rate decreases to the same as for the sample with EDC. This means that both 
samples showed similar results in the washing solutions, but the kill-rates for the samples 
with EDC were much lower. 
As the anti-inflammatory coating shall be used in a medical device with blood contact, it is 
important to understand the behavior of the anti-inflammatory coating during usage. 
Therefore, the coating was incubated with blood and the blood was analyzed for APO010 
content. Small amount of APO010 were detected in the blood sample with and without EDC. 
But functionality of anti-inflammatory coating with neutrophils showed the expected results 
and the analyzed blood samples showed no transition in the full blood count. In addition, no 
cytotoxicity was found in mouse fibroblasts. 
Summing up, the assays performed with blood suggest that no relevant detectable amounts 
of APO010 have detached from the surface even after washing with blood or PBS. Thus, the 
results indicate that the anti-inflammatory coating is stable and functional even after contact 
with blood. 
Thus, more detailed results of the blood compositions would be interesting. Therefore, 
chemotaxis assays with full blood cultures would be of great interest, but are difficult to 
handle due to the huge amount of different components in the blood. 
In this part an aa-based stabilizing formulation with only seven amino acids at pH 6.5 was 
used as last coating step. As the formulation was only added to analyze the coating via SEM 
no stability tests were performed. In the next chapter three different formulations will be 
investigated to analyze the stability effect of the formulations. By the characterization of the 
anti-inflammatory coating via SEM, it could be shown that the stabilizing formulation was 
dried skin-shaped and irregular with sharp-edged deposits on the bottom. As the shape of 
the stabilizing formulation has no high impact on the stability, this was not further 
investigated. However, to avoid inhomogeneous results due to the drying process in lab 
scale, in the next chapter in the upscaling whole medical devices were used. In this setting 
defined contact points should generate reproducible drying results.  
The characterization of the surface in general was not possible due to the low APO010 
concentrations. Most characterization methods as FTIR need smooth surfaces and high 
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protein concentrations of at least 1 mg/ml. The contact angle method to differ the surface 
properties before and after coating of the anti-inflammatory coating showed only differences 
by adding the stabilization formulation.   
Anti-inflammatory coatings are used for implants or prostheses [119, 120], hernia repair 
[121], disorders [122] or are used in general to differentiate monocytes into macrophages 
[123]. This anti-inflammatory coating is an innovative approach for a medical device with 
blood contact, with high requirements in stability and functionality. Thus, it can possibly show 
the way for new biofunctional coatings in the medical device sector. 
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CHAPTER IV 
 
UPSCALING OF THE COUPLING PROTOCOL TO SERIAL 
PRODUCTION SCALE 
 
4 Introduction 
This chapter describes the upscaling of the anti-inflammatory coating to a serial production 
scale. The anti-inflammatory coating had to be upscaled stepwise in order to generate a 
homogenous distribution on the PMP hollow fibers. In the previous chapters the anti-
inflammatory molecule was selected, the coating was developed in a lab scale model and in 
a circuit setting to investigate the flow behavior of the solutions in the coating procedure. 
In the final lab scale model a very low concentration of 20 ng/ml of APO010 was determined 
as functional.  This low concentration requires a fast und homogenous binding of the anti-
inflammatory molecule APO010 in the EDC crosslinking step, whereby it is crucial to 
consider this aspect during the development of an upscale process.  
In this upscaling process, several intermediate steps were included, whereby the bench 
setting with three 1.1 x 1.1 cm PMP pieces was first transferred to the circuit setting with 
three PMP circles with 20 mm diameter. The circuit setting then was upscaled to the coating 
of one medical device with a PMP surface area of 10 800 cm2. This was transferred to the 
coating of 6, then 20 and then 22 medical devices.  
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One medical device consists of 54 10 x 10 cm PMP mats, which are 90° rotated on top of 
each other. The surface area was simply calculated for a flat area, whereby the fiber tube 
structure was disregarded. 
Incubation times and concentrations of the coating components will be investigated in this 
chapter. A stabilization formulation is included in the anti-inflammatory coating to protect the 
coating during drying, and sterilization via EtO. Three different formulations will be tested in 
this part. The stabilization formulation F1 has only seven amino acids (aa) [55, 124]. F2 is 
more complex with 15 aa and 2 dipeptides and F3 consists of 8 aa, one sugar, and 
Polysorbate.  
The formulations were selected based on the knowledge that amino acids can stabilize 
proteins and on the fact that in nature an intracellular high osmolality can protect the 
organism during water stress as with high environmental salt concentrations [65, 75]. The 
combination of amino acids and sugars can effectively stabilize biologics in the dried state as 
many organisms can survive dehydrated in a process called anhydrobiosis, when they 
concentrate disaccharides like trehalose intracellularly [76, 77]. 
The upscaling process is a crucial step in the design of the anti-inflammatory coating, which 
shall be used for invasive medical devices. Therefore, the three serial production runs were 
performed in a clean room under terms and conditions of the ISO 11607 [125]. 
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 Materials and methods 4.1
Table 4-1. Equipment 
Name  Reference 
Analytical balance, AT460 Delta Range Mettler-Toledo, Columbus, Ohio, USA 
Balance KERN & SOHN GmbH, Balingen, Germany 
Balance Scout Pro SPU 123 VWR International GmbH, Ismaning, Germany 
Centrifuge Biofuge fresco, max.13 000 rpm or 
16 060 x g 
Heraeus, Hanau, Germany 
Centrifuge Megafuge 1.0R, max. 4000 rpm or 
3345 x g 
Heraeus, Hanau, Germany 
CO2 incubator Sanyo Denki K.K, Moriguchi, Japan 
Filter holder device (diameter 25 mm, PSU) Whatmann, Maidstone, United Kingdom 
Filter holder device (diameter 50 mm, PC) Sartorius, Göttingen, Germany 
Flexible-tube pump MCP IDEX Health&Science (ISMATEC), Wertheim, 
Germany 
Flow cytometer BD Accuri C6 BD Biosciences, San Jose, Germany 
Flowmaster FMT 300 IDEX Health&Science (ISMATEC), Wertheim, 
Germany 
Fusion photometer PerkinElmer, Inc., Waltham, Massachusetts, USA 
Helios Gamma Spectrophotometer Thermo Fisher Scientific, Waltham, Massachusetts, 
USA 
Incubator BINDER GmbH, Tuttlingen, Germany 
Karl-Fischer-Coulometer KF 831 Metrohm GmbH & Co, Filderstadt, Germany 
Micro-Centrifuge Galaxy 14 D,  
max. 13 000 rpm or 14 000 x g  
VWR International GmbH, Ismaning, Germany 
Micro-Centrifuge Sprout, 2000 x g Kisker Biotech GmbH & Co. KG, Steinbach, Germany 
Microscope Axiovert 40C  Carl Zeiss AG, Oberkochen, Germany 
Mini-Shaker PSU-2T Biosan, Riga, Latvia 
Mini-vortexer, Vortex V-1 plus Kisker Biotech GmbH & Co. KG, Steinbach, Germany 
Multiflow pump Stöckert Instrumente, Munich, Germany 
Nanophotometer 7122 V2.3.1 Implen GmbH, Munich, Germany 
Neubauer counting chamber Glaswarenfabrik Karl Hecht GmbH & Co K, 
Sondheim/Rhön, Germany 
NovaFlow c Ultrasonic Flowcomputer Novalung GmbH, Heilbronn, Germany 
SevenEasy pH-Meter Mettler-Toledo, Columbus, Ohio, USA 
Sterile bench Kojair, Vilppula, Finland 
Thermo-Shaker Kisker Biotech GmbH & Co. KG, Steinbach, Germany 
Vakuum oven Yamato Scientific Co., Ltd., Tokyo, Japan 
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Name  Reference 
Water bath Memmert GmbH + Co.KG, Schwabach, Germany 
 
Table 4-2. Biomolecules and amino acids 
Name Reference 
Alanine, L- (EP, USP) AppliChem GmbH, Darmstadt, Germany 
Anti-Adiponectin/Acpr30, 0.2 mg/ml in PBS 
(binds polyclonal to aa 19-244 )  
R&D Systems, Minneapolis, Minnesota, USA 
APO010, 490 µg/ml in PBS, Active 
Pharmaceutical Ingredient 
Oncology Venture, Hoersholm, Denmark 
Arginine, L- (USP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Aspartic acid, L- (EP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Bovine Serum Albumin (BSA) Sigma-Aldrich, St. Louis, Missouri, USA 
Fas-Fc, lyophilized (extracellular part of Fas 
receptor fused to an Fc-domain) 
kindly provided by Prof. Martin Zörnig, Georg-
Speyer-Haus, Frankfurt, Germany 
Glutamic acid, L- (EP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Glycine (EP, USP, JP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Glycyl-L-glutamine monohydrate (≥ 97 % HPLC) Sigma-Aldrich, St. Louis, Missouri, USA 
Glycyl-L-tyrosine (≥ 98 %) Sigma-Aldrich, St. Louis, Missouri, USA 
Histidine, L- (EP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Isoleucine, L- (USP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Leucine, L- (≥ 98 % HPLC) Sigma-Aldrich, St. Louis, Missouri, USA 
Lysine acetate salt (USP) Sigma-Aldrich, St. Louis, Missouri, USA 
Lysine, L-, HCl (EP, USP, JP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Methionine, L- (≥ 99 %) Sigma-Aldrich, St. Louis, Missouri, USA 
Phenylalanine, L- (EP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Proline, L- (EP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Recombumin Alpha 10% (albumin) Novozymes A/S, Bagsværd, Denmark 
rhIL-8 recombinant human R&D Systems, Minneapolis, USA 
Serine, L- (EP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Sodium-Heparin, 250000 IU Rathiopharm, Ulm, Germany 
Streptavidin conjugated to horseradish 
peroxidase (Streptavidin-HRP) 
R&D Systems, Minneapolis, Minnesota, USA 
Threonine, L- (EP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
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Name Reference 
Tryptophan, L- (EP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Valine, L- (USP) Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
 
Table 4-3. Materials 
Name  Reference 
Aqua B. Braun, purging solution, sterile and 
pyrogen-free = H2O 
B. Braun Melsungen AG, Melsungen, Germany 
DuPont™ Tyvek® Steriking® Bags Wipak Oy, Nastola Plant, Nastola, Finland 
EDC (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide 
hydrochloride) 
Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Ethanol, 70 % Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Hydranal Coulomat AD Sigma-Aldrich, St. Louis, Missouri, USA 
Hydranal Water Standard KF-Oven Sigma-Aldrich, St. Louis, Missouri, USA 
Oxygenator  Novalung GmbH, Heilbronn, Germany 
OXYPLUS
®
, Polymethylpentene (PMP) hollow 
fibers for gas exchange 
Membrana, Wuppertal, Germany 
PBS w/o Mg
2+
/ Ca
2+
  Biochrom GmbH, Berlin, Germany 
Polysorbate 20 Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Skim milk powder Sigma-Aldrich, St. Louis, Missouri, USA 
Sulfo-NHS (N-hydroxysulfosuccinimide) Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Sulfuric acid (H2SO4), 96% Sigma-Aldrich, St. Louis, Missouri, USA 
TMB (3,3’,5,5’-Tetramethylbenzidine) Invitrogen, Carlsbad, California, USA 
Trehalose Dihydrate (USP/NF, EP, JP) Pfanstiehl, INC., Waukegan, Illinois, USA 
Trypanblue, 0.4 % Sigma-Aldrich, St. Louis, Missouri, USA 
 
 
Table 4-4. Media and solution 
Name Reference 
Fetal bovine serum (FBS) Superior Biochrom GmbH, Berlin, Germany 
L-Alanyl-L-Glutamine, 200 mM Biochrom GmbH, Berlin, Germany 
RPMI 1640 Medium w/ 20 mM HEPES, w/o 
NaHCO3, w/o L-Glutamine 
Biochrom GmbH, Berlin, Germany 
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Table 4-5. Cell lines 
Name  Cell type characteristics 
Human blood  Different healthy donors 
 
4.1.1 Isolation of neutrophils 
Neutrophils were isolated as described in 2.1.2. Human blood was collected from healthy 
donors in neutral S-monovettes (Sarstedt) spiked with 5 U/ml Na-Heparin. 
Cell culture medium: RPMI 1640 Medium w/ 20 mM HEPES 1640, 10 % FBS, 
2 mM L-Alanyl-L-Glutamine 
4.1.2 Chemotaxis assay 
The chemotaxis assay as described in 2.1.6 was modified in this chapter to investigate the 
impact of the anti-inflammatory coating in direct contact to the neutrophils. Therefore, the 
coated PMP slides were placed in the upper compartment as shown in Figure 4-1 and were 
fixed by silicone rings with a cut-out of 0.5 cm x 0.5 cm in the center.  
Cell culture medium or cell culture medium with chemoattractant IL-8 (1 ml, 25 ng/ml) were 
added into the lower compartment of the chemotaxis chamber, then the coated PMP-slide 
was added to the upper compartment and fixed with a silicon ring and 500 μl of cell 
suspension (0.1 x 106 cells/ml) were layered on top. Then the samples were incubated for 
1 h at 37 °C. 
After incubation, the contents of the lower compartments were transferred to a FACS tube 
and 125 μl of the samples were measured with the BD Accuri C6 flow cytometer (BD 
Biosciences). The number of events in the previously determined gate was counted. A vitality 
test was carried out before and after the chemotaxis incubation as described in 2.1.6. All 
samples were normalized to the untreated negative control for each group (with and without 
IL-8), respectively. 
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Figure 4-1. Schematic representation of the modified chemotaxis chamber. 
The chamber is divided into two compartments: the upper compartment contains the neutrophil 
suspension and the coated PMP-slide (broken red line), which is fixed with a silicon ring (light blue 
lines at the edge of the upper compartment), the lower compartment contains cell culture medium 
(negative control) or cell culture medium with the chemoattractant IL-8. Between the two 
compartments there is a porous membrane with a pore size of 3 μm. The neutrophils can actively 
migrate through the pores and after 1 h incubation the neutrophil suspension in the lower 
compartment is analyzed by flow cytometry.  
 
4.1.3 Anti-inflammatory coating 
The coating of the anti-inflammatory coating is described in detail in 3.1.5 and was carried 
out as described there. In addition, the anti-inflammatory coating was upscaled to several 
medical devices. 
4.1.3.1 The bench setting 
The bench setting is described in 3.1.5.2.1. 
4.1.3.2 The circuit setting 
The circuit setting is adapted from one mat in a holder device as described in 3.1.5.2.2 to 
three mats in a holder device to simulate layers as in the medical device. Three mats were 
layered 90° to each other. The circuit setting was filled with 8 ml of each coating solutions as 
described below and incubated with a flow rate of 15.7 ml/min. 
First, 8 ml EDC coating solution (0.5 mM in H2O) was incubated with the PMP for 15 min and 
the setting was washed 1 min with H2O. Second, 8 ml APO010 solution (20 ng/ml to 
100 ng/ml in PBS) was added and incubated for 30 min. The solution was removed and the 
mat was washed 5 min with H2O. Third, the reaction was quenched by adding 8 ml albumin 
(0.01 % in H2O) for 15 min. The solution was removed and washed 15 min with H2O. 
Afterwards, the mats were analyzed by ELISA. 
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Figure 4-2. Schematic illustration of coupling approach in adapted circuit setting. 
Three round PMP slides with 20 mm diameter were layered 90° to each other in the holder device (3) 
in the circuit. The circuit has a total volume of 8 ml (20 mm holder device) and the coating solution (1) 
is pumped through the circuit via a flexible-tube pump (Flexible-tube pump MCP, ISMATEC, Germany) 
(4) into a collecting container (2). Flow rate 15.7 ml/min. 
 
4.1.3.3 The upscaling setting 
In the upscaling setting, the coating procedure was optimized for one medical device in 
circuit as shown in Figure 4-3. 350 ml coating solution was used in this setting for all coating 
solutions. 
First, 350 ml EDC coating solution (0.5 mM in H2O) was incubated with the PMP for 15 min 
and the setting was washed with 350 ml H2O. Second, 350 ml APO010 solution (20 ng/ml to 
100 ng/ml in PBS) was added and incubated for 30 min. The solution was removed and the 
mat was washed with 1 l H2O. Third, the reaction was quenched by adding 350 ml albumin 
(0.01 % in H2O) for 15 min. The solution was removed and the setting was washed with 
1 l H2O. Afterwards, the samples were collected as described below.  
For sample preparation, the medical device was opened and the samples were collected 
according to Figure 4-4. The 54 PMP mats contained in the device were cut out by a scalpel 
and were numbered from 1 to 54 in the direction of the initially flow direction. For sample 
preparation, three pieces (1.1 x 1.1 cm) of position A, B and C were cut out by a manual 
punch and were further analyzed by the different ELISAs. 
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A     B 
 
 
 
 
 
 
Figure 4-3. Image of the medical device and schematic illustration of the coupling approach in 
the upscaling setting. 
A Image of the medical device without cover on the sides. The device consists of 54 PMP hollow fiber 
mats, whereby mat 1 is the first in flow direction. By filling the device, it is always filled from the bottom 
to the top. The Luer Lock ports (white with yellow caps) on the top on both sides enable the removal of 
air during coating and priming and can be used as pressure sensors. The 54 PMP mats are layered 
90° to each other in the device, respectively. At the edge, the mats are fixed with PU (light yellow) to 
keep the mats in the middle of the device in the right position. 
B The circuit has a total volume of 350 ml and the coating solution (1) is pumped through the medical 
device (3) via a flexible-tube pump (Multiflow pump, Stöckert Instruments, Germany) (4) into a 
collecting container (2). The medical device is filled from the bottom to the top by the port indicated by 
the circle. The medical device consists of 54 PMP mats, whereby mat 1 is the first in flow direction.  
Flow rate 0.5 – 1 l/min. 
 
 
Figure 4-4. Illustration of the sample collection of the medical device from the top view.  
As the medical device is filled from the bottom to the top by the port indicated by the circle, the PMP 
mats were numbered serially from 1 to 54, whereby mat 1 is the first in flow direction. For homogeneity 
coating studies, the PMP mat numbers 2, 10, 27, 44 and 54 were analyzed at three different 
positions A, B and C. The position A indicates the area on the mats, which was coated first, then the 
area which was coated second (position B) and third (position C). By analyzing these three positions 
and the different mat numbers in the device, it can be investigated, if the whole device is coated 
homogenously or not. 
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4.1.3.4 The upscaling to serial production scale 
In the serial productions runs the anti-inflammatory coating was upscaled to several medical 
devices. The coating was performed as in the other settings, but here three different amino 
acid (aa)-based stabilization formulations were used as last protection layer during 
sterilization and storage as indicated in Table 4-6. 
Table 4-6. AA-based stabilization formulations 
AA-based stabilization 
formulations 
Content 
F1 (aa-based formulation 
with 7 aa), 20 g/l 
Ala, Arg, Glu, Gly, His, Lys-HCl, Trp 
pH 6.5 in H2O 
F2 (aa-based formulation 
with 15 aa and 2 
dipeptides), 30 g/l 
Ala, Arg, Asp, Glu, His, Ile, Leu, Lys-Acetate, Met, N(2)-Gly-Gln,  
N(2)-Gly-L-Tyr, Phe, Pro, Ser, Thr, Trp, Val 
pH 6.5 in H2O  
F3 (aa-based formulation 
with 8 aa, one sugar and 
Polysorbate), 30 g/l 
Arg, Asp, Glu, His, Lys-HCl, Ser, Thr, Trp, Trehalose, Polysorbate 20  
pH 6.5 in H2O 
 
First serial production run 
In the first serial production run, six medical devices were coated in line with a flow rate of 
2 l/min (Figure 4-5), whereby the solution was pumped in circle after the whole setting was 
filled. The coating solutions were used in a total volume of 5.8 l. This correlates to a 
theoretical ratio of 1.79 ng/cm2 APO010 per device. In Table 4-7 the separate steps of the 
coating are shown. 
 
Figure 4-5. Schematic setting of the first serial production run. 
In the first serial production run six medical devices were coated in a flow system, whereby no EtO 
treatment was performed.  
Coating settings: 0.5 mM EDC, 20 ng/ml APO010, 0.01 % albumin, 20 g/l aa-based stabilization 
formulation F1, volume 5.8 l, flow rate 2 l/min. The flow rate was detected before #1 and #6. The 
pressure was detected before #1, #4 and after #6. 
 Chapter IV: Upscaling of the coupling protocol to serial production scale 
 
 
 
101 
 
Table 4-7. Coating scheme of first serial production run 
 Coating step / concentration Time Flow rate / pressure  
1 Flushing with H2O 5 min 2 l/min 
2 Blowing out 20 sec 1 bar 
3 EDC / 0.5 mM in H2O (pH 5.0) 15 min 2 l/min 
4 Flushing with H2O 5 min 2 l/min 
5 Blowing out 20 sec 1 bar 
6 APO010 / 20 ng/ml in PBS (pH 7.2-7.5) 45 min 2 l/min 
7 Flushing with H2O 5 min 2 l/min 
8 Blowing out 20 sec 1 bar 
9 Albumin / 0.01% in H2O (pH 4.5) 15 min 2 l/min 
10 Flushing with H2O 5 min 2 l/min 
11 Blowing out 20 sec 1 bar 
12 Stabilization formulation F1 / 20 g/l in H2O (pH 6.5) 30 min 2 l/min 
13 Blowing out 20 sec 1 bar 
14 Drying 50 °C vacuum oven o/n vacuum 
 
Second serial production run 
In the second serial production run 1, 20 medical devices were coated in-line with APO010 
(33.35 ng/ml), albumin and the aa-based stabilization formulation F2 (volume 6 l, flow rate 
1.5 l/min) and in the second serial production run 2 another set of 20 medical devices was 
coated with APO010 (33.35 ng/ml), albumin and aa-based stabilization formulation F1 
(volume 6 l, flow rate 1.5 l/min). The coating solutions were used in a total volume of 6 l. All 
solutions were pumped in circle after the whole setting was filled. The first flow direction was 
from left to right and was then changed every 5 min. The APO010 concentration used in 
these two runs correlates to a theoretical ratio of 0.925 ng/cm2 APO010 per device. 
In Table 4-8 separate steps of the coating are shown. After coating of medical devices 1 to 
20 (stabilized with F2) and medical devices 21 to 40 (stabilized with F1) different steps were 
performed with the medical devices. Nine medical devices were directly investigated to test 
the coating, four medical devices were used for a bioburden test and 27 medical devices 
were EtO-treated (Table 4-9). 
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Figure 4-6. Schematic setting of the second serial production run 1 and 2. 
In the second serial production run 1 20 medical devices were coated with APO010 (33.35 ng/ml), 
albumin and F2 (volume 6 l, flow rate 1.5 l/min) and in the second serial production run 2 another 
set of 20 medical devices was coated with APO010 (33.35 ng/ml), albumin and F1 (volume 6 l, flow 
rate 1.5 l/min).  
Coating settings: 0.5 mM EDC, 33.35 ng/ml APO010, 0.01 % albumin, 30 g/l F2 or F1, volume 6 l, flow 
rate 1.5 l/min. The flow rate was detected before #1/ #21 and #11/ #31. The pressure was detected 
before #1/ #21, #5/ #25 and after #10/ #30 (run 1 with F2/run 2 with F1). Afterwards, an EtO treatment 
and storage at different conditions were carried out. 
 
Table 4-8. Coating scheme of second serial production run 1 and 2 
 Coating step / concentration Time Flow rate / pressure  
1 Flushing with H2O 5 min 1.5 l/min 
2 Blowing out 20 sec 1 bar 
3 EDC / 0.5 mM in H2O (pH 5.0) 15 min 1.5 l/min 
4 Flushing with H2O 5 min 1.5 l/min 
5 Blowing out 20 sec 1 bar 
6 APO010 / 33.35 ng/ml in PBS (pH 7.2-7.5) 45 min 1.5 l/min 
7 Flushing with H2O 5 min 1.5 l/min 
8 Blowing out 20 sec 1 bar 
9 Albumin / 0.01% in H2O (pH 4.5) 15 min 1.5 l/min 
10 Flushing with H2O 5 min 1.5 l/min 
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 Coating step / concentration Time Flow rate / pressure  
11 Blowing out 20 sec 1 bar 
12 Stabilization formulation F1 or F2 / 30 g/l in H2O  
(pH 6.5) 
30 min 1.5 l/min 
13 Blowing out 20 sec 1 bar 
14 Drying 50 °C vacuum oven o/n vacuum 
 
Table 4-9. Overview of workflow for the 2x 20 medical devices of the second serial production 
run 1 and 2 
Number 
of 40 
 Position number Analysis 
9 of 40 w/o EtO treatment # 21, 25, 30, 32, 35, 40 
# 1, 15, 20 
Coating efficacy assay 
4 of 40 w/o EtO treatment # 32, 33 
# 12,13 
Bioburden 
27 of 40 EtO treatment # 22, 23, 24, 26, 27, 28, 29, 
34, 36, 37, 38, 39 
# 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 
14, 16, 17, 18, 19 
 
1 of 27 Priming test # 11 Coating efficacy assay 
detachment assay 
2 of 27 Bioburden # 34 
# 14 
Bioburden 
12 of 27 Storage  
for 20 days at 
different 
temperautres 
5°C:    # 22, 39 
           # 2, 19 
RT:     # 23, 38 
           # 3, 18 
55 °C: # 24, 37 
           # 4, 17 
Coating efficacy assay 
12 of 27 Back-up # 26, 27, 28, 29, 36 
# 5, 6, 7, 8, 9, 10, 16 
Storage at RT 
 
 
In the second serial production run 1 and 2 the stability testing of the medical devices were 
tested according to the norm for medical devices. Therefore, the stability testing was 
performed by accelerated aging until real-time aging studies are available. According to ISO 
11607 the medical devices were packed in Tyvek® bags and sterilized as described in 4.1.4 
[125]. The accelerated aging studies are based on the Arrhenius reaction rate function as 
described in the norm ASTM F 1980 [126]. By this theory an accelerated aging factor (AAF) 
can be calculated with an accelerated aging temperature (TAA) of 55°C, a room temperature 
(TRT) of 23°C, an aging factor (Q10) of 2 which is most common.  
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This results in an accelerated aging time (AAT) of 20 days, which correspond to a 6 month 
real-time storage as depicted in the following equations (1-3): 
       
 
(       )
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(     )
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 (           )
    
                                      (3) 
 
Third serial production run 
In the third serial production run, 22 medical devices were coated with APO010 (35 ng/ml), 
albumin and F3 (volume 6 l, flow rate 1.5 l/min) in a circuit setting as shown in Figure 4-7. 
The coating solutions were used in a total volume of 6 l. All solutions were pumped in circle 
after the whole setting was filled. This correlates to a ratio of 0.885 ng/cm2 APO010 per 
device. 
As described above the medical devices were packed, sterilized and  the accelerated aging 
protocol was designed according the ISO 11607 and ASTM F 1980 [125, 126]. By this theory 
an accelerated aging factor (AAF) can be calculated with an accelerated aging temperature 
(TAA) of 55°C, a room temperature (TRT) of 23°C, an aging factor (Q10) of 2 which is most 
common. This results in an accelerated aging time (AAT) of 80 days, which correspond to a 
2 year real-time storage as depicted in the following equations (1-3): 
       
 
(       )
  
 
        (1) 
      
(     )
  
             (2) 
    
       
    
                                      (3) 
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Figure 4-7. Schematic setting of the third serial production run in a circle setting. 
In the third test run 22 medical devices were coated with APO010 (35 ng/ml), albumin and aa-based 
stabilization formulation F3 (volume 6 l, flow rate 0.2-0.3 l/min). The flow rate was detected after #5. 
The pressure was detected after #5 and #6. Afterwards, an EtO treatment and storage at different 
conditions were performed. 
 
Table 4-10. Coating scheme of third serial production run 
 Coating step / concentration Time Flow rate / pressure  
1 Flushing with H2O 5 min 0.2- 0.3 l/min 
2 Blowing out 5 min 1 bar 
3 EDC / 0.5 mM in H2O (pH 5.0) 15 min 0.2- 0.3 l/min 
4 Flushing with H2O 5 min 0.2- 0.3 l/min 
5 Blowing out 5 min 1 bar 
6 APO010 / 35 ng/ml in PBS (pH 7.2-7.5) 45 min 0.2- 0.3 l/min 
7 Flushing with H2O 5 min 0.2- 0.3 l/min 
8 Blowing out 5 min 1 bar 
9 Albumin / 0.01% in H2O (pH 4.5) 15 min 0.2- 0.3 l/min 
10 Flushing with H2O 5 min 0.2- 0.3 l/min 
11 Blowing out 5 min 1 bar 
12 Stabilization formulation F3 / 30 g/l in H2O (pH 6.5) 30 min 0.2- 0.3 l/min 
13 Blowing out 5 min 1 bar 
14 Drying 50 °C vacuum oven o/n vacuum 
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Table 4-11. Overview of workflow for the 22 medical devices of the third serial production run 
Number 
of 22 
 Position number Analysis 
4 of 22 w/o EtO treatment # 1, 2, 3, 4 Coating efficacy assay 
18 of 22 EtO treatment # 5-22  
15 of 18 Storage and 
accelerated 
aging 
20 d, RT: # 5, 6, 7 
20 d, 55 °C: # 14, 15, 16 
50 d, 55 °C: # 17, 18, 19 
80 d, 55 °C: # 20, 21, 22 
Coating efficacy assay 
3 of 18 Coating 
distribution 
# 11, 12, 13 Coating efficacy assay 
3 of 18 Back-up # 8, 9, 10 Storage at RT 
 
 
4.1.4 EtO Sterilization 
An EtO sterilization process was carried out from an external service provider (Rose GmbH, 
Tier) with selected medical devices after coating and drying of the anti-inflammatory coating.  
The devices were treated with EtO in the cycle B 01 according to DIN EN ISO 11135-1:2007. 
The main conditions of EtO treatment for medical devices were as followed: pre-conditioning 
(10 – 48 h, 45 °C – 53 °C, 45 % – 80 % relative humidity), sterilization (100 vol% EtO for 4 – 
5 h, 45 °C – 53 °C, and several flushing cycles), and post-conditioning (22 – 54 h, 45 °C – 
53 °C, and >7-fold/h air change). 
4.1.5 Read-out for monitoring coating efficacy  
The coating efficacy assay, previously called non-functional ELISA, is carried out in this 
chapter to monitor the coating efficacy and the homogenous distribution of the coating. The 
coating efficacy assay is described in 3.1.8. 
4.1.6 Functional Enzyme-linked Immunosorbent Assay (ELISA) 
The functional ELISA is carried out in this chapter to investigate the functional coupling of 
APO010 and is described in 3.1.7. 
4.1.7 Detachment assay 
The detachment ELISA is carried out in this chapter to investigate the stability of the coating 
and is described in 3.1.9. 
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4.1.8 Residual moisture 
The residual moisture was measured by Karl-Fischer-titration using an 831 KF Coulometer 
and an 832 KF Thermoprep by Metrohm. The assay was done with HYDRANAL®-Coulomat 
AD and HYDRANAL®-Water Standard KF-Oven at 140°C to 160°C. The residual moisture 
from the water standard was extracted at 160°C. The moisture content of the 1.1 x 1.1 cm 
PMP mats was extracted at 120°C. Therefore, approximately 150 mg of each sample was 
weighed into 6R glass vials. 
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 Results 4.2
This section describes the upscaling of the anti-inflammatory coating to a serial production 
scale. Several intermediate steps were included, whereby the bench setting was transferred 
to the circuit setting. The circuit setting was transferred to the coating of one medical device 
called upscaling setting here and this was transferred to the coating of 6, then 20 and then 
22 medical devices. 
4.2.1 Transfer of the bench setting to circuit setting 
The transfer of the coating protocol in the bench setting to circuit setting was a crucial step in 
the upscaling process. In this step, the settings were performed parallel to each other and 
were compared with two analytical methods to evaluate the coating process: the functional 
ELISA and the non-functional ELISA. The functional ELISA was used to detect the functional 
FasL domain of the APO010 and thereby to detect the amount of functional coupled 
APO010. The non-functional ELISA was used to detect the amount of coupled APO010 via 
the Adiponectin domain of APO010. 
In the circuit setting, different APO010 concentration were investigate in order to test, which 
is the lowest detectable APO010 concentration in both ELISAs. We aimed at a preferably low 
APO010 concentration, because it is known from chapter 2 that only 2 ng/ml APO010 results 
in high activity in the apoptosis assay. When APO010 is coated to PMP, APO010 
concentrations from 20 to 1000 ng/ml were used in chapter 3.  
In this chapter, APO010 concentrations of 20 ng/ml, 50 ng/ml, 75 ng/ml and 100 ng/ml shall 
be tested. The results of these investigations are presented in Figure 4-8. It is shown that the 
approaches of the bench and the circuit setting can be distinguished from the negative 
controls (nc) F (functional (f) = 0.18 ± 0.07 RU, non-functional (nf) = 0.10 ± 0.03 RU) and  
G (f = 0.11 ± 0.03 RU; = 0.12 ± 0.01 RU).  
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Approach setting Coating steps ng APO010/cm
2
 
A Bench setting V = 0.6 ml, 0.5 mM EDC 15 min, 100 ng/ml APO010 
30 min, 0.01 % albumin 15 min 
 
8.3 ng/cm
2
 
B Circuit setting V = 8 ml, 0.5 mM EDC 15 min, 100 ng/ml APO010 
30 min, 0.01 % albumin 15 min 
 
42.5 ng/cm
2
 
C Circuit setting V = 8 ml, 0.5 mM EDC 15 min, 75 ng/ml APO010 
30 min, 0.01 % albumin 15 min 
 
31.85 ng/cm
2
 
D Circuit setting V = 8 ml, 0.5 mM EDC 15 min, 50 ng/ml APO010 
30 min, 0.01 % albumin 15 min 
 
21.2 ng/cm
2
 
E Circuit setting V = 8 ml, 0.5 mM EDC 15 min, 20 ng/ml APO010 
30 min, 0.01 % albumin, 15 min 
 
8.5 ng/cm
2
 
F Bench setting V = 0.6 ml, 0.5 mM EDC 15 min, PBS 30 min 
0.01 % albumin 15 min 
 
0 ng/cm
2
 
G Non coated - 0 ng/cm
2
 
 
 
Figure 4-8. Schematic illustration of different settings analyzed by functional and non-
functional ELISA. 
APO010 was coupled via EDC (0.5 mM) to PMP in the bench setting and circuit setting with different 
concentrations of APO010 (20 to 100 ng/ml). The reaction was quenched with 0.1 % albumin. The 
coating success was analyzed via the functional and non-functional ELISA. The bench setting has a 
coating volume of 0.6 ml, whereby the circuit setting has a volume of 8 ml. This results in a different 
APO010 to area relation. The column chart shows the relative absorbance 450-550 nm in relative units 
[RU], whereby the relative absorbance is proportional to the amount of bound APO010 (Mean ± SD 
from n=3). 
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The relative absorption signals of the bench setting A (f = 0.31 ± 0.06 RU, nf= 1.27 ± 
0.11 RU) were lower than those of the circuit setting B (f = 0, 64 ± 0.24, nf = 2.18 ± 0.36 RU), 
which corresponds to the lower APO010 amount per area of PMP (8.3 ng/cm2 compared to 
42.5 ng/cm2, (Figure 4-8)). In the dilution series of the circuit setting from B to E (100 ng/ml to 
20 ng/ml), there was a deviation in batch C where the non-functional signal (nf = 1.26 ± 
0.08 RU) was identical to D (nf = 1.47 ± 0.26 RU). At the same time, the functional signal of 
approach B (f = 0.64 ± 0.24 RU) was identical to C (f = 0.78 ± 0.21 RU) and D (f = 0.64 ± 
0.14 RU). The approaches C and D do not differ strongly in the APO010 amount 31.9 ng/cm2 
and 21.2 ng/cm2. The signal of E (f = 0.43 ± 0.12, nf = 0.93 ± 0.05 RU) with the lowest 
APO010 amount of 8.5 ng/cm2 was comparable with the bench setting approach A, where 
8.3 ng/cm2 was used. Therefore, a range between 20 ng/ml and 50 ng/ml APO010 in the 
coating solution seems ideal for further upscaling. A higher concentration of 100 ng/ml 
APO010 delivers no benefit in the functional ELISA. However, the functional relevance of the 
whole coating has to be tested later on the end setting. 
 
In a second step, the EDC step was varied. Sulfo-NHS can be added to EDC during 
crosslinking to stabilize the instable intermediate. In the previous experiments no Sulfo-NHS 
was added to the EDC crosslinker. To test if the crosslinking process is improved, Sulfo-NHS 
was mixed to EDC in a ratio of 2.5:1 in the next experiment. 
Different crosslinking solutions were tested in the circuit setting (Figure 4-9): The approach A 
with 0.5 mM EDC / 1.25 mM Sulfo-NHS crosslinking solution shows the highest non-
functional signal (nf = 1.19 ± 0.10 RU), whereby the functional signal (f = 0.37 ± 0.08 RU) 
was comparable to approach C with 1 mM EDC crosslinking solution (f = 0.40 ± 0.11 RU). 
The non-functional signal of the coating with 1 mM EDC crosslinking solution (nf = 0.87 ± 
0.12 RU) was comparable to the coating with 0.5 mM EDC crosslinking solution (nf = 0.92 ± 
0.03 RU), whereby the functional signal of B was lower (f = 0.21 ± 0.03 RU). The negative 
control signals D (nf = 0.04 ± 0.00 RU; f = 0.06 ± 0.01 RU) and E (nf = 0.06 ± 0.05 RU;  
f = 0.05 ± 0.01 RU) differed only slightly from 0 and were thus significantly lower than that of 
the coatings. Due to the slight differences in the results with or without Sulfo-NHS, the 
protocol was not changed in the following. 
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Approach setting Coating steps ng APO010/cm
2
 
A Circuit setting V = 8 ml, 0.5 mM EDC + 1,25 mM Sulfo NHS 15 min, 
50 ng/ml APO010 30 min, 0.01 % albumin 15 min 
 
21.2 ng/cm
2
 
B Circuit setting V = 8 ml, 0.5 mM EDC 15 min, 50 ng/ml APO010 
30 min, 0.01 % albumin 15 min 
 
21.2 ng/cm
2
 
C Circuit setting V = 8 ml, 1 mM EDC 15 min, 50 ng/ml APO010 
30 min, 0.01 % albumin 15 min 
 
21.2 ng/cm
2
 
D Circuit setting V = 8 ml, 1 mM EDC 15 min, PBS 30 min, 0.01 % 
albumin 15 min 
 
0 ng/cm
2
 
E Non coated - 0 ng/cm
2
 
 
 
Figure 4-9. Circuit settings with different coating procedures analyzed by functional and non-
functional ELISA. 
APO010 was coupled (50 ng/ml) via EDC (0.5 mM or 1 mM w/ or w/o 1.25 mM Sulfo-NHS) to PMP in 
the circuit setting. The reaction was quenched with 0.1 % albumin. The coating success was analyzed 
via the functional and non-functional ELISA. The circuit setting has a volume of 8 ml. This results to an 
APO010 to area relation of 21.2 ng/cm
2
. The column chart shows the relative absorbance 450-550 nm in 
relative units [RU], whereby the relative absorbance is proportional to the amount of bound APO010 
(Mean ± SD from n=3). 
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In the third step, the incubation time of APO010 was optimized. Therefore, the circuit setting 
was tested with 30, 45, 60 and 75 min APO010 incubation and compared by the functional 
and non-functional ELISA (Figure 4-10). 
 
setting Coating steps ng APO010/cm
2
 
Circuit setting V = 8 ml, 0.5 mM EDC 15 min, 20 ng/ml APO010 
different incubation times (30, 45, 60, 75 min), 
0.01 % albumin 15 min 
 
8.5 ng/cm
2
 
 
Figure 4-10. Schematic illustration of different incubation times for APO010 in circuit setting. 
APO010 was coupled (20 ng/ml) via EDC (0.5 mM) to PMP in the circuit setting with different 
incubation times (30, 45, 60, 75 min). The reaction was quenched with 0.1 % albumin. The coating 
success was analyzed via the functional and non-functional ELISA. The circuit setting has a volume of 
8 ml. This results to an APO010 to area relation of 8.5 ng/cm
2
. The column chart shows the relative 
absorbance 450-550 nm in relative units [RU], whereby the relative absorbance is proportional to the 
amount of bound APO010 (Mean ± SD from n=3). 
 
An incubation time for APO010 of 45 min indicates the highest non-functional signal (nf = 
0.43 ± 0.06 RU). However, statistically, the non-functional signals of the batches with 30 min 
(nf = 0.37 ± 0.04 RU) and 60 min (nf = 0.38 ± 0.06 RU) incubation time are equal. In this 
experiment, the low APO010 concentration of 20 ng/ml results in low functional signals of all 
approaches, which cannot distinguished from the signals of negative control (f = 0.06 ± 0.04 
RU).  
In summary, the experiments indicate to use the following upscaling parameters: a range 
between 20 ng/ml and 50 ng/ml APO010 and an incubation time of 45 min. In addition, 
0.5 mM EDC without the usage of Sulfo-NHS results in good non-functional ELISA results. 
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The functional ELISA results deliver too low absorption signals when 20 ng/ml APO010 was 
used for coating. 
The coupling efficacy of APO010 to the PMP mats is very important due to the high costs of 
APO010. Therefore, it was investigated indirectly via the detachment assay how much 
APO010 is in the solution before and after the coating process. In addition, it was tested if 
there is any APO010 left in the washing solutions. Figure 4-11 shows that the APO010 
concentration is 16.2 ng/ml APO010 before the coating and 2.0 ng/ml after the coating in the 
solution. This means that only 12.42 % did not bind to the PMP mats. In the washing 
solutions 1 to 5 no APO010 could be detected. 
 
Figure 4-11. Results of the coating efficiency of APO010 before and after the coating. 
The anti-inflammatory coating was carried out with the bench setting and an APO010 concentration of 
20 ng/ml. After the incubation of APO010 with the PMP mats the mats were washed five times with 
H2O (washing solution 1 to 5). Each solution was detected with the detachment assay. The column 
chart shows the amount of bound APO010 [ng/ml] (Mean ± SD from n=3).  
 
4.2.2 Transfer from the circuit setting to the upscaling setting 
For the transfer of the circuit setting to the medical devices, in the first experiment one 
medical device was coated with a volume flow of 0.5 l/min to test the feasibility of the coating 
in the flow. The flow rate corresponds to the used flow rate in the circuit setting. Then, the 
device was opened and tested at different mat positions in the device as described in 4.1.3.3. 
The non-functional absorption signals of the analyzed samples of mat 2, 10, 27, 44 and 54 of 
position A, B and C are shown in Figure 4-12 A. The mean value indicates a homogeneity of 
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the coating by low standard deviation (nf = 0.32 ± 0.07 RU) and differs from the negative 
control signal (nf = 0.07 ± 0.02 RU). With regard to the homogeneity, there was no trend 
between the different positions on the individual mats. The coating was equally distributed to 
the mats. 
The total PMP mat area per device is approximately 10 800 cm2, which results in a ratio of 
0.65 ng/cm2 APO010 per area. In these experiments a higher APO010 amount was not 
possible to use due to availability. 
Due to the low absorption signals after coating with the flow rate of 0.5 l/min, it was tested, if 
a higher flow rate can increase this signal. In a second experiment, two devices were coated 
with a volume flow of 1 l/min, whereby one was tested directly after the coating and drying, 
the other was sterilized by EtO after it was packed in a Tvyek-bag. To stabilize the coating 
during this process, the devices were coated with an aa-based formulation 20 g/l F1 after the 
albumin treatment for 30 min and were dried without a washing process to deposit the 
protective formulation on the coating. The aa formulation with seven amino acids was used in 
this first experiment expecting good stabilization effect as known by literature [55, 124]. 
For the device, which was tested after coating and drying, the non-functional absorption 
signals of the analyzed samples of mat 2, 10, 27, 44 and 54 of position A, B and C (prepared 
according to Figure 4-4) are shown in Figure 4-12 B. The mean value indicates a 
homogeneity of the coating by low standard deviation (nf = 0.60 ± 0.05 RU) and differs from 
the negative control signal (nf = 0.10 ± 0.06 RU). With regard to the homogeneity, there was 
no trend between the different positions on the individual mats. The coating was equal 
distributed to the mats. By doubling the flow rate from 0.5 l/min to 1 l/min, the absorption 
signal is doubled as well. 
In order to test whether the sterilization with EtO has an influence on the homogeneity of the 
coating, a second device was tested as described above. Figure 4-12 C shows the results of 
the device. The mean value indicates a homogeneity of the coating by low standard deviation 
(nf = 0.24 ± 0.05 RU) and differs from the negative control signal (nf = 0.04 ± 0.02 RU). With 
regard to the homogeneity, there was no trend between the different positions on the 
individual mats. The coating was equal distributed to the mats, but compared to the device 
before EtO treatment, the absolute amount of APO010 was 2.5 fold lower after EtO 
sterilization. This means, the coating could not be fully protected by the stabilization 
formulation. 
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A               
  
 
 
 
 
 
B  
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
Figure 4-12. One medical device coated by the upscaling setting and analyzed by non-
functional ELISA. 
APO010 was coupled (20 ng/ml, 45 min) via EDC (0.5 mM, 15 min) to PMP in the upscaling setting 
with a flow rate of 0.5 l/min (A) or 1 l/min (B, C) which changed every 5 min. The reaction was 
quenched with 0.1 % albumin (15 min). 20 g/l stabilization formulation F1 was added on top of the 
coating for stabilization (30 min). In C the medical device was EtO sterilized after coating.  
The coating success was analyzed via the non-functional ELISA. The column chart shows the relative 
absorbance 450-550 nm in relative units [RU], whereby the relative absorbance is proportional to the 
amount of bound APO010 (Mean ± SD from n=3), nc = negative control (no APO010 was coated). 
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4.2.3 The serial production scale 
The goal of these experimental series was to transfer the coupling protocol into a serial 
production scale.  
In a first step, the development of a routine assay to monitor the quality of the anti-
inflammatory coating during serial production was necessary.  
In the second step, the adaptation of the lab-scale coating procedure to the serial production 
procedure had to be done. A homogenous distribution of covalently coupled APO010 within 
each device and in different devices after serial production had to be confirmed.   
Two main questions were addressed in general: Was the coating procedure efficient and is 
the coating stable and functional after sterilization and storage. For the monitoring of the first 
issue, the “coating efficacy assay” was performed. This assay is the previously described 
non-functional ELISA, which detects the Adiponectin domain on APO010. An additional 
functional assay for the quantification of the neutrophil activity was used (chemotaxis assay). 
For the monitoring of the second issue, the “detachment assay” was performed. This assay 
is based on a sandwich-ELISA, which was previously described. It is highly sensitive in the 
detection of detached APO010 molecules in the washing solutions.  
The overall goal is to confirm that even after prolonged storage there is no specific signal 
above the assay cut-off. In Figure 4-13 a workflow of the quality control (QC) assays is 
shown. 
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Figure 4-13. Schematic workflow of the QC assays after serial coating. 
 
 
Three serial production runs were performed in order to generate a homogenous upscaling 
protocol. An overview of these runs is depicted in Table 4-12. In a first production test run the 
anti-inflammatory coating protocol, which was established in the bench and circuit setting, 
was transferred to the serial production scale. In this run, six medical devices were coated in 
line. In the second serial production run 2x 20 medical devices were coated in a similar 
setting as the first production run. The stabilization formulation F2 and F1 were compared 
with each other in this run. In the third production test run 22 medical devices were coated in 
a circle for better distribution of the coating solutions.  
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Table 4-12. Overview of the three serial production runs 
Serial production 
run 
Description 
First serial  
production run 
6 medical devices (in-line)  
1.79 ng/cm
2
 APO010 per Device 
Coating solutions: APO010 20 ng/ml, albumin, stabilization formulation F1 
Volume 5.8 l  
Flow rate 2 l/min 
Second serial 
production run 1 
20 medical devices (2x10 in-line) 
0.925 ng/cm
2
 APO010 per Device 
Coating solutions: APO010 (33.35 ng/ml), albumin and stabilization 
formulation F2  
Volume 6 l 
Flow rate 1.5 l/min 
Second serial 
production run 2 
20 medical devices (2x10 in-line) 
0.925 ng/cm
2
 APO010 per Device 
Coating solutions: APO010 (33.35 ng/ml), albumin and stabilization 
formulation F1 
Volume 6 l 
Flow rate 1.5 l/min 
Third serial  
production run 
22 medical devices (in circle) 
0.885 ng/cm
2
 APO010 per Device 
Coating solutions: APO010 (35 ng/ml), albumin and stabilization  
formulation F3 
Volume 6 l 
Flow rate 0.2-0.3 l/min 
For composition of formulation F1, F2 and, F3 see Table 4-6. 
4.2.3.1 The first serial production run 
The first serial production run was carried out with six medical devices in-line, whereby 
positon #1, #3 and #6 were investigated further by the coating efficacy assay. The medical 
devices #2, #4 and #5 were tested externally specifically for their gas exchange quality. The 
gas exchange showed no anomalies, which means that the anti-inflammatory coating did not 
change the functionality of the gas exchanger (data not shown).  
The results of the coating efficacy assay are shown in Figure 4-14 B. In each medical device, 
there is a homogenous coating distribution from mat 2 to mat 54, respectively. But from 
medical device #1 to #3 and from #3 to #6 there is a reduction of APO010 coating by 
approximately 20 %. The cut off of the ELISA was defined as 0.1 relative absorbance units 
(RU) due to unspecific signal on negative controls < 0.1 RU. The relative absorbance is an 
indirect measure for the amount of coupled APO010 on PMP. The goal to reach a 
homogenous distribution from medical device #1 to #6 was not fulfilled with this setting. 
Therefore, a second serial production had to be done in a modified setting. The amount of 
devices was increased in the setting to have more medical devices to analyze. 
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B 
 
 
 
 
 
 
 
 
Figure 4-14. Results of the first serial production of six medical devices. 
A Schematic illustration of the first serial production run. Six medical devices were coated in-line by 
flow (0.5 mM EDC, APO010 20 ng/ml, 0.01 % albumin, 20 g/l stabilization formulation F1, total volume 
5.8 l, flow rate 2 l/min).  
B Samples of different PMP mat (mat 2, 10, 27, 44, 54) of different mat positions A, B and C and 
different medical devices #1, #3, #6 were investigated by the coating efficacy assay (ELISA). NC 
means that the PMP was coated with all components except APO010. The column chart shows the 
relative absorption 450-550 nm in relative units [RU], whereby the absorption signal of the ELISA is 
proportional to the amount of bound APO010. Error bars represent SD from the mean of n=3 (intra-
assay). The cut off was defined due to RU values <0.1 obtained for the NC. 
 
4.2.3.2 The second serial production run 
In order to avoid a flow direction dependent gradient of the coating, the flow was changed 
every five minutes (setting shown in Figure 4-15 A). The second serial production run 1  and 
2 were carried out with 20 medical devices, respectively, whereby 2x 10 medical devices 
were in-line. In run 1 the medical devices (#1-20) were flushed in the last step with the 
stabilization formulation F2 and in run 2 the medical devices (#21-40) were flushed with the 
stabilization formulation F1.  
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To adapt the coating protocol to the larger total volume and surface area, the APO010 
concentration was increased from 20 ng/ml to 33.35 ng/ml in the second serial production 
with 20 medical devices.  
From the 40 medical devices coated with the anti-inflammatory coating, nine medical devices 
were tested immediately after production to determine the coating efficacy (Figure 4-15 B). 
Four medical devices were used in a bioburden test, which was performed externally, to 
confirm sterility. The remaining 27 medical devices were sterilized with EtO by the standard 
procedure for medical devices after packed in Tyvek® bags as described in 4.1.3.4. 
After EtO treatment, twelve medical devices were stored at different temperatures (5 °C, RT 
and 55 °C) and tested after 20 days for stability and functionality. The accelerated aging 
procedure was performed according to the norm for medical devices [125, 126]. An 
accelerated temperature of 55 °C for 20 days correlates with six months real-time storage at 
RT and therefore provides important evidence for stability of the coating. The other medical 
devices were tested directly after the coating by means of the coating efficacy assay, 
bioburden tests, and by means of the detachment assay. One of those medical devices was 
filled with 0.9% NaCl solution, which is normally used as priming solution before filling the 
medical device with the patient blood and referred here as “priming test”. After circulation of 
the NaCl priming solution, the solution was investigated by the detachment assay to analyze 
detached APO010. For the priming test, medical device 11 was representatively used and 
incubation solutions were analyzed after different time points.  
 
Nine medical devices were directly tested by means of the coating efficacy assay. These 
medical devices were taken from the first, middle, and end position in the coating. The first 
flow direction was from left to right and was then changed every 5 min. Thus, device #1 and 
#11 were filled first with the coating solution, then #2 and #12, and so on. Figure 4-15 B 
shows, that the devices at the same position in the setting bound the same amount of 
APO010. Due to the low concentration of APO010 the devices on the first positions bound 
more APO010 than those on the last position. This results in a flow direction dependent 
reduction of bound APO010 from medical device #1/#11 to #10/#20 in run 1 and #21/#31 to 
#30/#40 in run 2, whereby in the first 5 min of flow direction from left to right the coupling of 
APO010 was determined. The change of flow direction every five minutes is not sufficient for 
a homogeneous distribution of APO010 in all devices. However, within each medical device 
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a homogenous coating distribution ranging from mat 2 to mat 54 was found. This result 
shows that the medical devices were filled completely during the coating procedure.  
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
Figure 4-15. Results of the second serial production of 2x 20 medical devices. 
A Schematic design of the second serial production system with 2x 20 medical devices. 2x 20 medical 
devices were coated via EDC 0.5 mM with APO010 (33.35 ng/ml), albumin (0.01 %) and stabilization 
formulation F2 (Volume 6 l, flow rate 1.5 l/min) and another set of 20 medical devices was coated via 
EDC 0.5 mM with APO010 (33.35 ng/ml), albumin (0.01 %) and stabilization formulation F1 (Volume 
6 l, flow rate 1.5 l/min). B Samples of different PMP mats (2, 54) of different mat position A and C were 
investigated by the coating efficacy assay (ELISA). The column chart shows the relative absorption 450-
550 nm in relative units [RU], whereby the absorption signal of the ELISA is proportional to the amount of 
bound APO010. Error bars represent SD from the mean of n=3 (intra-assay). The cut off was defined 
due to RU values <0.1 obtained for the negative control. 
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In addition to the relative absorption signal in Figure 4-15, in Table 4-13 the reduction of the 
absorption signal from the first medical device to the middle medical device in-line and from 
the middle medical device to the last medical device in-line is shown. The reduction of the 
absorption signal was found to be comparable in the second serial production run 1 and 2.  
This means that both runs performed in the same way and are comparable. In addition, from 
this data it can be assumed that the medical devices more distal from the coating solution 
source receive less APO010 compared with those more proximal. But, the anti-inflammatory 
coating distribution is homogenous within each device. A modified coating set-up should 
therefore be applied to allow similar flushing of all medical devices at the same time. 
 
Table 4-13. Reduction of absorbance in percent flow direction during coating process 
 Flow direction 
 
 
 
 
Reduction of absorption [%] 
Batch 1 
#1 to # 15 42.61  
#15 to # 20 27.83  
Batch 2 
#21 to # 25 45.62 
# 25 to # 30 21.86 
# 31 to # 35 41.77 
# 35 to # 40 17.80 
 
In order to determine the potential effects of EtO sterilization on the coating efficacy, EtO-
sterilized medical devices and non-sterilized medical devices were tested in the coating 
efficacy assay. In this experiment, medical devices with similar positions (# 1, #11, #21, #31 
and #10, #20, #30, #40) in the coating process were compared, whereby only #11 and #10 
were EtO sterilized (Table 4-14). No loss of absorption signals of the anti-inflammatory 
coating after EtO sterilization compared to non-sterilized medical devices were observed as 
the absorption signals for the devices # 1, #11, #21, and #31 are similar and as well for the 
devices #10, #20, #30, and #40. 
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Table 4-14. Results of coating efficacy assay of medical devices w/o and with EtO treatment  
Medical device with EtO 
Mean (± SD) [RU] 
w/o EtO 
Mean (± SD) 
# 1   1.05 (± 0.03) 
# 11 1.19 (± 0.12)   
# 21   1.23 (± 0.21) 
# 31   1.07 (± 0.03) 
# 10 0.34 (±  0.16)   
# 20   0.37 (± 0.09) 
# 30   0.32 (± 0.11) 
# 40   0.33 (± 0.22) 
 
The coating efficacy assay was conducted to find out, whether priming of medical devices 
with NaCl may result in unappreciated reduction of APO010 coupling. The priming procedure 
is done to fill the extracorporeal system with NaCl and to remove potential air bubbles. The 
results are shown in Figure 4-16. Even after 1 h washing of medical device #11 (after EtO 
sterilization) with 0.9 % NaCl, APO010 is homogenously distributed throughout the whole 
oxygenator with a mean absorption signal of 1.19 ± 0.12 RU. Compared to the previously 
shown ELISA results of medical devices from the same position as #11 (Table 4-14) there is 
no loss of APO010 observed. The filling behavior and air removal of the medical device in 
the priming test was unchanged to a non-coated medical device, which means that the 
coating has not changed the mode of action of the device.  
 
The detachment assay was conducted to find out whether the priming of medical devices 
with NaCl may result in unappreciated detachment of APO010. Usually, the priming solution 
would reach the patient circulation and thus detached APO010 molecules will be infused into 
the blood circulation.  
After up to 60 min washing with a flow rate of 1 l/min of the medical device #11 with 
0.9 % NaCl solution no APO010 molecules were detected in the washing solutions. At a 
concentration of ≥ 0.098 ng/ml APO010 the detachment assay delivers stable results. As 
shown in Figure 4-17 B, the coating was found to be stable even after EtO sterilization and 
washing.  
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Figure 4-16. Results for device #11 after washing with NaCl for 1 h in circulation. 
Device #11 was washed for 1 h with 0.9 % NaCl solution in flow (1 l/min). Afterwards, the device was 
opened and samples of different PMP mats (2, 10, 27, 44, 54) of different mat position A, B and C 
were collected and analyzed by the coating efficacy assay. Negative control (nc) means that the PMP 
was coated with all components except APO010. The column chart shows the relative absorption 450-
550 nm in relative units [RU], whereby the absorption signal of the ELISA is proportional to the amount of 
bound APO010. Error bars represent SD from the mean of n=3 (intra-assay). The cut off (lower dotted 
line) was defined due to RU values <0.1 obtained for the negative control. 
 
 
A                        B 
 
 
 
 
 
 
Figure 4-17. Results of the detachment assay of washing solutions of medical device #11. 
A Dilution series for quantitative analysis of APO010. B Washing solutions of medical device #11 
detected by the detachment assay. The column chart shows the relative absorption 450-550 nm in relative 
units [RU], whereby the absorption signal of the ELISA is proportional to the amount of bound 
APO010. Error bars represent SD from the mean of n=3 (intra-assay). The specificity of the 
detachment assay is ≥ 0.098 ng/ml APO010. 
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As mentioned above several medical devices were stored after EtO sterilization for 20 days 
at 5 °C, RT and 55 °C. Subsequently, the medical devices were opened and samples were 
collected. As shown in Figure 4-18  there was a flow direction dependent APO010 reduction 
from medical device in-line from left to right from about 70 % as shown in the nine medical 
devices analyzed directly after the coating as well. Therefore, it was assumed that no loss of 
APO010 after sterilization and storage was found compared to the control devices #1 and 
#21, which were tested previously (Figure 4-15).  
As well, no difference in coating efficacy was found after storage of medical devices 
stabilized with the stabilization formulation F1 or F2. In order to compare medical devices 
flushed with different stabilization formulations, medical devices from similar positions during 
the coating procedure (Figure 4-18 A) were analyzed (e.g. medical device #2 with medical 
device #22; medical device #3 with medical device #23). The same colors in Figure 4-18 A 
indicate which pairs of run 1 and 2 were compared with each other (Figure 4-18 B). The 
results are comparable with the previously generated results in Figure 4-15. There is the 
same flow direction dependent APO010 reduction. Therefore, the storage for 20 days at 
different temperatures had no influence on the coupled APO010. Both stabilization 
formulations seem to protect the coating identical during sterilization and storage.  
Summing up, the anti-inflammatory coating is stable with the stabilization formulation F1 and 
F2 after sterilization and accelerated aging at 55 °C, whereby 20 days accelerated aging 
corresponds to six months real-time storage. 
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A   
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
Figure 4-18. Results of the coating efficacy assay to quantify coupled APO010 on PMP after 
EtO treatment and after storage. 
A Schematic illustration of medical device position during coating. Run 1 is #1-20 (stabilization 
formulation F2), run 2 is #21-40 (stabilization formulation F1). The same color indicates which pairs of 
batch 1 and 2 have to be compared with each other. B The first two columns (grey) show the control 
samples, whereby uncoated means that the uncoated PMP was used, negative control means that the 
PMP was coated with all components except APO010. The other samples were taken of PMP mat 4 of 
mat position A of the different medical devices. All samples were investigated by the coating efficacy 
assay. # 1 is a control, which was tested in earlier experiments, medical device 2, 22, 19, 39 were 
stored at 5 °C, medical device 3, 23, 18, 38 were stored at RT and medical device 4, 24, 17, 37 were 
stored at 55 °C for 20 days. The column chart shows the relative absorbance 450-550 nm in relative units 
[RU], whereby the range of 0 to 2.0 is proportional to the amount of bound APO010. Error bars 
represent SD from the mean of n=3. The cut off was defined due to RU values <0.1 obtained for the 
negative control. 
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Figure 4-19. Results of chemotaxis assay to test the functionality of coupled APO010 on PMP 
w/o and with EtO treatment and after storage. 
The same color indicates which pairs of batch 1 and 2 have to be compared with each other. The 
functionality of the PMP mats from medical devices w/o and with EtO treatment and after 20 days 
storage at 5 °C, RT and 55 °C were tested in the chemotaxis assay. Data is normalized to the 
negative control (100 %) in %. Error bars represent SD from the mean of n=3. Blood was donated by 
the same donor at two days. 
Two-way ANOVA: * < 0.1, ** < 0.01, *** < 0.001, **** < 0.0001. 
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By the neutrophil activity assay the PMP mats from the medical devices stored at different 
temperatures for 20 days were additionally tested on functionality. As depicted in Figure 
4-19, the anti-inflammatory coated PMP mats reduced chemotactic activity of neutrophils 
even after sterilization and storage. However, the reduction value of all medical devices is 
very similar and shows not the excepted difference dependent on the APO010 concentration 
as shown in Figure 4-18. In addition, the medical devices stored at 55°C perform similar than 
those stored at 5°C or RT. The medical devices #1 (**), #21 (****), #22 (**), #24 (**), #37 
(****), #18 (****), #38 (*), #19 (***), #39 (****) show significant reduction of chemotactic 
activity compared to the negative control, however there is an irregular variation of 
chemotactic activity of the medical devices.  
The medical devices #3 and #23 were stored for 20 days at RT, #2 stored at 5°C, #4 stored 
at 55°C, and #17 stored at 55°C showed no statistically difference to the negative control and 
therefore were not sufficient stabilized or had not coupled enough APO010. These results 
indicate the tendency, that medical devices stabilized with F1 (medical device #21-40) show 
stronger reduction than those stabilized with F2 (medical device #1-20). A more complex 
formulation is therefore not necessary for this approach. However, the goal to reduce 
neutrophil activity at least about 10 % could be observed for all medical devices, expect #23 
which had a chemotactic activity of 92.17 % ± 3.25 %. 
 
After the storage of selected medical devices for 20 days at different temperatures samples 
from the medical devices were taken as described above. These anti-inflammatory coated 
PMP samples were washed for 1 h with PBS. Subsequently, washing solutions were 
harvested and analyzed. As shown in Figure 4-20 B, no APO010 molecules were detected in 
the washing solutions indicating that the anti-inflammatory coating is highly stable even after 
sterilization and 20 days storage at different temperatures. 
To confirm that there is no unappreciated non-specific coupling of APO010 to the PVC tubing 
of the circuits, the PVC tubing of the medical device-set were tested via the coating efficacy 
assay. As shown in Figure 4-21, the PVC tubing which is connected to the medical devices 
were negatively tested on the presence of APO010. As an internal positive control, PMP from 
medical device 11 was included. This data shows that, based on the anti-inflammatory 
protocol, APO010 specifically binds to PMP and not to the PVC tubing. 
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A           B 
 
 
 
 
 
 
 
Figure 4-20. Results of the detachment assay to detect detached APO010 molecules after 
sterilization and 20 day storage. 
A Dilution series for quantitative analysis of APO010. B Washing solutions of differently stored (5°C, 
RT, 55°C for 20 days) medical devices detected by detachment ELISA. Error bars represent SD from 
the mean of n=3. 
 
 
 
 
 
 
 
 
 
Figure 4-21. Results of the coating efficacy assay with PVC tubing with and without EtO 
sterilization. 
12 mm pieces of tubing of different medical devices were prepared and analysed by the coating 
efficacy assay. PMP mats of medical device 11 served as positive control. The column chart shows 
the relative absorption 450-550nm in relative units [RU], whereby the absorption signal of the ELISA is 
proportional to the amount of bound APO010. Error bars represent SD from the mean of n=3 (intra-
assay). 
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Residual moisture is a crucial issue during sterilization and storage. In general, a residual 
moisture around 2 % is specified within biofunctionalized medical devices. Therefore, the 
goal was to limit moisture below 2 % at the end of the production process. The medical 
devices were dried o/n at 50°C in a vacuum oven and afterwards the residual moisture was 
determined by Karl-Fischer-Titration. The figure shows that residual moisture values are very 
low (≤ 1.1 %) for all medical devices. The positive control is medical device #11 after it was 
washed for 1 h with NaCl and afterwards dried at 37 °C. The high value of 6.4 % indicated 
that the time was not sufficient for drying the PMP mats completely (Figure 4-22), but the 
drying method of the medical devices in the serial production run had not to be optimized. 
 
 
 
 
 
 
 
 
Figure 4-22. Results of residual moisture [%] of different medical devices. 
Residual moisture was measured by Karl-Fischer-Titration referenced to air moisture. The positive 
control is medical device #11 after it was washed with 0.9 % NaCl and dried at 37 °C. 
 
Summary of the second serial production run 
The anti-inflammatory coating process was transferred to the serial production scale, 
however a homogenous distribution of the coating from the medical devices was not fulfilled 
so far. The devices, which were positioned more distal from the coating solution source 
receive less APO010 compared with those more proximal. The quality control (QC) assays 
after sterilization, storage and accelerated aging for 20 days at different temperatures were 
carried out successfully, but had to be repeated with the final setting. In the next serial 
production run the coating system was optimized to generate a homogenous distribution of 
the coating on all medical devices. 
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4.2.3.3 The third serial production run 
The third serial production run was modified to obtain a more homogenous distribution of the 
coating efficacy compared with second serial production runs 1 and 2. Therefore, a circular 
approach with 22 medical devices was tested. It was expected that all medical devices 
receive the same amount of the coating solutions for the same time period.  
After the coating of the devices, an EtO treatment and storage at different conditions were 
performed and the coating distribution was tested. In the third serial production run the 
stabilization formulation F3 was tested which includes 8 amino acids, trehalose and 
Polysorbate 20. Here it was tested, if sugar and Polysorbate 20 show positive effects on 
stabilization of the dried anti-inflammatory coating as known by literature [67, 69]. 
By the coating efficacy assay a homogeneous distribution of anti-inflammatory coating could 
be confirmed. However, the overall absorption was slightly lower compared with the second 
production run 1 and 2. The data of this third serial production run show that less APO010 
molecules (0.885 ng/cm2 APO010 per device) bound per area PMP when 22 devices were 
homogenously flushed at once by the circular setting compared to first serial production run 
(1.79 ng/cm2 APO010 per device) and the second serial production run (0.925 ng/cm2 
APO010 per device). 
In Figure 4-23, the homogenous distribution of APO010 between all medical devices is 
depicted with a mean of 0.64 ± 0.14 RU. The mean values of all samples show that the 
APO010 distribution between different medical devices is homogenous, however partly with 
high standard deviations. A reason for this relatively high deviation might be the unexpected 
loss of pressure during the EDC coating step due to technical reasons. The lower flowrate of 
0.3 l/min is due to the round settings, whereby the flow is reduced by the several medical 
devices. In this setting, it was not possible to increase the pressure in order to increase the 
flow rate.  
The accelerated aging procedure shows that the medical devices show no crucial difference 
in absorption after the different storage condition. The accelerated aging for up to 82 days at 
55 °C shows no loss of absorption signal, which corresponds to 2 years real-time storage. 
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Figure 4-23. Results of the coating efficacy assay to quantify coupled APO010 on PMP after 
third serial production run. 
A Schematic illustration of medical device position during coating.The 22 medical devices were coated 
with APO010 (35 ng/ml), albumin and aa-based stabilization formulation F3 (volume 6 l, flow rate  
0.2 - 0.3 l/min). The flow rate was detected after #5. The pressure was detected after #5 and #6.  
B PMP pieces were cut from positions A, B and C out of mat 2 and 54 from the medical device 1 to 22. 
The medical devices were different treated. The column chart shows the relative absorbance 450-550 nm 
in relative units [RU], whereby the range of absorption is proportional to the amount of bound APO010. 
Error bars represent SD from the mean of n=3. 
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Summary of the third serial production run 
In summary, the third serial production run was the most successful one. It was the first time 
that a homogenous coating of all medical devices was reached. The lower absorption signal 
is due to the lower APO010 amount to PMP area. The concentration of APO010 can be 
increased, when a higher number of medical devices are coated at the same time. 
Furthermore, the coating flow rate could be increased by using a setting where a higher 
pressure is feasible.  
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 Discussion 4.3
The upscaling of the anti-inflammatory coating to a serial production scale was a crucial step 
in finishing of this work. Due to the very low concentration of the anti-inflammatory molecule 
APO010, the upscaling had to be performed in several steps to ensure efficient coupling.  
In the beginning, the bench setting was transferred to a circuit setting and different APO010 
concentrations were tested in the functional and non-functional ELISA. It became clear that 
in the circuit setting both ELISAs generated detectable results in a range of 20 to 50 ng/ml 
APO010, whereby the functional ELISA needs a higher APO010 concentration than the non-
functional ELISA. At this step in the upscaling it was difficult to decide for a final 
concentration, because this decision depends on functional behavior, which can differ on the 
final setting. The total amount of coupled APO010 is depending on the APO010 
concentration and the surface area of PMP. Therefore, the development range was defined 
by two main points: First, what can be measured by ELISA? Second, is the chosen 
concentration of APO010 sufficient for the desired anti-inflammatory effect? 
Therefore, in the next steps the crosslinking reagent Sulfo-NHS was added for optimal 
coupling of APO010 and the incubation time of APO010 was tested, to enable the most 
efficient coupling strategy in the circuit setting. The efficiency was analyzed indirectly in the 
coupling solution to show if APO010 is completely coupled and to investigate if material is 
wasted. Due to the slight differences in the results with or without Sulfo-NHS, the protocol 
was not changed. All these steps were necessary for economic efficiency. 
Then, one medical device was coated with a flow rate of 0.5 l/min, another with a flow rate of 
1 l/min and the above defined parameter. Interestingly, it was shown that a higher flow rate 
doubles the amount of coupled APO010. After incubation with F1 as stabilization formulation, 
drying the device, and EtO sterilization the coating was analyzed again. After the sterilization 
the absorption signal was 2.5 fold lower than without EtO, which means that the stabilization 
was not as successful as basically described before [55]. One reason could be that here EtO 
was used as sterilization method and in previous work beta sterilization was performed [55].  
Hence, the sterilization stress is very different for each method and it is necessary to adapt 
the formulation in regard to the stress model. In literature it was shown that up to 250-
1,000 mg EtO/l, temperatures of 40-60°C, and relative humidities of 50-90 % were used to 
inactivate Bacillus subtilis [127]. This means a protein, sterilized by EtO, has to be stabilized 
for medium temperatures, high humidity and as well strong chemical degradation by EtO. 
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EtO is highly reactive due and reacts by alkylation, which leads to denaturation of proteins 
and inactivation of microorganisms [128]. Therefore, the selection of a stabilization 
formulation is a separate development project, which could not be covered in this thesis. 
Thus, only three different formulations were used as basis for further development.  
When upscaling to 6 medical devices in-line no homogeneous distribution of APO010 could 
be found from device #1 to #6. A reduction of 20 % from #1 to #3 and #3 to #6 shows that 
the setting is not optimal for the coupling. One main problem is that APO010 is not saturated 
in the coupling solution and therefore the device on first position (#1) gets the biggest 
amount due to the fast crosslinking process with EDC.  
In order to increase the amount of devices for analysis and for further upscaling, a setting 
with 20 medical devices was tested. The setting was in-line with 2x 10 devices. The flow 
direction was changed every 5 min to increase the homogeneous distribution of the coating 
solution. However, the same picture as in the first run was seen. Interestingly, in this setting 
each medical device on the same position in-line showed the same absorption signal. This 
observation made clear, that the only setting, which can generate a homogeneous 
distribution of the coating can be a setting where every medical device gets the same 
amount of the coating solution at the same time. Therefore, the third setting was designed in 
a circle with 22 devices. 
Due to the flow dependent decrease of APO010 coupled to the medical devices in the 
second serial production run form the first to the last device, it was suspected that due to the 
different APO010 concentrations on the medical devices a loss of functionality due to 
sterilization or storage would be difficult to interpret. But the medical devices were tested as 
planned in the workflow and performed very successful. Fortunately, the same pattern of flow 
dependent decrease in APO010 was observed after the different treatments. Overall no loss 
of absorption signal after EtO sterilization was observed in comparison with the results 
generated with one medical device during the upscaling transfer. There, a 2.5 fold decrease 
after EtO treatment was shown.   
The idea for two runs in the second serial production run was to test a second stabilization 
formulation F2. The more complex formulation F2 includes more excipients than F1 and 
therefore the amount of different substances could improve the anti-inflammatory coating 
stability especially during drying and subsequent EtO sterilization [75]. As it was shown by 
the second serial production run, there were no differences shown after EtO sterilization with 
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both formulations in the non-functional ELISA. One reason should be the optimized 
performance during the manufacturing of the medical device, which lead to shorter handling 
times and therefore less stress on the anti-inflammatory coating.  
The medical devices were tested on their washing performance with the result that there was 
no loss of the anti-inflammatory coating as no APO010 molecules could be detected in the 
detachment assay. After storage of the medical devices at 5°C, RT and 55°C for 20 days no 
loss of absorption signal was detectable. In this case the problem was that there was already 
a loss in absorption signal form device #1 to #20 and from #21 to #40 due to the 
inhomogeneous coating, as described above. Therefore, the shown pattern complicates to 
distinguish the different stress treatments. This was even more difficult when considering the 
results of the functionality assay. The functionality assay, which measures the chemotactic 
activity of neutrophils, showed a different pattern than the coating efficacy assay for the 
same stored medical devices. Not all medical devices could reduce the neutrophil activity 
significantly compared to the negative control. There is a tendency that the medical devices, 
which were stabilized with F1 performed better than those which were stabilized with F2, but 
overall the effect is small.  
However, the goal to reduce neutrophil activity at least about 10 % could be observed for all 
medical devices, except #23 which had a chemotactic activity of 92.17 % ± 3.25 %. The 
corresponding incubation solutions of the stored medical devices showed no detached 
APO010 in the detachment assay after storage at different temperatures, which confirms the 
stability of the coating. 
In addition to the experiment with neutrophils, functional blood experiments would be of great 
interest, because they would show the functional effect in blood as it will be in the medical 
use. But working with freshly prepared neutrophils or with blood involves a lot of problems. 
Biological material is extremely different form each donor, for which reason the results can 
differ and different settings need to be performed with the same sample to enable 
comparison. To test the anti-inflammatory effect fresh blood and to ensure statistical relevant 
data a clinical study with trauma patients with an activated immune system would be of great 
interest as these kind of patients would need this application. 
Not only the functionality of the anti-inflammatory coating in blood is of great interest, but the 
anti-inflammatory coating itself. It is known that the oxygenator with PMP generates a biofilm 
of fibrin, thrombocytes, erythrocytes, and blood proteins which lowers the efficacy of the gas 
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exchange. The biofilm can extend up to 50 µm, whereby the wall thickness of the PMP 
hollow fiber is 70 µm. By extension of the wall thickness the gas exchange is disturbed and 
the oxygenator has to be exchanged. As well the cellular detachment is very strong on the 
woven thread and the contact points of the neighbored fibers [12]. The same observation 
was shown in chapter 3 in the SEM images, where the stabilization formulation built a film 
like structure on the woven thread.  
The third serial production setting was performed with 22 medical devices in a circular set-
up. The 22 devices were tested directly after the coating, after EtO sterilization and after 
storage of 20 days at RT and after 20 days, 50 days and even 82 days at 55 °C. All tested 
devices generated the same result in the coating efficacy assay.  
For in vivo use in humans of the anti-inflammatory coating it is essential that the anti-
inflammatory coating is specifically bound to the PMP surface. Therefore, it was tested if 
there were any APO010 molecules bound to the PVC tubing. The result was that no APO010 
was bound to the PVC tubing, therefore it is assumed that as well no other components of 
the device are affected. Residual moisture of the coating delivers insight of a stable drying 
process, whereby for each device the same residual moisture should be observed. This was 
the case for the second serial production scale. Low residual moisture is important to reduce 
a loss of the coating before sterilization. No relevant residual moisture within medical devices 
was found after production.  
In external investigations no relevant changes in the function of the gas exchange were 
found after anti-inflammatory coating (data not shown) and sterility of anti-inflammatory 
coating was confirmed by bioburden assays (data not shown). 
To sum up, in this work an anti-inflammatory coating on an inert PMP hollow fiber was 
established from bench setting to a serial production scale. The coating is stable during 
circulation as shown in the priming test and as well during blood contact as shown in chapter 
3. In the serial production runs the aa-based stabilization formulations were able to stabilize 
the coating during drying, sterilization, and storage, but could be further investigated for more 
detailed information. The serial production scale was optimized to a circular setting in order 
to generate a homogenous distribution in all medical devices. Due to the very low amount of 
APO010 on the surface the most known analytical methods are not sensitive enough. 
Therefore, the established ELISAs are the best available methods to qualify the anti-
inflammatory coating. 
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CHAPTER V 
 
GENERAL SUMMARY AND OUTLOOK 
 
5 General summary 
This work deals with the question how to design an anti-inflammatory surface coating, which 
avoids or reduces material-mediated innate immune responses on the example of the 
material polymethylpentene (PMP). PMP is a polymer, which can be manufactured as hollow 
fibers and is used in medical devices like oxygenators and enables the exchange of oxygen 
and carbon dioxide in the blood. 
 
In chapter 1 the background, especially for the design of an anti-inflammatory coating, was 
discussed in detail. Five potential anti-inflammatory molecules were selected based on the 
idea that activated neutrophils expressing Fas on their surface can be inactivated by contact 
with the selected molecules. Those five molecules are anti-Fas molecules, which have 
optimal binding and trimerization properties to Fas: SuperFasL, MegaFasL, Fc-FasL, E09 
and CH11. SuperFasL, MegaFasL (two variants) and Fc-FasL are recombinant proteins, 
which trimerize to homotrimers. Three FasL domains are located in spatial proximity enabling 
the induction of apoptosis in all Fas positive cells. This structure makes the proteins 
extremely efficient because it enables the trimerization of the Fas receptor, which allows the 
activation of the extrinsic apoptosis pathway. IgG1 E09 and IgM CH11 are monoclonal 
antibodies. E09 has been reported to induce apoptosis in an effective way although the 
affinity to the Fas receptor is relatively weak [60]. CH11 has been used previously for anti-
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inflammatory approaches [61] but was shown to be instable over a longer period of storage 
time. Therefore, CH11 was only used as a control molecule for establishing the assays. 
 
In chapter 2 the five anti-inflammatory molecules were investigated on their efficiency to 
induce apoptosis in the Jurkat cell line and neutrophils. Therefore, read out models for the 
investigation process were developed. Apoptosis and neutrophil activity assays have been 
established as the anti-inflammatory molecules have pro-apoptotic function. Soluble and 
immobilized effector molecules were systematically evaluated on their potential to induce 
apoptosis and to reduce neutrophil activity. Except the E09 antibody, each anti-Fas molecule 
induced apoptosis in > 20 % of target cells and impaired neutrophil activity in > 10 % of 
target cells. Therefore, the defined goals were reached. The APO010 is the most suitable 
molecule due to its availability in Good Manufacturing Practice (GMP) quality. In addition, 
clinical safety data for systemic application are available for APO010 as well [102, 103].  
 
In chapter 3 it was focused on the design of the anti-inflammatory coating. For the anti-
inflammatory coating, first, the polymethylpentene (PMP) hollow fiber was plasma activated 
with O2 to generate carboxyl groups. Second, the plasma activated PMP reacts with EDC. 
The activated PMP can react in a third step with APO010, which results in a stable amid 
bond. Afterwards, the reaction was quenched with recombinant albumin. Crosslinking with 
EDC results in covalent coupling of APO010 and albumin to the PMP. Albumin interacts as 
blocking reagent with free PMP groups and avoids unwanted binding of blood components. 
In the last step an amino acid-based stabilizing formulation was added to the coating and will 
protect the coating during drying, sterilization, and storage. Each compound has already 
been approved to be safe for clinical applications. 
Covalent and stable binding of APO010 to PMP was shown in leaching experiments. Five 
washing steps are recommended after crosslinking APO010 with EDC for removing residual 
non-covalently bound APO010 from PMP. Functionality was shown by reduced chemotactic 
activity of neutrophils after challenging with the anti-inflammatory coating. Hemocompatibility 
of PMP coated with the anti-inflammatory coating was shown in the circuit setting with human 
blood. Moreover, no cytotoxic effects of fluid samples harvested from circuits with the anti-
inflammatory coating could be observed. The characterization of the surface in general was 
not possible due to the low APO010 concentrations. Most characterization methods as FTIR 
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need smooth surfaces and high protein concentrations of at least 1 mg/ml. The contact angle 
method to differ the surface properties before and after coating of the anti-inflammatory 
coating showed only differences by adding the stabilization formulation.  Therefore, only the 
developed ELISAs, apoptotic and chemotactic assays could determine the coating quality. 
 
In chapter 4 the upscaling process to serial production scale is reported. Therefore, the 
coating had to be adapted from bench setting to several medical devices, whereby three 
upscaling steps were necessary to generate a homogeneous distribution of the coating. In 
the first and second serial production runs there was a flow dependent decrease of APO010 
coupled to the medical devices. 
However, it could be demonstrated that in the second serial production run 1 and 2 the anti-
inflammatory coating is stable after EtO sterilization analyzed by the coating efficacy assay, 
as well as after storage, and prolonged washing for up to 1 h. The anti-inflammatory coating 
is functional even after EtO sterilization and storage of 20 days at different temperatures, 
whereby not all medical devices delivered the same functionality data in chemotaxis assay 
with freshly isolated neutrophils.  
In the third serial production run the medical devices were coated in a circular setting which 
generated a homogenous distribution of APO010 in all 22 medical devices. After storage for 
up to 82 days at 55 °C there was no loss of APO010 in the coating efficacy assay, which 
correlates to 2 years real-time storage, the normal minimal durability of medical devices.  
It was investigated that the anti-inflammatory coating can be analyzed easily by the coating 
efficacy assay after the coating procedure, as well as after sterilization, and storage. 
Washing experiments after 1 h washing delivered no detached APO010. The APO010 
detachment can be quantified by the detachment assay at a concentration of ≥ 0.098 ng/ml. 
In addition, the anti-inflammatory coating is specific to the PMP hollow fibers as no unspecific 
binding to PVC tubings after serial production could be detected. The performed drying 
process was optimal for the medical devices as no relevant residual moisture within medical 
devices was found after production. As well the mode of action of the medical device, the gas 
exchange of the PMP hollow fibers, was investigated externally with the result that no 
relevant changes in the function of the gas exchange were found after anti-inflammatory 
coating. The sterility of the anti-inflammatory coating was ensured by externally sterility tests. 
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In summary, in this work an anti-inflammatory coating on an inert PMP hollow fiber was 
established from bench setting to a serial production scale. The coating is stable during 
circulation and as well during blood contact as shown in chapter 3. The aa-based 
stabilization formulations were able to stabilize the coating during drying, sterilization, and 
storage. The serial production setting was optimized to a circular setting in order to generate 
a homogenous distribution in all medical devices.  
However, due to the very low amount of APO010 on the surface the most known analytical 
methods are not sensitive enough to detect the molecule on the surface directly. Therefore, 
the established ELISAs are the optimal methods to qualify the anti-inflammatory coating.  
Anti-inflammatory coatings are used for implants or prostheses [119, 120], hernia repair 
[121], disorders [122] or are used in general to differentiate monocytes into macrophages 
[123]. This anti-inflammatory coating is an innovative approach for a medical device with 
blood contact, with high requirements in stability and functionality. Thus, it can possibly show 
the way for new biofunctional coatings in the medical device sector. 
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 Outlook 5.1
As the third serial production in a circular setting delivered the best results with a 
homogeneous anti-inflammatory coating even after storage at accelerated temperatures at 
55 °C for 82 days, the setting should be further validated.  
In addition, it is necessary to test the functionality of the coating with blood of patients, 
preferably of trauma patients, to investigate the reduction of inflammatory signal in the blood. 
For this study, the blood needs to be fresh, in order that all components behave as natural as 
possible. To ensure statistical relevant data a clinical study would be of great interest. On 
basis of these experiments the anti-inflammatory coating can be further developed for a 
usage in medical devices.  
The biofunctional anti-inflammatory coating is a novel technology to reduce unappreciated 
material-induced immunogenic responses. In principle, it should be possible to transfer this 
technology to other surfaces. This could allow for expansion of the positive effects to other 
medical devices in direct blood contact.  
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